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Tuberculosis, a common and deadly infectious disease is caused by the pathogen 
Mycobacterium tuberculosis. The recent emergence of multi-drug and extreme multi-
drug resistant strains poses an even greater obstacle o controlling the disease, 
particularly in areas where efficient and effective health systems have not been properly 
addressed. Current treatments using first line drugs typically require extended use and 
strict compliance by patients, which is often not adhered to. As a result, there is an urgent 
need for new and highly effective drugs to combat this disease.  
Mycobacterium tuberculosis relies on mycothiol, a low molecular mass thiol used to 
circumvent oxidative stress generated by activated macrophages and to deal with 
antibiotics such as rifamycin. Enzymes involved in the biosynthesis of mycothiol have 
been elucidated over the past ten years and some have been designated to be essential in 
the growth of Mtb, with mycothiol disulfide reductase (Mtr) being one. Mtr is involved in 
the reduction of oxidized mycothiol (MSSM) to mycothiol (MSH) upon exposure of the 
microbe to oxidative stress. The rational behind this study involves the use of 
naphthoquinones grafted onto the mycothiol template as subversive substrates against 
Mtr. 
Initially, we had planned to clone and express Mtr in Corynebacterium glutamicum (C. 
glutamicum) to try to obtain enhanced expression levels of Mtr, and although the 
expression of the enzyme was not successful we were able to confirm that C. glutamicum 
does indeed depend on MSH as has been previously sugge ted but not actually proven. 
MSH was isolated from C. glutamicum with the aid of a new derivatising agent 2-bromo-
acetonaphthone (BAN) and characterized using a combination of NMR and mass 
spectrometry. Consequently, we were also able to esabli h that MSSnaph (obtained 
during the isolation process of MSH) is an alternative and better substrate for Mtr with a 
km,app  of 23 µM, a  kcat and kcat/km of 15.56 s
-1 and 8.17 x 105 respectively, as compared to 






Synthesis of subversive substrates proceeded throug the initial formation of 2-azido-2-
deoxy-3,4,6-tri-O-acetyl-D-glucopyranosyl acetate (7). Phenyl-3,4,6-tri-O-acetyl-2-azido-
1-thio-α-D-glucopyranoside (12) was generated from this and, after reduction of the 
azide, linked to the carboxy terminus of substituted naphthoquinones using standard N-3-
(dimethylaminopropyl)-N-ethyl-carbodiimide (EDC) and Hydroxybenzotriazole (HOBt) 
coupling procedures. Deacetylation using the Zemplén procedure gave the target 
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a R1 = OAc
b R2 = OH
deacetylation
 
The compounds exhibited specific activities ranging between 0.29 µmol/min/mg and 0.42 
µmol/min/mg at 40 µM, and inhibition levels ranging between 4 and 14% at 40 µM when 
tested against Mtr. The Phenyl-2-deoxy-2-[3'-(8''-hydroxy-3''-methyl-1'',4''-dioxo-1'',4''-
dihydronaphthalen-2''-yl)propanamido]-1-thio-α-D-glucopyranoside (35b) was the only 
compound that exhibited bacteriocidal effects when t sted against Mtb using the 
radiometric respiratory technique based on the Bactec system. 
A range of thioglycosides and O-glycosides was also evaluated (at 500 µM) as possible 
inhibitors of Mtr and found to be of poor inhibitory nature exhibiting percentage 
inhibitions that ranged between 1.86-12.75% and 3.39-20.2% respectively. We also 





first time that Mtr is also inhibited by the activated isoniazid, with percentage inhibitions 
ranging from 16.4% to 66%. Attempts to prepare Ethionamide-NAD(P) adduct mixtures 
using the same procedure were however, not successful. The finding that INH-NAD(P) 






AcCys    Acetyl-cystein  
AcCySmB   Bimane derivative of N-acetylcysteine  
Accq-fluor   6-aminoquinolyl-N-hydroxysuccinimidyl carbamate  
ATP    Adenosine triphosphate  
BAN    2-bromo-2’-acetonaphtone  
BF3.OEt2   Boron triflouride etherate  
Boc2O    Di-tert-butyldicarbonate  
CD3OD   Deuterated methanol  
CH3CN   Acetonitrile  
Cl3CCN   Trichloroacetonitrile  
COSY    Correlation spectroscopy  
DCM    Dichloromethane  
DEPT-NMR   Distortionless enhancement by polarization ransfer  
DMAP   4-Dimethyl aminopyridine  
DMSO   Dimethyl sulfoxide  
DNA D  eoxyribonucleic acid  
EDC    N-3-(dimethylaminopropyl)-N-ethyl-carbodii mide  
EDTA    Ethylenediaminetetraacetic acid  
EPO Medium used for growing electroporation competent cells (described in 
Appl Microbiol Biotechnol, 1999, 52: 541-545) 
EtOAc   Ethyl acetate  
FAD    Flavin adenine dinucleotide  
GlcNAc   N-acetylglucosamine  
GlcNAc-Ins   1-D-myo-inosityl-2-acetamido-2-deoxy-alpha-D-glucopyranoside  
GSH    Glutathione  
HBr    Hydrogen bromide  
HOBt    Hydroxybenzotriazole  




INH-NAD(P)   Isonicotinoylated nicotinamide adenine dinuclotides                            
IPTG    Isopropyl-beta-D-thiogalactopyranoside Kcat                      
kcat    Turn over number 
kcat/km    Overall catalytic efficiency  
LB    Lurea broth  
LBG    Lurea broth containing filter sterilized glucose  
mBBr    monobromobimane  
Mca    Mycothiol S-conjugate amidase  
MDR    Multidrug resistance  
MeOH   Methanol  
MSH    Mycothiol  
MshA    1L-myo-inositol-1- phosphate 1--D-N acetylglucosaminyltransferase  
MshB  1-O-(2-acetamido-2-deoxy--D-glucopyranosyl)-D-myo-inositol 
deacetylase  
MshC  ATP-dependent L-cysteine: 1-O-(2-amino-2-deoxy-D-glucopyranosyl)-D-
myo-inositol ligase  
MshD    Mycothiol synthase  
MSmB   Monobromobimane derivative of mycothiol  
MSSM   Mycothiol disulfide  
Mtr    Mycothiol disulfide reductase  
NADPH   Reduced nicotinamide adenine dinucleotide phos hate  
NADP+   Oxidized nicotinamide adenine dinucleotide phosphate  
NADH   Reduced nicotinamide adenine dinucleotide  
NAD+    Oxidised nicotinamide adenine dinucleotide  
NaN3    Sodium azide  
NMR    Nuclear magnetic resonance  
NQ    Naphthoquinone  
PCR    Polymerase chain reaction  
PMSF    Phenylmethylsulphonyl fluoride  




ROI    Reactive oxygen intermediate  
SDS-PAGE   Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Tf2O    Trifluoromethanesulfonic (triflic) anhydride xv  
TfN3    Triflyl azide  
THF    Tetrahydrofuran  
TLCK    N-p-tosyl-L-lysine-chloromethyl ketone  
TMS    Trimethyl silyl  
TPCK    N-p-tosyl-L-phenylalanine-chloromethyl ketone  
TR    Trypanothione reductase  
TS2    Trypanothione disulfide  
XDR    Extensively drug resistant tuberculosis 
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1.1 Origins of Mycobacterium tuberculosis 
 
For the most part, mycobacteria are saprophytic organisms abundantly found in soil and 
untreated water, with some species being pathogens (Rook et al., 2007). It is therefore 
most likely that during the early stages of the evoluti n of the animal kingdom, chance 
mutations in mycobacteria managed to produce species capable of parasitizing animals. 
As a result, earlier on, it was hypothesised that tere might have been a direct progression 
from a mycobacterial pathogen in livestock to a bacterium that would have evolved to the 
closely related Mycobacterial tuberculosis, as the domestication of animals occurred, 
particularly cattle. Consequently, Mycobacterium bovis (M.bovis) which results in 
tuberculosis (TB) like pathogenesis in cattle was seen to be the most likely precursor of 
Mycobacterium tuberculosis (Mtb) (Steele and Ranney, 1958). 
 
The appeal in this hypothesis is understandable givn the fact that it was formulated long 
before the advent of modern DNA sequencing and related techniques. Thus, recent 
studies have shown a marked similarity of DNA and 16S rRNA sequences among the 
members of the Mtb complex, while they show varying degrees of phenotypes, 
pathogenicity and host tropism (Brosch et al., 2002).  In spite of this, closely related 
bacteria can be differentiated by the identification of rare synonymous single nucleotide 
polymorphism analysis (sSNP), which also suggests that M.bovis must have evolved at 
the same time as Mtb (Sreevatsan et al., 1997). 
 
Although a lot of progress has been achieved with rega ds to Mtb evolutionary studies, it 
appears there is still open debate about the origins of tuberculosis  in animals and humans 
and that it may be a while before the question is resolved, as is evident from Bosch et al., 
2002, where they hypothesized that the common ancestor of the tubercle bacilli could 
have been a human pathogen already resembling either Mtb or Mycobacterium canetti 
(M. canetti).  
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Unfortunately the impact Mtb has had on ancient populations cannot be statisticlly 
demonstrated and compared with what present societies have to contend with, where 
approximately one third of the world’s population, and mostly in developing countries is 
affected (figure 1.1) (Rook et al., 2007). 
 
Figure 1.1: Estimated TB incidence rate for 2005. WHO, 2005    
 
 
1.2 Mtb pathogenesis and macrophage interaction 
 
The transmission and perpetuation of the pathogen is both simple and ingenious and 
prove a daunting task to deal with therapeutically. Tuberculosis is an ailment that is 
almost exclusively transmitted by aerosolised droplets containing infectious Mtb by an 
individual’s cough and inhaled by an uninfected person. The primary destination of the 
inhaled bacilli is the alveoli in the lungs, and upon reaching the oxygen exchanging sacs, 
they are engulfed by dendritic cells in the lung interstitium and alveolar macrophages, 
where they replicate (Kaufmann and McMichael, 2005).  
 
Following the initial site of primary infection and replication the pathogen then spreads to 
local lymph nodes within the lung and is ultimately dispersed to remote locations in the 
body, hence, every so often, some patients present with tuberculous meningitis (TBM). 
Furthermore, Mtb has developed the striking ability to establish and maintain latency 
throughout its early stages of infection, and during this period, the disease, is generally 
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asymptomatic, particularly in adults. Although the ost’s immune response manages to 
control the primary infection, the bacterium is in most cases never eradicated. Individuals 
who are at this stage of infection usually do not have clinically apparent tuberculosis but 
nevertheless, harbour the pathogen that only reactivates at a later stage. As a result, 
infected people merely become vectors of Mycobacterium tuberculosis (Kaufmann and 
McMichael, 2005). 
 
It has long been established that alveolar macrophages, the first line of defence in the 
lung, possess antimicrobial activity. When activated by cytokines (figure 1.2), the gamma 
interferon and tumour necrosis factor-alpha, macrophages are capable of generating a 
hostile environment that includes an acidic pH, reactive oxygen intermediates (ROIs), 
lysosomal enzymes and toxic peptides (Keane et al., 1997; Nathan and Hibbs, 1991). In 
addition, reactive nitrogen intermediates (RNIs), generated through a reaction initiated by 
the expression of an inducible nitric oxide synthase (iNOS also called NOS2) contribute 
in producing nitric oxide thereby ensuring an unsustainable environment. Moreover, 
RNIs have been demonstrated to be effective against v rulent mycobacteria in mouse 
macrophages (Miller et al., 2004; Flynn and Chan, 2001).    
 
However, a selection of intracellular pathogens, including mycobacteria, has evolved and 
devised mechanisms to reside in the macrophages while avoiding destruction. Essentially 
three different strategies in use have been observed so far; micro-organisms like 
Leishmania spp. and Coxiella burnetti reside and proliferate in the harsh environment of 
mature phagolysosomes. While Listeria monocytogenes and Shigella spp. avoid delivery 
to phagolysosomes by secreting lytic enzymes that degrade the phagosome membrane 
thus allowing their escape to the nutrient-rich cytoplasm, whereas, pathogens like 
Mycobacterium spp., Toxoplasma gondii, Brucella spp., and the promastigote form of 
Leishamania spp. are capable of inhibiting phagolysosomes biogenesis, consequently 
creating immature compartments lacking the means to kill and degrade pathogens 




In theory, intracellular pathogens capable of utilizing macrophages synthesize molecules 
that allow them to resist the harsh environment of phagolysosomes and Mtb in particular, 
have been shown to display a number of virulent factors which have been implicated in 
their resistance to the sustained attack of toxic molecules produced by their host. Some of 
these molecules, including proteins and thiols serve a critical role in maintaining the 
redox status of the oxidatively active macrophage for the benefit of the pathogen 
(Raynaud et al., 1998; Forman and Torres, 2001; Dermine and Desjardins, 1999). 
 
 
Figure 1.2: Schematic representation of events that take place during tuberculosis infection: M. 
tuberculosis enters the host within inhaled droplets and this, re ults in three possibilities: (i) Elimination of 
the pathogen by the host’s immune system. (ii) Infection quickly develops into tuberculosis. This is not 
uncommon in immuno-compromised individuals, particularly HIV infected patients who stand a chance of 
developing tuberculosis 800-fold times compared to immuno-competent individuals. (iii) Infection does not 
progress into a disease due to the containment of the bacilli in granulomas. In diseased individuals 
however, the M. tuberculosis is no longer in granulomas because caseation (necrotic degradation of bodily 
tissue) results in distribution and consequent transmission of M. tuberculosis. Upon inhalation, the 
mycobacteria are engulfed in alveolar macrophages and dendritic cells (DC). In draining lymph nodes, 
mycobacterial antigens are presented to different T cell populations (CD4+ T cells, CD8+ T cells, and CD 1 
restricted T cells) by the DC’s and macrophages, which are activated by interferon gamma (IFN-γ) and 




1.3 Thiols in intracellular redox reactions 
 
1.3.1 Glutathione (GSH) 
 
The protection of cells from reactive oxygen and nitrogen intermediates has been 
observed to rely on the presence of thiols, which assist in the maintenance of cellular 
redox potentials and protein thiol disulfide ratios. The tripeptide γ-L-glutamyl-L-
cysteinylglycine (glutathione) is the most studied and best characterised thiol that has 
been detected in most Gram-negative bacteria and nearly all eukaryotic organisms, except 
those lacking mitochondria and chloroplast (Hand an Honek, 2005, Fahey, 2001). 
 
In addition to participating in free radical and peroxide detoxification, glutathione 
functions in metabolism, catalysis, transport and as a storage form of cysteine moieties. It 
also forms conjugates with a variety of compounds such as drugs and xenobiotics and is a 
cofactor for a range of enzymes. Synthesis of GSH from constituent amino acids takes 
place intracellularly and exported from cells, where it participates in intra and interorgan 
transfer of cysteine moieties and in the protection of cell membranes (Meister, 1988). A 





Figure 1.3: A comprehensive overview of GSH biochemistry. AA, amino acids; X, compounds that react 
with GSH to form conjugates. GSH synthesis from L-glutamate and L-cysteine is achieved by two 
sequential ATP dependent reactions that utilise γ-glutamylcysteine synthetase (1) to form the intermdiate, 
γ-glutamylcysteine. This is followed by glutathione synthetase (2) that adds glycine to the C-terminal e d 
of γ-glutamylcysteine to form the end product. The transfer of the γ-glutamyl moiety of GSH to an amino 
acid or peptide acceptor is catalyzed by γ-glutamyltranspeptidase (3), resulting in the production 
mercapturates. Cysteine and glycine required in GSH biosynthesis are generated by dipeptidases (4) 
utilizing dipeptides. γ-glutamylcyclotransferase (5) catalyzes the formation of 5-oxoproline which feeds 
onto an ATP dependent 5-oxoprolinase (6) to give glutamate. GSH conjugates to a variety of electrophilic 
ligands through the action of GSH-S-transferase (7) thus accomplishing its detoxification capabilities. 
During oxidizing conditions, GSH is transformed into the disulfide (GSSG). GSH is maintained in its 
reduced form by glutathione disulfide reductase which utilizes NADPH as a cofactor. (12) Enzymes 3→6 
play key roles in the pathway for GSH synthesis, as they generate much required substrates (Meister, 1988; 
Noctor et al., 1998; Board et al., 1978; Mazelis and Creveling, 1978; Telakowski-Hopkins et al, 1986).  





1.3.2 Mycothiol (MSH) 
 
Although different microorganisms may employ a widespread thiol, certain intracellular 
pathogens depend on different antioxidant systems that display a type of chemistry that is 
analogous to that initially observed with glutathione. For instance, apart from GSH and 
ovothiol A (N1-methyl-4-mercaptohistidine), the bis-glutathionyl conjugate of 
spermidine, termed Trypanothione [N1 ,N8-bis(glutathionyl)spermidine] is specific to the 
pathogenic protozoa of the genera Trypanosoma and Leishmania (Ariyanayagam and 
Fairlamb, 2001). Whereas, most Actinomycetes, including Mtb exclusively synthesize 1-
D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amino-2-deoxy-α-D-glucopyranoside (Mycothiol, 
figure 1.4) as their major low molecular mass thiol (Spies and Steenkamp, 1994). 
 
Mycothiol was first isolated as a symmetrical disulfide (MSSM, figure 1.4) from 
Streptomyces sp. AJ 9463 by Sakuda et al., (1994) while searching for an intermediate in 
allosamidin biosynthesis. Shortly thereafter, Mycobacterium bovis (M.bovis) was shown 
to contain the same compound as the only major low molecular mass thiol, isolated as a 
bimane derivative (MSmB) (figure 1.4) (Spies and Steenkamp, 1994). The same structure 
was later reported to be present in Streptomyces clavuligerus designated U17 as a 
previously unidentified thiol, with apparent wide distribution amongst the members of the 





Figure 1.4: Mycothiol (MSH), Mycothiol disulfide (MSSM) and Mycothiol bimane (MSmB). 
 
1.3.3 MSH Biosynthesis 
 
Subsequent to isolating and establishing the structu e of mycothiol (Sakuda et al., 1994; 
Spies and Steenkamp, 1994), studies were carried out to elucidate its biosynthesis (figure 
1.5) using a synthetic 1D-myo-inosityl-2-amino-2-deoxy-α-D-glucopyranoside (GlcN-
Ins) to assay extracts of M. smegmatis for enzyme activity. The study was able to show 
enzyme (ligase, MshC, Rv2130c) activity corresponding to an ATP dependent ligation of 
L-cysteine with GlcN-Ins to generate Cys-GlcN-Ins and an acetyltransferase activity 
(MshD, Rv0819) which produced mycothiol from acetyl-CoA and Cys- GlcN-Ins 
(Bornemann et al., 1997). 
 
To further elaborate on the abovementioned studies, M. smegmatis was confirmed to 
produce GlcN-Ins and Cys-GlcN-Ins as intermediates in the biosynthesis of mycothiol by 
directly measuring their levels in cell extracts (Anderberg et al., 1998). However, earlier 
studies left undefined the biochemical reactions involved in the formation of GlcN-Ins, 
and by comparing the steps already defined for MSH production with those for a 
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glycosylphosphatidylinositol (GPI) anchor production which contains as a component an 
isomer of GlcN-Ins with an α(1,6) linkage it was shown that 1D-myo-inosityl-2-
acetamido-2-deoxy-α-D-glucopyranoside (GlcNAc-Ins) is a precursor for GlcN-Ins by 
demonstrating a deacetylase (MshB, Rv1170) activity using GlcNAc-Ins as a substrate 
(Newton et al., 2000b).   
 
Although the three genes (mshB, mshC, and mshD) involved in the biosynthesis of 
mycothiol had been identified, the biochemical reactions catalyzed by a putative 
glycosyltransferase (MshA) (Newton et al., 2003) had not been established until recently 
when it was shown that the production of GlcNAc-Ins is only possible when the 
participating substrates are UDP-N-acetylglucosamine a d 1L-myo-inositol-1-phosphate 
(1L-Ins-1P). This reaction generates UDP (uridine diphos ate) and 3-phospho-1D-myo-
inosityl-2-acetamido-2-deoxy-α D-glucopyranoside (GlcNAc-Ins-P) where the latter is 
dephosphorylated by a postulated phosphatase, designated MshA2 to yield GlcNAc-Ins 
(Newton et al., 2006a). 1L-Ins-1P can also be produced from exogenous inositol, as 
demonstrated by Gammon et al., (2003) where they illustrated the inhibition of 






















































































































































































The formation of GlcNAc-Ins proceeds through the action of a glycosyltransferase 
(MshA). MshA catalyzes the reaction between UDP-N-acetylglucosamine and 1L-myo-
inositol-1-phosphate to generate GlcNAc-Ins-P. The latter is dephosphorylated by a 
phosphatase (MshA2).  GlcNAc-Ins is then deacetylated by MshB to yield GlcN-Ins 
wherein a cysteine is ligated in an ATP dependent reaction catalyzed by MshC.  
Mycothiol is ultimately produced by the acetylation f the cysteinyl amine of Cys-GlcN-
Ins, catalyzed by an acetyltransferase (MshD). An alternative route for the production of 
1L-Ins-P through the usage of exogenous inositol thatis processed by a postulated 
inositol kinase (InoK). Although this enzyme has not yet been identified in Mtb, the ATP-
dependent reaction it catalyzes in lily pollen and wheat germ using myo-inositol as a 
substrate (Loewus et al., 1982) is also expected to occur in Mtb (Newton et al., 2006a). 
 
Evidence for the existence of a myo-inositol transporter in Mtb was given impetus by 
observing that the putative product of i lT in Bacillus subtitlis exhibits considerable 
similarities with many bacterial sugar transporters. In B. subtitlis, the iolABCDEFGHIJ 
and iolRS operons are known to be involved in inositol utilizat on and their transcription 
is regulated by the IolR repressor  and induced by inositol (Yoshida et al., 2002).  
 
Furthermore, this gene was shown to be the primary inositol transporter in this organism 
since mutants (with inactivated iolT) showed growth defects when grown on inositol as 
the main carbon source (Yoshida et al., 2002). Exploiting the iolT protein sequence to 
search for Mtb orthologs using the blastp search of the TB genome n TubercuList 
(http://tuberculist.epfl.ch), the only strong probable match was found to be Rv3331 that 
was 26% identical in a 432 residue overlap annotated s a probable sugar transport 
intergral membrane protein. A homolog with a 24% identity in a 384 residue overlap was 
also found in M. smegmatis emphasizing that Rv3331 could be the best candidate to 







1.3.4 Mycothiol dependent detoxification 
 
1.3.4.1 NAD/MSH-dependent formaldehyde dehydrogenase 
 
Oxidative demethylation of amino acids or degradation of one carbon compounds like 
methanol, methyl halides, methane, methylated amines a d sulphur compounds is usually 
accompanied by concomitant generation of formaldehy (Ling and Tung, 1948). In 
normal cells, formaldehyde is toxic even at low concentrations due to non-specific 
reactivity with proteins (Fraenkel-Conrat and Mecham, 1948) and nucleic acids. To 
circumvent potential biochemical disturbances, glutathione producing organisms 
eliminate formaldehyde with the aid of a NAD/GSH-dependent formaldehyde 
dehydrogenase whereas Gram-positive bacteria (Amycolatopsis methanolica and 
Rhodococcus erythropolis) contain the factor dependent enzyme termed NAD/MySH-
dependent formaldehyde dehydrogenase (Misset-Smits et al., 1997).  
 
The S-hydroxymethylmycothiol formed by the spontaneous reaction between MSH and 
formaldehyde, is converted into a mycothiol formate ester, which is expected, by analogy 
with the GSH-dependent pathway to be further hydrolyzed to generate formic acid and 
MSH through a thiol esterase as is the case with glutathione based systems. However, 
since no thiol esterase activity has been detected, d spite an esterase motif being present 
in some Mtb gene products an alternative path involving an aldehy e dehydrogenase that 
converts the mycothiol formate ester to a carbonate es r followed by hydrolysis to give 
MSH and CO2 has been suggested. The NAD/MSH-dependent formaldehyde 
dehydrogenase has also been found to be highly specific for its substrate and that it 
cannot be used interchangeably with its GSH counterpart (Misset-Smits et al., 1997; 
Norin et al., 1997). 
 
The NAD/MSH-dependent formaldehyde dehydrogenase ha however, been ruled out as 
an essential detoxification enzyme in Mtb based on the fact that no thiol esterase activity 
had ever been detected since it is assumed that like GSH, MSH reacts spontaneously to 
form S-hydroxymethylmycothiol adduct that is converted to a MSH formate ester 
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(Misset-Smits et al., 1997). Although MSH and GlcN-Ins may not be essential for in vitro 
survival of M. smegmatis, it remains indispensable for Mtb as confirmed by studies where 
the disrupted mshC gene in Mycobacterium tuberculosis Erdman produced no viable 
clones possessing either reduced levels of MSH or the mshC product (Sareen et al., 
2003). 
 
1.3.4.2 Mycothiol S-Conjugate Amidase 
 
Mtb uses a more general mycothiol dependent detoxification pathway that is capable of 
protecting against a range of electrophilic toxins such as alkylating agents, halogens and 
chlorine derivatives. The discovery of this pathway was based on studies that centred on 
the treatment of M. smegmatis with monobromobimane (mBBr) and the cleavage of the 
resultant MSmB to generate GlcN-Ins and the bimane derivative of N-acetylcysteine 
(AcCySmB) (Newton et al., 2000a). The bimane fluorescent label is a derivative of syn-
9,10-dioxabimane: 1,5-diazabicyclo[3.3.0]octa-3,6-diene-2,8-dione that has been 
efficiently used to label the reactive thiol groups in haemoglobin, membrane proteins and 
glutathione of normal human red cells under physiological conditions (Kosower et al., 
1979) 
 
The Mycothiol S-conjugate amidase (Mca) responsible for this cleavage was purified 
from M. smegmatis and comparison of the N-terminal sequence pointed to an Mtb 
ortholog Rv1082. The gene encoding this enzyme was also found to have a homolog 
(mshB, Rv1170) that possesses weak Mca activity but substantial deacetylation activity 
with the biosynthetic precursor (Newton et al., 2000b). The mca gene from Mtb was 
cloned and expressed in E. coli, and found to have substrate specificity similar to that of 
the M. smegmatis amidase. It showed no activity with MSH, GlcNAc-Ins and the 
mycothiol disulfide reductase (to be discussed in detail at a later stage) but rather a 
preference for the MSH moiety of the conjugates, and relatively low specificity with 




In addition to mBBr, conjugates of mycothiol with N-ethylamide (NEM), 7-
diethylamino-3-(4’-maleimidyl-phenyl)-4-methylcoumarin (CPM), cerulenin, 3-(N-
maleimidopropionyl)-biocytin, and rifamycin S, prepared under physiologically relevant 
conditions were shown to be substrates for Mca. Despite the ongoing search for natural 
substrates, MSmB remains the best substrate studied so far with a Km value of 95 ± 8µM 
and a kcat of 8 s
-1 while rifamycin displayed kcat/ km values that were 3-5% of that for 
MSmB (Newton et al., 2000a; Steffek et al., 2003). 
 
The electrophiles used to generate the S-conjugates for the amidase are generally not 
natural toxins except for cerulenin and rifamycin S (Steffek et al., 2003). Cerulenin is a 
secondary metabolite that has antifungal and antibiotic properties (Hata et al., 1960) 
whilst rifamycin S is an antibiotic synthesised by the Gram-positive Nocardia 
mediterranei (White et al., 1974). Studies utilizing these antibiotics substantiate findings 
that Mca could be crucial in the detoxification of antibiotics (figure 1.6), particularly 









































































































Figure 1.6: Mycothiol dependent detoxification 
 
The detoxification pathway (figure 1.6) is based on experiments where M. smegmatis 
grown in the presence of mBBr was found to be void of cellular mycothiol by alkylation 
of the thiol group to form MSmB. Subsequent analysis of the medium did not show any 
MSmB proving that mycothiol bimane was not exported from the cells but was cleaved 
intracellularly by the amidase to produce GlcN-Ins and the AcCys S-conjugate (AcCys-
mB) termed mercapturic acid, as is the case with the final excreted product in the 




Further studies aimed towards a better understanding of the role Mca and MSH play in 
xenobiotic detoxification led to the generation of a mutant of the mca gene in M. 
smegmatis and subsequent exposure to mBBr and the antibiotic rifamycin S. It was 
observed that M. smegmatis accumulated the S-conjugate of the alkylating agents, and 
exhibited susceptibility upon exposure to electrophilic toxins such as iodoacetamide, 
chlorobenzene, and oxidants such as plumbagin and me adione. Subsequent treatment of 
the mutant with the antituberculous antibiotic strep omycin rendered the mycobacterium 
even more susceptible as it led to a 10-fold decrease in the MIC compared to the parent 
strain M. smegmatis mc2 155 (Rawat et al., 2004). Based on these observations, it is 
reasonable to speculate that inhibiting Mca might sensitize M. tuberculosis to antibiotics. 
 
1.4 Mycothiol disulfide reductase 
 
During the process of peroxide reduction mentioned arlier, the formation of 
intramolecular disulfide of mycothiol (MSSM) is unavoidable and the reducing capacity 
of MSH is consequently compromised. It is theoretically possible that MSSM formation 
could undoubtedly deplete MSH pools and compromise the various MSH dependent 
pathways. MSH in M. smegmatis has been shown to be maintained in a highly reduced 
state with redox ratios that range from 200 to 1000 (Newton et al., 2005) through the 
action of a corresponding mycothiol disulfide reductase (Patel and Blanchard, 1999). 
 
Mycothiol disulfide reductase (Mtr) or mycothione rductase as proposed by Patel and 
Blanchard, (1999) belongs to the family of dimeric flavoproteins that promote the 
transfer of electrons between pyridine nucleotides and disulfide/dithiol compounds, and 
direct catalysis via FAD and a redox active disulfide. The “thione” ending is discussed in 
a review by Newton and Fahey, 2002. Some of the most extensively studied enzymes in 
this group include lipoamide dehydrogenase, glutathione reductase, trypanothione 
reductase and mercuric ion reductase (Patel and Blanchard, 1999; Racker, 1965; Shames 
et al., 1986). Although these enzymes may be derived from different sources and exhibit 
strict preferences for substrates, they nonetheless show considerable similarities such as 
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significant amino acid homology and the ability to undergo thiol disulphide exchanges 
(Arscott et al., 1997; Mustacich and Powis, 2000).  
 
The catalytic mechanism of the flavoenzymes have ben thoroughly investigated and 
long established by spectroscopic and kinetic techniques as well as by protein 
crystallography, and Mtr catalysis has been shown to mirror that of other members within 
this family. The reaction generally begins with the flavin reduction by NADPH, the 
reduced flavin then reduces the cysteine disulfide in the active site and the nascent active 
site dithiol ultimately cleaves the disulfide of the substrate (MSSM), where active site 
cysteines sequentially react with MSSM to generate mixed disulfides (MSS-E). The 
active site thiolate then attacks ES-SM to reform the active site disulfide and liberating 
the second molecule of MSH. Ultimately two molecules of MSH are released and the 
cysteine disulfide in the active site is reformed (Krauth-Siegel et al., 1998; Patel and 
Blanchard, 1999; O’Donnell and Williams, 1984). 
 
The sequence of catalytic steps outlined above for Mtr is based on the detection of 
various components usually expected to be part of the flavoenzyme active site. The 
presence of the flavin cofactor was determined by spectral characterization of oxidized 
Mtr that gave the spectrum eg λmax 260-265nm as observed for other flavoproteins 
(disulfide reductases). Reductive titration of Mtr with NADH confirmed the possible 
charge transfer complex of FAD and the putative thiolate of the active site. These results 
together with reductive alkylation and steady state kinetics experiments confirmed a 
kinetic mechanism that is synonymous with the catalytic steps already established for 
flavoenzymes in which the reduced FAD transfers reducing equivalents to the redox 
active disulfide to generate the stable reduced enzyme that is able to reduce MSSM via 





Figure 1.7: NADPH dependent MSSM reduction. NADPH reduced FAD transferring reducing equivalents 
to the disulfide of the active site, which consequently reduces the disulfide of MSSM to produce 2 
molecules of MSH.  This figure is adapted from Patel nd Blanchard, 1999. 
 
In addition to these mechanistic studies, the bioinformatic analysis of the putative Mtr 
amino acid sequence also confirms this enzyme as a member of the pyridine nucleotide 
disulfide reductase family where it shares homology with Crithidia fasciculata 
trypanothione reductase (28%) and human glutathione reductase (31%). A Closer look at 
the amino acid sequence alignment (figure 1.8) further revealed the presence of the 
conserved redox-active cysteines (Cys-XXXX-Cys) and a nucleotide binding motif 





Figure 1.8: Amino acid sequence alignment of C.fasciculata trypanothione reductase, human glutathione 
disulfide reductase and M. tuberculosis mycothiol disulfide reductase. Tyrosine114 and tyrosine197 
involved in the substrate binding site and NADPH binding site respectively seem to be conserved in 
various reductases. However, Y197 in Mtr is substituted with a phenylalanine residue. The essential 
catalytic His-444-Glu-449 ion pair is conserved in the three reductases. The figure is adapted from Patel 
and Blanchard, 1999. 
 
Homology with GSH and trypanothione disulfide reductases (figure 1.8) permitted the 
cloning and expression of the Mtr (Rv2855) in M. smegmatis. The enzyme was reported 
to be a 50kDa homodimer with a kcat for MSSM that is 400 mol per mol of FAD per 
minute, which is one to two orders of magnitude slower than other disulfide reductases 
(Patel and Blanchard, 1999). Due to the slow auto-oxidation rate of MSH as compared to 
that of glutathione, N-acetylcysteine or cysteine (N wton et al., 1995), it was suggested 
that this rate may be sufficient to maintain reduced MSH levels in mycobacteria. The 
Michaelis-Menten constants measured for MSH and NADPH were found to be in 
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agreement with those of the corresponding substrate of GSH and trypanothione 
reductases (Patel and Blanchard, 1999). 
In addition to preference for MSSM, Mtr was also shown to be active against the 
truncated substrate des-myo-inositol mycothiol disulfide (figure 1.9), with a km of 400 
µM as compared to 70 µM for the authentic mycothiol disulfide, indicating an absolute 
requirement for the glucosamine moiety. It was also demonstrated that the presence of the 
des-myo-inositol mycothiol disulfide as a mixture of α and β diastereomers did not affect 
the activity of the enzyme since the mixture was completely converted to des-myo-
inositol mycothiol (Patel and Blanchard, 1998).  
 
 
Figure 1.9: des-myo-inositol mycothiol. Figure adapted from Patel and Blanchard, 1998. 
 
1.5 Mtb essential genes in MSH biosynthetic pathway 
 
Analysis of M. smegmatis mutants disrupted in the four genes encoding the proteins 
needed for MSH biosynthesis have led to conclusions that mycothiol and mycothiol-
dependent enzymes protect the mycobacterial cell against attack from various toxic 
agents and different types of stresses. M. smegmatis mutants deficient in MshB have been 
shown to produce low levels of MSH (about 20%) as compared to the parent strain 
(mc2155), the mutants remained viable and MSH production was never abolished. 
Moreover, they showed resistance to isoniazid whilst they appeared more susceptible 
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when grown in the presence of rifampin. Increased MSH production was restored when 
the mutants were complemented with the mshB gene confirming that the enzyme is 
important for MSH production (Rawat e al., 2003; Buchmeier et al., 2003; Newton et 
al., 2000a).  
 
Contrary to MshB defective mutants, M. smegmatis clones disrupted in mshC were 
unable to produce mycothiol. Moreover, they were also found to possess increased 
susceptibilities to free radicals, alkylating agents and to a wide range of antibiotics such 
as erythromycin, penicillin G, rifamycin, vancomycin, rifampin and azithromycin. 
However, the mutants exhibited resistance to isoniazid nd this is consistent with studies 
involving MshB mutants. MshC has consequently been co sidered essential for the 
growth of M. tuberculosis (Sareen et al., 2003, Rawat et al., 2002), whilst MshB is not 
since its absence in M. tuberculosis and M. smegmatis does not completely eliminate 
mycothiol and growth is not deterred either (Rawat et al., 2003). 
 
To assess the viability of M. smegmatis deficient in mshA, a chemically derived mutant 
and one generated by transposon mutagenesis were treat d with isoniazid and compared 
to the parent strain M. smegmatis mc2155. The MIC’s of isoniazid were found to be 1 
µg/ml for the parent strain and more than 250 µg/ml for each of the mutants. When the 
transposon mutant was complemented with the mshA gene and compared to the chemical 
mutant after treatment with isoniazid, the MIC’s were found to be 2.7 µg/ml and 28 
µg/ml respectively, demonstrating extensive reversion to the parental phenotype. In this 
regard, the mshA gene in M. smegmatis proves to be crucial in MSH biosynthesis. The 
isoniazid resistance observed corroborates previous st dies in which MSH deficient 
strains exhibited isoniazid resistance. It has been postulated that MSH may be directly or 
indirectly involved in the activation of isoniazid (Newton et al., 2003; Koledin et al., 
2002). 
 
The gene encoding the acetyltransferase has also been shown not to be essential in the 
growth of M. tuberculosis since mshD mutants accumulate substantial levels of Cys-
GlcN-Ins, a small amount of MSH and two alternative thiols, N-formyl-Cys-GlcN-Ins 
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and N-succinyl-Cys-GlcN-Ins. The mutant did not exhibit any heightened sensitivity 
upon exposure to hydrogen peroxide, cumene hydroperoxide or tert-butyl hydroperoxide, 
indicating that it most probably relied on one of the alternative thiols (Newton et al., 
2005). 
 
Although Mca is not a biosynthetic enzyme, its role as a detoxifying agent remains 
crucial for the proliferation of Mtb and disruption of mca renders the M. smegmatis 
mutants vulnerable to a wide range of electrophilic toxins, antituberculous antibiotic 
streptomycin and oxidants such as menodione and plumbagin. However, the mutant did 
not show any sensitivity towards hydrogen peroxide, cumene hydrogen peroxide, and 
nitrofurantoin, possibly due to the fact that these oxidants cannot form stable S-
conjugates that may require Mca for cleavage as compared to the naphthoquinones.  
 
There has not been a lot of transposon mutagenesis studies carried out on mtr so as to 
conclusively make phenotypic characterisations of such mutants and resolve the 
enzyme’s indispensability. Nevertheless, findings by McAdam et al., 2002, that showed 
viability of M. tuberculosis mutants generated by transposon mutagenesis in mtr 
suggested the gene to  be non essential, whereas, high density Himar-1 studies carried out 
by Sassetti et al., 2003, demonstrated that m r is required in M. tuberculosis for optimal 
growth. 
 
Taking into consideration the urgent need for new and effective anti-tubercular drugs, 
due to the persistence of the disease, the emergence of multidrug resistant (MDR) strains 
and more recently, extensively drug resistant (XDR) strains (Dorman and Chaisson, 
2007), several enzymes involved in mycothiol biosynthesis and metabolism (table 1.1) 
hold promise for the development of active compounds against the mycobacterium. 
Moreover, according to Sacchettini et al., 2008, ideal TB drug targets should be required 
for bacterial growth and persistence and it must be feasible to temper with their activity 





Table 1.1:  Potential drug targets 
Gene Rv Significance Potential 
mshA Rv0486 Essential for Mtb growth. Drug target 
mshB Rv1170 Inactivation does not fully 
prevent MSH biosynthesis. 
May hold promise if targeted in 
conjunction with other gene products, 
i.e. inhibiting the product of this gene 
together with Mca and one of the other 
essential enzymes. 
mshC Rv2130c Essential for Mtb growth Drug target 
mshD Rv0819 Inactivation does not fully 
prevent MSH biosynthesis. 
Production of alternative 
thiols by the mutant 
Has potential as a drug target 
mca Rv1082 Mutants susceptible to 
electrophilic toxins and 
oxidants 
Drug target 













1.6 Mycothiol analogs 
 
The genes and their respective products outlined in table 1.1 accept substrates and 
produce products that eventually give rise to mycothiol. It is therefore, precisely for this 
reason that compounds based on the GlcN-Ins moiety that bear groups on the nitrogen 
that resemble those of the respective transition state , are seen as potential inhibitors for 
any one of the enzymes involved in the biosynthesis, detoxification and reduction of 
mycothiol (knapp et al., 2002). However, such inhibitor studies are hampered by the 
scarcity of mycothiol. Although MSH can be isolated from whole cells (Spies and 
Steenkamp, 1994), amounts recovered are not sufficient for large scale experiments. A 
subsequent modification of the isolation and purification procedure developed by 
Steenkamp and Vogt, 2004, generates reasonable yields but poses a limitation when 
structural modifications are required and as such, synthetic approaches are a necessity. 
Previous synthetic studies concerning the preparation of a suitably protected D-myo-
inositol, its resolution and the subsequent generation of an α-glycoside were hampered by 
convoluted syntheses (Borneman et al., 1997; Jardine t al., 2002; Nicholas et al., 2002).  
 
Interestingly, Mca has been shown to be active against a mycothiol-S-bimane analogue 
(inositol replaced with S-cyclohexyl) (figure 1.10) exhibiting specific activity of 7500 
nmol min-1 mg protein-1 as compared to 14200 nmol min-1 mg protein-1 for the authentic 
mycothiol-S-bimane (knapp et al., 2002). In addition to the truncated des-myo-inositol 
disulfide (section 1.5), Mtr has recently been shown to be active against the methyl and 
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Figure 1.10: Mycothiol analogs. Structures adapted from knapp et al., 2002 and Stewart e al., 2007. 
 
The enzyme activities exhibited against the mycothiol-S-bimane analogue, the MSSM 
analogs and the truncated des-myo-inositol disulfide leads to a few conclusions with 
regard to the inositol portion of mycothiol: that it may not always be essential for 
substrate recognition by certain MSH processing enzymes, that neither the inositol 
hydroxyls nor the glycosidic linking atom (O vs. S) plays a major role in enzyme binding. 
These observations also suggest that these analogs can provide a platform upon which to 






1.7 Mca and MshB inhibitors 
 
In an attempt to design and optimize potent inhibitors, Nicholas et al., 2002, screened a 
synthetic library comprised of bromotyrosine derivati es alongside a set of related natural 
product inhibitors, isolated from an Australian non-verongid sponge, Oceanapia sp. 
(figure 1.11) (Nicholas et al., 2001). The IC50 values generated from these studies varied 
from 3 µM for compound 1 to 2.7 mM for compound 13 (Nicholas et al., 2002). This 
data, taken together with the fact that compounds 1 to 4 feature a spirocyclic isoxazoline 
core or a reduced bromophenyl oximinoamide functionality as is the case for compounds 
5 and 6, led the authors to several conclusions regarding structure-activity relationships.  
 
In view of the fact that compounds 1 and 6 appeared to be the most effective, whereas, 
compounds 3 and 4 exhibited IC50 values that were comparable to the synthetic set, 
compounds 13 and 14, it was concluded that the potency of compounds 1, 3 and 4 could 
not be attributed to the presence of the spirocycli isoxazoline system since the equally 
inhibitory compounds 6, 13 and 14 comprise the reduc  bromophenyl oximinoamide 
functionality. These observations suggested that the spirocyclic ring system is not 
necessary to achieve good inhibition (Nicholas et al., 2002), and that bromotyrosine 
derivatives containing a Mca specific portion could lay a foundation for a more specific 
and potent inhibition, as illustrated by Metaferia et al, 2007a, through the synthesis of 
MSH-inspired mimicking analogs that centred on the incorporation of a quinic acid 
template to replace the inositol ring of natural MSH (figure 1.11). 
 
Two of the ensuing compounds (14a and 14b) in this synthesis exhibited a 45% inhibition 
at 50 µM.  The reason for using a reduced quinic acid as a surrogate for inositol instead of 
the cyclohexane was that since it has some hydroxyls and is more polar than cyclohexane 
it would be involved in hydrogen bonding. In a different study carried out in our lab 
(Marakalala, M.J. 2008, PhD Thesis) using compounds 35-38 (discussed in chapters 5 
and 6) it was found that the phenyl ring is a better inositol surrogate than all the other six 













































































R1 R2 R3 R4 R5 R6
8 Br H H H F H
9 Br H H CH3 H CH3
10 Br H H H NH2 H
11 F H F H F H
12 F H F H NH2 H
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Figure 1.11: Compounds 1-7 are bromotyrosine derived inhibitors, whereas, compounds 8-14 are a 
synthetic suit. The synthetic compounds 8-9 displayed IC50 values in the range of 60-200 µM. Compounds 
11 and 12 were poor inhibitors. Compounds 15 and 16 are MSH-inspired inhibitors. Compounds 14a and 
14b incorporating a quinic acid ring as an inositol replacement. Structures adapted from Nicholas et al., 
2002 and Metaferia et al, 2007a. 
 
Given that the active sites of Mca and MshB have ben shown to share 42% sequence 
identity (Steffek et al., 2003) based on sequence alignments, Metaferia et al, 2007b 
synthesised spiroisooxazoline-like analogs (figure 1.12) built on the thioglycoside 
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scaffold targeting the two homologous enzymes. Interestingly, the spiroisooxazoline 
containing derivatives proved quite potent in the dual inhibition of Mca and MshB, 
substantiating the notion that inhibitors bearing a portion specific to the enzyme’s active 
site could be very useful against significant enzymes in the MSH biosynthetic pathway. 
n
 
Figure 1.12: Compounds found to inhibit MshB and Mca. The sulfonamides 16 and 18, the 
homophenylalanine trifluoroacetate 20 and the heterocycles 21, 22, 24 and 25 were found to inhibit both 
MshB and Mca. Compound 23 only showed weak inhibition owards Mca whereas, compounds 21, 22 and 







The quinones (figure 1.13) are a heterogeneous group of highly reactive compounds 
found in several natural products and endogenous biochemicals. Over the years, they 
have become indispensable tools as specific metabolic inhibitors in enzyme research and 
as useful drugs in the control of disease (Webb,1966; Bolton, 2006), for instance, 
atovaquone, a substituted 2-hydroxynaphthoquinone is used therapeutically to treat 
Plasmodium falciparum malaria (Kessl et al., 2003). General antimicrobial activities due 
to these compounds had long been established using the simplest substance of this class, 
ρ-benzoquinone and observing its bactericidal actions against a staphylococcus isolate, 
Staphylococcus py. aur (Cooper, 1913). 
 
Even though the antimicrobial nature of quinones had long been postulated, their potent 
biological actions had never been correlated with specific mechanisms. Enzyme 
inhibition has since been shown to be possible through complexes formed between 
quinones and the ion of the enzyme, as illustrated in tyrosinase catalyzed oxidations 
(Arthur and Mclemore, 1955), and that a quinone-quinol system can be generated using 
xanthine oxidase and following the reduction of a quinone by monitoring its oxidation-
reduction potential (Dixon, 1926). In essence, the reduction of a quinone results in the 
oxidation of the enzyme, which is one of a few mechanisms by which quinones can 
inhibit enzymes. This type of inhibition was validated by studies carried out on the 
inactivation of papain by selected oxidants that included a quinone. The subsequent 
inactivation was shown to be reversible by treating he enzyme with hydrogen sulphide 
and other reducing agents (Hellerman and Perkins, 1934).  
 
Oxidation-reduction reactions of quinoid or quinol substances usually involve the 
formation of a semiquinone intermediate, the existence and stability of which depends 
mostly on the pH and nature of the quinone. In some instances, this intermediate had 
been a challenge to isolate as its identification te ded to be colorimetric. It was also 
found to crystallize in cultures of Bacillus chlororaphis without the culture medium 
showing the typical green colour that the intermediate is usually associated with 
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(Michaelis, 1935). Thus the semiquinone, which exists only to a slight extent, seems to be 
the active form in producing certain effects on metabolic processes in that it may be 
reduced to the hydroquinone, oxidized to the quinone, dimerize to form quinhydrone, or 
react with various metabolites (Michaelis and Schubert, 1937). 
 
Since naphthoquinones can form adducts with thiols and that it is possible to discern 
between toxicity that can be ascribed to their redox cycling ability, which results in the 
formation of free radicals, as opposed to toxicity due to such addition reactions, by 
introducing substituents at the sites where thiols would react for example, 2,3-
dimethylnaphthoquinone is used to evaluate the activity of naphthoquinones as redox 
cyclers and does not mop up thiols. This led to the realisation of another type of 
inhibition conferred by quinones involving sulfhydrl groups of enzymes. 
 
The finding was made as a consequence of succinate dehydrogenase inhibition using a 
variety of quinones, including p-benzoquinone and 2-methyl naphthoquinone which were 
shown to decrease toxicity almost tenfold. This decrease in toxicity provided an 
explanation for the absence of clinical toxicity with natural vitamin K. In addition to the 
2-methyl group, vitamin K contains a long side chain t the 3 position thus making any 
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Figure 1.13: Examples of quinones, some of which are used in inhibition studies. Structures adapted from 
Webb, 1966. 
 
1.9 Subversive substrates for Trypanothione reductase 
  
The fact that glutathione disulfide reductase was able to catalyze a NADPH dependent 
electron transfer to 2,4,6-trintrobenzenesulfonate in the presence of oxygen with 
concomitant generation of hydrogen peroxide (Carlberg and Mannervik, 1986), set 
precedence for subsequent studies utilizing trypanothione reductase (TR) and suitably 
substituted naphthoquinone and nitrofuran derivatives. The rationale in using the latter 
derivatives was based on the notion that the semiquinone generated will reduce oxygen to 
superoxide anion radicals whilst regenerating the quinone. This would in turn subvert the 
physiological function of TR by increasing the levels of hydrogen peroxide and 





The study showed consistency with regard to observations made earlier concerning 
inherent enzyme inhibition by quinones. The naphthoquinone (NQ) derivatives tested 
against TR under aerobic conditions were not capable of inactivating the enzyme, 
whereas, the opposite is true when the reaction wascarried out under anaerobic 
conditions utilising the nitrofuran derivatives, causing irreversible inactivation. 
Moreover, in addition to their ability to act as sub trates for TR, the compounds were also 
found to inhibit enzymatic reduction of the physiological substrate, and subsequent 
exposure of Trypanosoma cruzi epimastigotes to these compounds resulted in 
trypanocidal activities (Henderson et al., 1988). 
 
Continuing the development of better and efficient subversive substrates in pursuit of an 
effective trypanocidal compound, Salmon-Chemin et al., 2001, synthesised and tested a 
series of 2-and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates 
targeted against Trypanosoma cruzi trypanothione reductase and lipoamide 
dehydrogenase. Three distinct series of 1,4-naphthoquin nes substituted at C-2 and C-3 
of the quinone moiety by alkylamino side chains of varying lengths were synthesised as 
potential inhibitors of Trypanosoma cruzi TR using menadione, plumbagin and juglone 
as parent molecules (figure 1.13a). NQ derivatives based on plumbagin were found to be 
reduced by Trypanosoma cruzi lipoamide dehydrogenase faster than the corresponding 
menadione derivatives. A derivative based on plumbagin lso proved to be a potent 
subversive substrate and effective uncompetitive inhib tor against trypanothione disulfide 
and NADPH.  
 
In addition to general inhibition, the influence of the spacer length was assessed on the 
inhibition of trypanothione disulfide (TS2) and, interestingly, the highest antiparasitic 
activity within a series of bis 1,4-NQ derivatives was observed with those compounds 






Figure 1.13a: Structure of trypanothione and one of the inhibitors. Structures adapted from Salmon-Chemin 
et al., 2001. 
 
1.10 Subversive substrates for Mtr 
 
Preliminary assessment of some commercial naphthoquin nes, for example, 2,6-
dimethylbenzoquinone, 5-hydroxy-1,4-naphthoquinone, 5,8-hydroxy-1,4-naphthoquinone 
and 2-methyl-1,4-naphthoquinone that have previously been shown to react with various 
flavoproteins was undertaken and their activities vrified using Mtr (Patel and Blanchard, 
1999). A more involved study utilising a series of synthetic and plant derived 
naphthoquinone derivatives based on the 7-methyljuglone parent structure (figure 1.14) 
has recently been completed, and the derivatives were evaluated for antibacterial activity 
against Mtb, as subversive substrates against Mtr and to establish structure-activity 




Figure 1.14: 7-methyljuglone derivatives used as subversive substrates against Mtr. Mahaptra et al., 2007. 
 
Compounds 28, 33 and 34 proved to be the most efficient exhibiting km values that 
ranged between 30 and 60 µM with admirable inhibitory potential, where their MIC’s 
were noted to be 22, 21 and 23 µM respectively. Interestingly, even though compounds 
26, 29, and 30 gave km values in the range of 200-500 µM, their MIC values (6, 3 and 
11µM) were considerably more appealing than all the comp unds tested. The 
discrepancies in km and MIC values of these compounds can be attributed to poor 
selectivities due to their nonspecific activity with other disulfide reductases which are 
also found in cells (Mahaptra et al., 2007), and as mentioned in section 1.8 and illustrated 
by Metaferia et al., 2007a, that inhibitors specific to MSH-biosynthetic enzymes could be 
accomplished through the design of MSH mimicking analogs. The same can also be 






1.11 Overview of the chemistry involved in the synthesis of subversive substrates 
 
Given the substantial homology between glutathione, trypanothione, and mycothiol 
disulfide reductases, and the fact that GSH and trypanothione have been shown to form 
disulfides upon exposure to increased levels of hydrogen peroxide, due to their respective 
enzyme-catalyzed reduction of quinones to semiquinone radicals (Patel and Blanchard, 
1999; Salmon-Chemin et al., 2001), one of the focal points of this project also centres on 
the use of naphthoquinone derivatives against mycothiol disulfide reductase. As 
mentioned earlier (section 1.6), the conspicuous abence of mycothiol and its 
biosynthetic enzymes in humans provides an extremely attractive drug target against M b, 
and Mtr was consequently chosen as an anti-tubercular target. 
 
As illustrated by Knapp et al., 2002, and recently by Metaferia et al., 2007a through their 
synthesis and use of simplified thioglycoside analog active against Mca, we envisaged a 
similar synthetic strategy that makes use of subversi  substrates built upon a thiophenol 
derived scaffold. During the course of this study, Stewart et al., 2007 also published the 
synthesis of a methyl glycoside analog of MSSM (figure 1.10) and demonstrated its 
activity with Mtr. Their study was also able to show that the benzyl portion of this 
MSSM analogue occupies the same site as inositol of the native substrate.  
 
The substitution of the inositol portion with a phenyl group is largely based on the 
difficulties encountered with the synthesis and resolution of the inositol and its alpha 
glycosylation step (Borneman et al., 1997; Jardine t al., 2002; Nicholas et al., 2002). On 
the other hand, thioglycosides have been shown to be rather resistant to degradation by 
glycosidases and also show slower hydrolysis by aqueous mineral acid than the 
corresponding O-glycosides (Knapp et al., 1996; Collins and Ferrier, 1995). Moreover, 
they are easy to prepare and should the need arise,they can act as good leaving groups 
upon complexation with a range of sulphur-specific reagents to form sulphonium cations 





1.12 Preparation of thioglycosides 
 
There are several strategies available for preparing thioglycopyranosides with high stereo 
and regioselectivity, most of which involve treating peracetylated pyranoses with thiols 
such as thiophenol or thioethanol in the presence of Lewis acid such as boron triflouride 
etherate (BF3.Et2O), to give predominantly 1,2-trans products depending on the nature of 
the C-2 neighbouring groups (Herzner et al., 2000). This assertion is well illustrated in 
the formation of the phenyl 1-thio-β-D-galactopyranoside when commercial penta-O-
acetyl-D-galactose is treated with a thiophenol in the presence of BF3.Et2O (Janczuk et 
al., 2002). An alternative method for preparing alkyl and aryl 1-thioglycosides employs 
the use of a thiourea that is reacted with acetylated glycosyl halides to give a 
pseudothiouronium salt that can be hydrolyzed to the desired 1-thio-glycopyranose with 
aqueous potassium carbonate (Bonner and Kahn, 1950;Lindhorst, 2003).   
 
In addition to their stability, thioglycosides are so versatile in that they can be converted 
into a variety of other common glycosyl donors upon exposure to an appropriate 
thiophilic promoter (figure 1.15). It has also been shown that acetylated thioglycosides 
can be deacetylated without degradation (see reviews by Davis, 2000; Demchenko, 
2003), which is another attractive feature, since acyl protecting groups were employed in 













































































Figure 1.15: Generation of a β-D-thioglycopyranoside from penta-O-acetyl-D-glucose, with subsequent 
activation by a wide variety of promoters to different glycosyl donors such as the bromide, imidate, 
fluoride, and the alcohol. This Figure is adapted from Lindhorst, 2003. 
 
1.13 N-protection of amino sugars 
 
One of the requirements for the target subversive substrates was the stringent 
stereoselective synthesis of the α-thioglycoside, as dictated by the α-GlcN-Ins portion of 
mycothiol, and as a result, a choice of a suitable C-2 non-participatory protective group 
had to be carefully selected since glucosamine hydrochloride was chosen as the 
foundation on which to initiate the synthesis. Even though there is a wide variety of 
groups that can be utilized for the N-protection of amino sugars (figure 1.16), most were 
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Figure 1.16: A selection of N-protecting groups. These groups tend to influence the formation of 1,2-trans 
glycosides during glycosylation steps. The phthalimido (Pht) and the N-tetrachlorophthalimido (TCP) 
groups are introduced by treating the free glucosamine with phthalic anhydride and N-tetrachlorophthalic 
anhydride respectively. Whilst TCP groups can be cleaved under mild conditions using ethylenediamine, 
the removal of the Pht group can be a mission that requires rather harsh conditions such as methanol-
hydrazine-hydrate at 100oC (Debenham et al., 1995; Jain et al., 1997). Protection of an amino sugar with a 
dithiasuccinoyl (Dts) group is achieved by treating lucosamine hydrochloride with 
bis(ethoxythiocarbonyl)sulphide in ethanol or S-carbomethyl O-ethyldithiocarbonate in methanol. Cleavage 
of the Dts group is attained by using thiols such as dithiothreitol or other reducing agents (Barany ad 
Merrifield, 1977). The introduction of Allyloxycarbonyl amides as protecting agents is achieved by treating 
the amino sugar with allyloxycarbonyl chloride and triethylamine in THF.  This figure was adapted from 
Lindhorst, 2003. 
 
In instances where C-2 protecting groups are participatory as in acetylated 
glucopyranosides, the glycosylation reaction normally proceeds through the formation of 
an oxocarbonium ion intermediate that when attacked by a nucleophile (e.g. -OH), leads 
to the formation of an orthoester which is eventually isomerised to the β-glycoside (e.g. 
the abovementioned phenyl 1-thio-β-D-galactopyranoside) (figure 1.17). By comparison, 
N-acetylated amino sugars tend to form stable 1,2-oxaz line derivatives which may be 
used as glycosyl donors with unavoidable generation of the 1,2-trans glycosides 

















































Figure 1.17: Glycosidation pathway where the C-2 group is participatory. This figure is adapted from 
Banoub et al., 1992, Lindhorst, 2003. 
 
1.14 2-azido-2-deoxy-3,4,6-tri-O-acetyl-D-glucopyranosyl acetate 
 
To effect the desired 1,2-cis thioglycosides used in th s thesis, azides were selected as 
suitable amino protecting groups due to their non participatory nature, less steric 
hindrances and their lack of hydrogen or carbon nuclei that complicate nuclear magnetic 
resonance (nmr) spectra (Nyffeler et al., 2002). Moreover, azides have been shown to be 
resistant to many reaction conditions and can be easily reduced to the corresponding 
primary amine using either the Staudinger reaction or hydrogen over palladium-on-







In general, there are various methods available for the preparation of azide derivatives, 
the earliest being the one developed by Lemieux and Ratcliffe, 1979, where sodium azide 
and ceric ammonium nitrate (CAN) are used to generate the azido radical that adds to 
glycals to afford 2-azido-2-deoxyglycosylnitrates. However, this method was established 
utilising glycals and generates epimeric mixtures of 2-azido-2-deoxy-1-O-nitropyranoses, 
the ratio of which is dependent on the structure of the glycal starting material.  
 
This is best illustrated by the azidonitration of the galactal in figure 1.18 where the 2-
equatorial product is highly favoured leading to 2-azido-deoxygalactose nitrate (36) 
whereas, the azidonitration of the glucal (37) affords mixtures of 2-azido-2-deoxy-D
gluco and D-manno derivatives (38 and 39). The regioselectivity observed for these 
transformations has been established to be influenced by the steric hindrance of the top 
face of the D-galactal derivative as opposed to that of the D-glucal derivative (Lemieux 
and Ratcliffe, 1979; Paulsen, 1984, Banoub et al., 1992).  
 
The fact that steric hindrances at the top face of the galactal are responsible for the 
observed regioselectivity was also confirmed in studies carried out by Seeberger et al., 
2000, where a series of C-4 and C-6 conformationally constrained glucals was shown to 
selectively furnish C-2 azido-deoxy-D-glucoses over their corresponding D-manno 
isomers when subjected to azidonitration, as shown in table 1.2.  
 
 





Table 1.2: Regioselective synthesis of C-2 azido-deoxy-D-glucoses using glucals constrained at C-4 and 
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The study also found that while the reaction of theac tylated D-glucal furnished the 
desired C-2 azide substituted D-glucose with selectivity over the D-mannose derivative, it 
was in fact the introduction of large protecting groups at C-3 that provided additional 
bulkiness and resulted in increased yields as well as excellent selectivities, as evident in 
the 14:1 and 20:1 ratios of the desired 2-azido-2-deoxy-D-glucose over the manno 
derivative when benzyl and TIPS protecting groups were used respectively (a). 
Surprisingly, the use of the sterically more demanding pivaloyl group exhibited lower 
selectivities (a). Selectivities were slightly lower in cases where benzylidene acetals (b) 
were used as opposed to isopropylidene (1), and increased yields were observed when di-
tert-butylsilane (c) protecting groups were used but exhibited low selectivities when 




The synthesis of 2-azido-2-deoxy-3,4,6-tri-O-acetyl-D-glucopyranosyl acetate was 
consequently adapted from Martin-Lomas et al., 2000; Cavender and Shiner Jr, 1972,  
where the azido moiety is introduced to D-glucosamine via a triflyl azide (TfN3) that is 
generated in a reaction between sodium azide (NaN3) nd trifluoromethanesulfonic 
anhydride (triflic anhydride) to afford the desired 2-azido-2-deoxy glucopyranoside. The 




Figure 1.19: Generation of Phenyl 3,4,6-Tri-O acetyl-2-azido-2-deoxy-1-thio-D glucopyranoside from D-
glucosamine (40). The latter is treated with sodium methoxide and DMAP in methanol and then treated 
with a freshly prepared solution of TfN3 and stirred for 18 hrs at room temperature. Methanol is removed 
under reduced pressure and the resulting residue is dissolved in pyridine and acetic anhydride is added at 
0oC. The mixture is stirred between 0 and 4oC for 10 hours. Flash chromatography gives (41) and treatment 
thereof with thiophenol in the presence of a Lewis acid (BF3.Et2O) generates (42). Crystallization of (42) in 
absolute ethanol gives the α-isomer. 
 
1.15 Aims and objectives 
 
The over-expression of Mtb recombinant proteins in Escherichia coli (E. coli) remains a 
challenge and in some instances poor protein yields are often observed even when 
mycobacterial genes are placed behind strong E. coli promoters. It is suspected that these 
difficulties may be due to differences in the GC contents of the two microorganisms 
where Mtb has been shown to have a GC content of about 70% as opposed to the 50% 
observed in E. coli (Matsuo et al., 1988; Lakey et al., 2000). 
 
This prompted us to (1) attempt the cloning and expression of the gene encodi g 
mycothiol disulfide reductase in Corynebacterium glutamicum (C. glutamicum) utilising 
pEC-XK99E, an E. coli-C. glutamicum shuttle expression vector developed by Kichner 
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and Tauch, 2003. This would be carried out in an attempt to enhance the amount of 
mycothiol disulfide reductase produced. 
(2) To synthesise subversive substrates based on a 1-O-(2-Amino-2-deoxy-α-D-
glucopyranosyl)-D-myo-inositol (GlcN-Ins) scaffold. 
(3) To carry out enzyme kinetic studies using the synthesised subversive substrates. 





Materials and Methods 
 
2.1 Molecular biology methods for cloning the mtr gene 
 
Corynebacterium glutamicum and the pEC-XK99E E. coli-C. glutamicumshuttle 
expression vector were a kind gift from Dr. Andreas Tauch of the Center for 
Biotechnology (CeBiTec) at the Universität Bielefeld, Germany, while the E. coli-
mycobacteria shuttle vector pSD26 was a donation frm Dr W. R. Jacobs (Department of 
Microbiology and Immunology, Albert Einstein College of Medicine) to Professor D.J. 
Steenkamp. Mtb DNA was obtained from Professor van Helden, Division of Medical 
Biochemistry, University of Stellenbosch, South Africa. One Shot® TOP10 chemically 
competent E. coli cells and the Zero Blunt® PCR cloning kit were purchased from 
Invitrogen. Restriction enzymes (Sac I, EcoR I, Kpn I and Xba I along with their buffers) 
and agarose were obtained either from Fermentas or Roche. Pfu DNA polymerase, IPTG 
T4 DNA ligase and the 1 kb DNA ladder were purchased from either Promega or Roche. 
The antibiotics, kanamycin and hygromycin were obtained from Calbiochem and Fluka 
respectively. The MinElute™ Gel Extraction and QiAprep® Spin Miniprep kits were from 
Qiagen, whilst the Wizard® SV Gel and PCR Clean-Up system was purchased from 
Promega. The NUCLEOBOND AX® for large scale purification of plasmids was 
obtained from Macherey-Nagel. Tryptone, yeast extract and agar were purchased either 
from Difco, Biolab, Fluka or Oxoid whilst, Middlebrook 7H9 Broth was exclusively 
obtained from Difco and Tryptic soy broth from Merck. Tween® 80, acetamide, ferric 
ammonium citrate and acrylamide, Acetonitrile E chromasolv®, TFA, Acetonitrile-d6, β-
NADPH, 4,4-dithiopyridine, and 2-bromo-2’-acetonaphthone were obtained from Sigma-
Aldrich. N,N’-methylenebisacrylamide was purchased from Fluka. Ammonium 
persulfate, sodium dodecyl sulphate and TEMED were purchased from BDH. Isoniazid 






2.1.1 Introduction of a His6tag sequence into the vector pEC-XK99E  
 
pEC-XK99E (6 µg) was digested with 20 U of the restriction enzyme Sac1 in the 
presence of a Sure/Cut restriction buffer A, diluted 10X upon addition to the mixture and 
incubated at 37 0C for 16 hours (as recommended by the supplier). The enzyme digest 
mixture was heated at 70 0C for 10 minutes to denature the enzyme and 20 U of the 
restriction enzyme EcoR1 were added and the reaction mixture incubated at 37 0C for a 
further 16 hours (the sequential digestion was done because of the close proximity of the 
restriction sites). The result of the digest was analysed on a 0.8% agarose gel, 
incorporating ethidium bromide and the DNA was visualised using a Fluor Chem 5500 
Imager. The band corresponding to the Sac1-EcoR1 restrict d plasmid was extracted 
from the agarose gel using the Wizard® SV Gel and PCR Clean-Up system or the 
MinElute™ Gel extraction kit, as per manufacturer’s instructions. This procedure was 
used in order to remove the piece that had been excised so it is not ligated back in when 
ligating the His6tag sequence in the gene (section 2.1.2). 
 
2.1.2 Preparation of the His6tag sequence 
 
Two oligonucleotide sequences (designated oligo 1 and the reverse sequence, oligo 2) 
were synthesized to generate Sac1 and EcoR1 recognition s tes upon ligation into the 
pEC-XK9EE,  oligo 1: 5’-ATGAAT TCA GCC ACC ACC ACC ACC ACC ACA GCA 
GCG GCC TGG CGC GCG GCA GCG AGC T-3’ and oligo 2: 3’-GTCG GTG GTG 
GTG GTG GTG GTG TCG TCG CCG GAC CAC GGC GCG CCG TCGC-5’. The 
His6tag and the thrombin are highlighted in red and green respectively. The progression 
of the envisaged process is shown below, starting with the cloning region of pEC-
XK99E. 
          EcoR1           Sac1 
5’-ATGG↓AA TTC GAG CT↓C GGT ACC CGG GGA TCC TCT AGA GTC GAC CTG CAG GCA TG 
C AAG CTT-3’ 
 





Ligation of the His6tag sequence into the cut vector would then reform EcoR1 and Sac1 
restriction sites (figure shown in chapter3)  
 
A nucleotide sequence coding for a His6tag was prepared by mixing 9.8 µg of each of the 
two complimentary oligonucleotides in 100 µl of nuclease free water. The mixture was 
heated to 95 0C for 5 minutes and allowed to cool to facilitate annealing of the 
oligonucleotides, the result being a sticky ended fragment (as shown below, figure 2.1). 
A 2% agarose gel was used to analyse the result of the annealed sequences. 
 
5’-AATTCAGCCACCACCACCACCACCACAGCAGCGGCCTGGTGCCGGGCGGCAGCGAGCT-3’ 
           3’-GTCGCTGGTGGTGGTGGTGGTGT CGTCGCCGGACCAGGCCCGCCGTCG-5’ 
 
Figure 2.1: Expected annealed oligonucleotides  
 
2.1.3 Generation of the pEC-XK99E-his 
 
The ligation of the His6tag sequence to the pEC-XK99E vector (linearized in 2.1.1) was 
performed by mixing 5ng of the His6tag sequence with 50 ng of the vector using 10X 
ligation buffer (1.2 µl) and 2 U of the ligase. The volume of the ligation mixture was 
made up to 12 µl with nuclease free water. The ligation reaction was incubated overnight 
at 4 0C. The reaction was stopped by incubating the ligation mixture at 70 0C for 10 
minutes. Confirmation of the ligation is described in 2.1.5. 
 
2.1.4 Transformation with One Shot® TOP10 competent cells 
 
Top10 competent cells (50 µl vial) were thawed on ice and the ligation reaction (2 µl) was 
added to the cells and incubated on ice for 30 minutes. This was followed by incubation 
at 42 0C for 45 seconds and immediately incubated on ice for 2 minutes. A pre-warmed 
(37 0C) SOC medium (250 µl) was then added and the transformation reaction incubated 
at 370C for 1 hour at 225 rpm in an orbital shaker. The vials with the transformed cells 
were then placed on ice and increasing volumes (typically, 10-100 µl) aseptically plated 
onto LB plates (10 g/l tryptone, 5g/l yeast extract, 5g/l NaCl and15g/l agar, pH 7.5) 
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supplemented with 50 µg/mL kanamycin. The plates were incubated overnight at 37 0C. 
Untransformed Top10 competent cells were used as control. 
 
2.1.5 Confirmation of the pEC-XK99E-his 
 
A total of 7 colonies from the LB plates prepared in section 2.1.4 were inoculated into LB 
media supplemented with 50 µg/mL kanamycin and grown overnight at 37 0C. The cells 
were harvested and the plasmids extracted using a QiAprep® Spin Miniprep kit. The 
resulting plasmids were cleaved with EcoRV and BamH1 and increasing volumes of the 
digest mixture were analysed on a 2% agarose gel. Th  sample that gave rise to a 685 bp 
band was used to transform Top10 competent cells (vector diagram and its characteristics 
are shown and discussed in chapter 3). Single colonies resulting from LB agar plates 
supplemented with kanamycin were grown in LB media and a large scale plasmid 
extraction using NUCLEOBOND AX® was carried out. The modified plasmids were then 
submitted for sequencing to confirm the presence of the His6tag (discussed in detail in 
chapter 3) 
 
2.1.6 Amplification of the mtr gene  
 
The mtr gene was amplified by PCR using 5’-GGTACCCCTACAAATGGAAACG-
3’ and 5’-TCTAGAGTCAACGCAGGCCAAG-3’ as the forward and the reverse primers 
respectively. The primers were synthesised to generate kpn1 and Xba1 recognition sites 
(underlined). The amplification reaction consisted of 76 ng of the template (Mtb DNA), 
400 ng of each primer in 10X pfu buffer, 0.2 mM of each dNTP, 6 U of pfu DNA 
polymerase, and the volume made up to 100 µl with nuclease-free water. PCR was 
carried out using an Eppendorf master cycler gradient with the following temperature 
profile:  
 
denaturation 98 0C for 5 minutes 
denaturation 98 0C for 1 minute, 35 cycles 
annealing 65 0C for 1 minute, 35 cycles 
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extension 72 0C for 2 minutes, 35 cycles 
final extension 72 0C for 10 minutes 
The PCR reaction (5 µl) was analysed on a 1.5% agarose gel 
 
2.1.7 Extraction of the mtr gene from agarose 
 
The agarose gel from section 2.1.6 was re-ran using 20 µl of the PCR reaction mixture 
and the band corresponding to the mtr gene was excised and purified using the 
MinElute™ Gel extraction kit. 
 
2.1.8 Ligation into pCR®-Blunt 
 
The ligation of the blunt ended mtr gene into the pCR®-Blunt vector was performed by 
mixing linearized blunt pCR®-Blunt vector (25 ng) with the blunt ended mtr gene (75 ng) 
in 10X ligation buffer. T4 DNA ligase (4 U) was added to facilitate ligation and the 
reaction volume was made up to 20 µl with nuclease-free water. The ligation reaction was 
incubated overnight at 4 0C. 
 
2.1.9 Transformation of Top 10 competent cells with pCR®-Blunt-mtr 
 
Transformation was essentially carried out as described in section 2.1.4. Twenty colonies 
were selected for growth in LB complemented with kanamycin and subsequent plasmid 
extraction was performed using the QiAprep® Spin Miniprep kit.  
 
2.1.10 Restriction endonuclease digestion of the pCR®-Blunt-mtr 
 
pCR®-Blunt-mtr was digested overnight with 10 U of each of the restriction enzymes 
(fastDigest®kpn1 and fastDigest®Xba1) in the presence of 10X fastDigest® buffer. 
Agarose gel (0.8%) electrophoresis was used to analyse the result of the digest and the 
band corresponding to the mtr gene was excised and purified using the Wizard® SV Gel 




2.1.11 Ligation of the mtr gene into pEC-XK99E-his to generate pEC-XK99E-his-
mtr 
 
The pEC-XK99E-his vector (50 ng) prepared in section 2.1.3 was mixed with the mtr 
DNA (45 ng) in 10X ligation buffer. T4 DNA ligase (2 U) was added and the volume of 
the reaction mixture made up to 14 µl with nuclease-free water. The ligation reaction was 
then incubated at 4 0C for 16 hours. 
 
2.1.12 Transformation of Top 10 competent cells with pEC-XK99E-his-mtr 
 
The ligation mixture (2 µl) was subsequently used to transform Top 10 competent cells 
following the procedure described before. The transformation mixture was aseptically 
plated in increasing volumes (50 µl, 100µl, and 150 µl) onto LB agar plates supplemented 
with kanamycin (50 µg/mL). Also included were the positive and negative controls 
(competent cells transformed with pEC-XK99E-his and competent cells only). Two 
colonies from each plate were inoculated into LB medium supplemented with kanamycin 
(50 µg/mL) and incubated overnight at 37 0C.  
 
2.1.13 Confirmation of the presence of the mtr gene 
 
Plasmid (pEC-XK99E-his-mtr) extraction was achieved through the use of QiAprep® 
Spin Miniprep kits and subjected to a restriction digest using kpn1 and Xba1 (10 U each) 
to confirm the presence of the insert (mtr gene). The digest was analysed by 
electrophoresis on an agarose gel (0.8%). The colony that contained the correct 
recombinant was inoculated into 50 mL of LB medium and after an overnight growth of 







2.1.14 pEC-XK99E-his-mtr electroporation into C. glutamicum 
 
2.1.14.1 Preparation of the EPO medium and LBG plates 
 
The method for growing electroporation-competent C. glutamicum cells was slightly 
modified from van der Rest e al., 1999. Isoniazid (400 mg), glycine (2.5 g), and Tween 
80 (0.1 mL) were dissolved in water (20 mL), filter sterilized and added into autoclaved 
LB medium to make up the EPO medium. Petri dishes containing LBG were poured as a 
mixture containing tryptone (5 g/l), NaCl (5 g/l), yeast extract (2.5 g/l), agar (15 g/l). 
Glucose (2%) was added as a filter sterilized solution immediately before pouring the 
plates. 
 
2.1.14.2 Preparation of competent C. glutamicum cells 
 
A freshly grown colony of C. glutamicum was selected from the Petri dishes, inoculated 
into LB medium (5 mL) and cultivated for 18 hours at 37 0C. The EPO medium (50 mL) 
prepared in section 2.1.14.1 was inoculated with the overnight culture and incubated at 37 
0C to an optical density (OD) of 0.25 at 600 nm. Upon reaching this OD, the temperature 
was lowered to 18 0C and the incubation continued for 28 hours, until the OD was 1. 
 
The culture was chilled on ice for 20 minutes and the cells harvested by centrifugation at 
10 000 g. The cells were washed four times with ice-cold 10% glycerol (50 mL) and 
resuspended in 10% glycerol (0.5 mL). Aliquots (100 µl) were stored frozen at -800C. For 
electroporation the cells were thawed on ice and 3 µl of the pEC-XK99E-his-mtr (section 
2.1.11) was added. 
 
The mixture was transferred to an electroporation cuvette, and the electroporation 
parameters set at 25 µF, 600 Ω and 2.5 kV. LBG (1 mL) was added immediately after 
electroporation, the cells were transferred into an Eppendorf tube and incubated for 6 
minutes at 46 0C This was followed by incubation at 30 0C for 1 hour, after which the 
50 
 
cells were plated on agar containing LBG supplemented with kanamycin (25 µg/mL). 
LBG plates were incubated at 30 0C for 2 days. 
 
2.1.14.3 Confirmation of the presence of pEC-XK99E-his-mtr in C. 
glutamicum cells 
 
Two colonies were inoculated into sterile distilled water (5 µl), and into this, 400 ng of 
the forward and the reverse primer (used in section 2.1.6) in 10X pfu buffer, 0.2 mM of 
each dNTP, and pfu (6 U) DNA polymerase were added. The volume was made up to 
100 µl with sterile distilled water. PCR was carried out as described in section 2.1.6. The 
results of the colony PCR were analyzed on agarose gel (1.5 %). C. glutamicum colonies 
harbouring pEC-XK99E-his-mtr were grown in LB medium, glycerol stocks were 
prepared and stored at -80 0C. Large scale plasmid isolation was also carried out for DNA 
sequencing experiments.  
 
2.1.15 Induction of the mtr gene expression with IPTG 
 
Glycerol stocks of C. glutamicum wild type (control) and C. glutamicum containing pEC-
XK99E-his-mtr and C. glutamicum (wild type) were used to inoculate LBG media 
supplemented with kanamycin (25 µg/mL) and incubated at 30 0C until an OD600nm of 1 
was reached. The culture flasks were then allowed to equilibrate to 25 0C, at which point 
IPTG (1mM) was added for induction of the mtr gene. Expression was attempted at this 
temperature in an orbital shaker at 225 rpm.  
 
A 4 mL aliquot was taken immediately and thereafter at 1 hour intervals up to 4 hours. 
The cell pellets of the aliquots were collected by centrifugation at 10000xg for 10 
minutes. The cells were resuspended in 50 mM Hepes buffer (300 µl) pH 7.6 containing 
EDTA (0.1 mM), protease inhibitors (120 µl), PMSF, TLCK, TPCK, and sonicated 
(using a Branson sonifier 250) for 2 minutes at 30 second intervals on ice at the following 
settings: output level 2.5 at 20% duty cycle and the temperature maintained at 4 0C. The 
sonicated mixture was centrifuged at 10000xg for 10 minutes at 4 0C. The pellets were 
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resuspended in 50 mM Hepes buffer (120 µl) and an equal volume 2X SDS-PAGE 
solubilisation buffer (0.125 M Tris/HCl, 20% (v/v) glycerol, 4% (w/v) SDS, 10% 2-
mercaptoethanol, and 0.2 mg bromophenol blue) was added. The corresponding 
supernatants were treated the same. The samples wer mixed by vortexing and heated at 
70 0C for 3 minutes and each sample (12 µl) analyzed by SDS-PAGE using a  10% 
polyacrylamide gel.  
 
2.1.16 Cloning of the mtr gene without the His6tag to generate pEC-XK99E-
mtr 
 
pEC-XK99E (1.4 µg) was sequentially digested with 10 U of each of the restriction 
enzymes kpn1 and Xba1 in the presence of kpn1 buffer at 37 0C for 16 hours. The 
enzyme digestion mixture was heated at 65 0C for 15 minutes to stop the reaction and the 
result of the digestion was analysed on a 0.8% agarose gel, incorporating ethidium 
bromide. A FluorChem 5500 Imager was used to visuali e the agarose gel. The band 
corresponding to the kpn1-Xba1 restricted plasmid was extracted from the agarose gel 
using the MinElute™ Gel extraction kit, as per manufacturer’s instructions. 
 
The mtr gene was amplified as previously described (section 2.1.6) using the same set of 
primers and PCR conditions. Blunt ligation was carried out as in section 2.1.8, except that 
300 ng of blunt mtr DNA was used. Transformation of the cells with pCR®-Blunt-mtr 
was also carried out as described before except that chemically competent E. coli DH5α 
cells were used instead of Top 10 cells. Transformation into DH5α competent cells was 
carried out as described in section 2.1.4 except that in addition to being supplemented with 
kanamycin, LB agar plates used to obtain colonies contained IPTG (1mM) since DH5α instead of 
TOP10 cells was used, and in such cases IPTG is required for the expression of the ccdB gene 
(discussed in chapter 3). Colonies were inoculated into LB media, grown overnight and the 
QiAprep® Spin Miniprep kit used to extract plasmids containing the blunt mtr gene. 
 
Restriction endonuclease digestion of pCR®-Blunt-mtr and the excision and purification 
of the mtr gene was essentially carried out as in section 2.1.10. Ligation of the mtr gene 
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into pEC-XK99E to generate pEC-XK99E-mtr was based on the procedure used in 
section 2.1.11. Transformation of E. coli DH5α cells with pEC-XK99E-mtr was 
performed as previously described in section 2.1.12 Plasmid extraction from colonies 
grown overnight in LB media containing kanamycin was achieved through the use of 
QiAprep® Spin Miniprep kit and a restriction digest utilizing kpn1 and Xba1 performed 
to confirm the presence of the mtr gene, results of which were analysed on an agarose gel 
(0.8%) stained with ethidium bromide. 
 
Electroporation of pEC-XK99E-mtr into electro-competent C. glutamicum cells was 
performed as described in section 2.1.14.2 and upon lating on LGB agar plates 
supplemented with kanamycin, colony PCR was carried out as a rapid means of verifying 
the presence of the mtr gene within C. glutamicum.  
 
2.1.17 Attempted induction of the mtr gene with IPTG 
 
Induction was carried out as described in section 2.1.15 and C. glutamicum, 
electroporated with pEC-XK99E, was used as a control. 
 
2.1.18 Preparation of mycothiol disulfide (MSSM) 
 
2.1.18.1 M. smegmatis culture 
 
M. smegmatis was cultured as described in Bornemann et al., 1997 and harvested in the 










2.1.18.2 Mycothiol isolation from M. smegmatis 
 
Mycothiol was isolated from M. smegmatis essentially as described by Steenkamp and 
Vogt, 2004. Packed cells (114g wet weight) were resuspended in 200 mL of a 1:1 
mixture (v/v) of acetontrile and perchloric acid (0.75 M) containing EDTA (2 mM). The 
cells were disrupted by sonication at 4 °C at the following settings: output control of 8, 
duty cycle of 30, and timer set at 10 minutes.  
 
The mixture was clarified by centrifugation at 1000 g for 10 minutes. The supernatant 
was adjusted to pH 4.8 by addition of solid K2CO3 and the resulting precipitate 
(potassium perchlorate) removed by centrifugation. The mycobacterial extract contained 
440 µmoles thiols and was then added dropwise with stirring to the reagent, 2-S-(2’-
thiopyridyl)-6-hydroxynaphthyldisulfide (880 µmoles), prepared beforehand as described 
by Steenkamp and Vogt, 2004. The reaction was incubated overnight at room 
temperature and the formation of S-2-(mycothiolyl)-6-hydroxynaphthyldisulfide was 
monitored using a Luna 5µ C-18 analytical HPLC column (250 x 4.6mm) under the
optimised conditions in table 2.1. The UV detector was set at 230nm and the flow rate at 
0.8 mL/min. 
 
Thiols were generally estimated by adding 20 µl of a sample to 970 µl of 25 mM K2HPO4 
buffer, pH 8.0, followed by the addition of 10 µl of 20 mM 4,4-dithiodipyridyl (dTdP). 
The absorbance was measured at 325 nm. 
 
Table 2.1:  HPLC conditions for monitoring the formation of S-2-(mycothiolyl)-6- 
 hydroxynaphthyldisulfide 
Time (min) 0 5 35 40 45 
TFA (0.1%) A 95% 95% 10% 10% 95% 
CH3CN           B 5% 5% 90% 90% 5% 
 
The mixture was then diluted five fold with water and passed through SepPak C18 
cartridges. The cartridges were washed with water and the S-2(mycothiolyl)-6-
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hydroxynaphthyldisulfide was eluted using 50% acetonitrile/water (v/v). The acetonitrile 
was removed by passing air, and the solution subsequently chromatographed isocratically 
using 25% buffer A (CH3CN) and 75% buffer B (0.1% TFA) on a Vydac C18 preparative 
column. 
 
Fractions containing S-2(mycothiolyl)-6-hydroxynaphthyldisulfide were lyophilised 
overnight and the resultant dry material dissolved in 3 mL of 25 mM sodium phosphate 
buffer (pH 8.7). The S-2(mycothiolyl)-6-hydroxynaphthyldisulfide mixture was then 
reduced with 25mg/mL NaBH4 (350 µl) and separated on an HPLC Vydac 218TP1022 
reversed phase preparative column. The separation was achieved using a method which 
starts with 100% buffer A (0.1% TFA) until 10 minutes, followed by the gradient from 
0% to 50% B (100% (CH3CN) until 55 min and then back to 100% A at 60 minutes. The 
MSH fractions were pooled, the pH converted to 8 with triethylamine and thereafter 
treated with diamide (12 µmol) for 15 minutes. The MSSM generated was separated from 
the excess diamide on a preparative Vydac C18 column. The acetonitrile was removed by 
passing air and the samples stored at -20 0C. 
 
2.1.19 Mycothiol isolation and confirmation of the presence of mycothiol in 
C. glutamicum 
 
C. glutamicum packed cells (74g) were resuspended in 222 mL of a 1:1 mixture (v/v) of 
acetontrile and perchloric acid (0.375 M) containing EDTA (2 mM). The cells were 
disrupted by sonication at the following settings: output control of 8, duty cycle of 30, 
and timer set at 10 minutes. The resulting homogenous suspension was clarified by 
centrifugation at 10000 g for 10 minutes. The supernatant was adjusted to pH 4.8 by 
addition of solid K2CO3 and the resulting potassium perchlorate precipitate removed by 
centrifugation at 10000 g for 10 minutes. The pH of the C. glutamicum thiol extract (116 
µmoles) was then adjusted to 7.6 and treated with 2-bromo-2’-acetonaphthone (BAN) 




The formation of mycothiol-2’-acetonaphthone (MSH-BAN) was monitored by HPLC 
using a Phenomenex Phenyl-Hexyl column (250 x 4.6 mm) under the optimised 
conditions in table 2.2. The UV detector was set at 248nm and the flow rate at 0.8 
mL/min. Collected fractions were verified to be BAN derivatives by monitoring 
absorbance at 248, 300 and 350 nm using the OceanOptics USB2000 spectrophotometer.  
 
Table 2.2: HPLC conditions for monitoring the formation of MSH-BAN 
Time (min) 0 5 30 33 35 37 
TFA (0.1%) A 90% 75% 65% 10% 10% 90% 
CH3CN           B 10% 25% 35% 90% 90% 10% 
 
The MSH-BAN extract was diluted with water to decreas  the acetonitrile content to 15% 
and loaded onto a column packed with a Vydac C18 resin. The column was initially 
washed with 2 bed volumes of water until the colour f the eluent changed from yellow 
to clear. The column was then eluted with 50% acetonitrile and the fractions confirmed to 
be BAN derivatives by checking absorbance at 248, 300 and 350 nm. Fractions showing 
a BAN spectrum and absorbing at 248 nm were pooled and purified by HPLC on a 
preparative Phenomenex Phenyl Hexyl column (21.8 x 250 mm) using conditions in table 
2.3 at a flow rate of 4 mL/min. 
 
Table 2.3: HPLC conditions for the separation of MSH-BAN from excess BAN 
Time (min) 0 5 30 33 35 37 40 
TFA (0.1%) A 90% 72% 65% 65% 10% 10% 90% 
CH3CN           B 10% 28% 35% 35% 90% 90% 10% 
 
Fractions eluting at 15 minutes that exhibited a BAN spectrum were pooled and the 
acetonitrile removed by bubbling air for 16 hours. The solution was subsequently 
lyophilised, dissolved in acetonitrile-d6 and submitted for 
1H, 13C, 2-D NMR (COSY and 






2.1.20 Assays for activity 
 
Samples taken during induction of the mtr gene with IPTG (sections 2.1.15 and 2.1.17) 
were assayed for enzyme activity using a continuous spectrophotometric assay at 30 0C.
The absorbance change at 340 nm was recorded by means of n OceanOptics USB2000 
spectrophotometer, and the standard assay consisted of Tris/HCl (44.5 mM) pH 7.6, 152 
µM NADPH, and MSSM (7.5 µM). Protein concentration was determined by the Bio-
Rad protein micro-assay procedure according to the manufacturer’s instruction, using 
bovine serum albumin as standard. 
 
2.1.21 Induction of the mtr gene with acetamide (pSD26-mtr) 
 
Three different media Issabelle (Issabelle, et al., 2003), Middlebrook, tryptone and yeast 
extract enriched Middlebrook supplemented with hygromycin (100 µg/mL) were 
prepared and inoculated with pSD26-mtr glycerol stocks (prepared in our lab by Dr M.J. 
Williams). Expression of the mtr was induced at 37 0C (OD600 = 1) by adding acetamide 
(0.2%), the liquid cultures were allowed to incubate for 16 hours at this temperature.  
 
2.1.22 Sonication and Assays for activity 
 
Sonication of M. smegmatis cells and electrophoresis (10% SDS PAGE gel) of the 
soluble fraction were performed as previously described for C. glutamicum in section 
2.1.15 except that the 50 mM Hepes buffer pH 7.6 containing EDTA (0.1 mM) used for 
re-suspension of the cells contained a protease inhibitor cocktail (Roche). Assays for 
activity were carried out essentially as described in section 2.1.20 except that 37.8 µM 2-








2.1.23 Acetamide concentration dependant induction 
 
Induction of the mtr gene at 37 0C with acetamide (0.1%, 0.2%, and 0.3%, in Issabelle, 
LB and Middlebrook media) was carried out as in section 2.1.21. Aliquots (5 mL) taken 
at 15, 30 and 45 hrs were centrifuged at 10000xg for 10 minutes, pellets were 
resuspended in 50 mM Hepes buffer pH 7.6 containing EDTA (0.1 mM) and a protease 
inhibitor cocktail (complete protease inhibitor cocktail, Roche). The cell suspensions 
were sonicated on ice and aliquots analyzed by SDS-PAGE (10 %) as in section 2.1.15.  
 
2.1.24 Acetamide concentration dependant induction at 20 0C 
 
Induction and sampling was carried out as in section 2.1.15, except that acetamide and 
M.smegamatis (as an expression host) were used instead of IPTG and C. glutamicum. 
SDS-PAGE analysis was performed as described in section 2.1.15. 
 
2.2 MSSnaph as an alternative substrate for Mtr and its kinetic parameters 
 
The ability of Mtr to utilise MSSnaph as a substrate was determined as in section 2.1.20, 
except that MSSnaph (10-55 µM) was used instead of MSSM.  
 
2.2.1 Reduction of 35-38 (Discussed in chapters 5 and 6) by Mtr 
 
The capability of Mtr to reduce 35-38 was determined by monitoring the oxidation of 
NADPH at 340 nm. The reaction mixture contained, in a final volume of 1 mL: 50 mM 
Tris/HCl (pH 7.6), NADPH (0.11 µmoles), and 35-38 (40 µM) at 30 0C. The reaction was 
started by adding Mtr (48 nM). Stock solutions of 35-38 were prepared in DMSO. 
 
2.2.3 Evaluation of 35-38 as substrates or inhibitors of Mtr 
 
Compounds 35-38 (40 µM) were incubated at 30 0C with Mtr (6 nM) and NADPH (0.11 
µmoles) in 50 µmoles Tris/HCl (pH 7.6) in a total volume of 1 mL and the reaction 
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initiated by adding MSSnaph (24.9 µM). The reaction was followed by monitoring the 
oxidation of NADPH at 340 nm.  
 
2.2.4 Anti-mycobacterial activities of 35-38 
 
In vitro anti-mycobacterial activities of 35-38 were assayed by the BACTEC system at 
the University of Stellenbosch, South Africa, following a procedure by Heifts and Good, 
1994. 
 
2.2.5 Evaluation of O-linked glycosides and bi-cyclic thioglycosides as inhibitors 
for Mtr 
 
Evaluation of O-linked glycosides and bi-cyclic thioglycosides as Mtr inhibitors was 
carried out as described in 2.2.3, except that SPh 2 to SPh 7 and Th 1 to Th 7 (structures 
shown in chapter 6) were used instead of 35-38. Both sets of compounds were evaluated 
at 500 uM. 
 
2.2.6 Preparation of INH-NAD and INH-NADP adducts 
 
The synthesis of INH adducts was carried out as described by Ducasse-Cabanot et al., 
2004). Briefly, 2mM INH, 2mM NAD+ and 4mM MnIII -PyrPh in 100 mM sodium 
phosphate buffer, pH7, were incubated for 20 min at room temperature to generate INH-
NAD. The INH-NADP adduct was prepared in exactly the same way except that NAD+ 
was replaced with NADP+. 
 
2.2.7 Purification of INH-NAD adduct mixture 
 
The pool of INH-NAD(P) adducts was separated from the contaminants by 
chromatography on Sep-Pak reversed phase C18 cartridges. The cartridge was 
equilibrated with an aqueous solution of ammonium acet te (75 mM) after an extensive 
wash with CH3CN. After the reaction mixture was loaded onto the S p-Pak C18 
cartridges, the elution of the contaminants by ammonium acetate (75 mM) was monitored 
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by measurement of the OD at 260 nm. The elution of the adduct mixture by water was 
monitored by measuring the OD at 326 nm.  
 
2.2.8 Preparation of MnIII -PyrPh 
 
MnIII -PyrPh was prepared as essentially described by Nguyen et al., 2001. Briefly, An 
aqueous solution of sodium pyrophosphate (200 mM) containing MnIII (OAc)3 (5mM) was 
acidified to pH 4.5 with phosphoric acid and stirred for 24 hrs at room temperature to 
produce red complex [MnII(H2P2O7)3]Na3. 
 
2.2.9 Mtr inhibition by INH-NAD(P) adduct mixture  
 
Inhibition of Mtr was carried out by incubating various concentrations of the INH-
NAD(P) adduct mixture (2 µM-10 µM) with MSSnaph (24.9 µM) and NADH (0.105 
µmoles) in 50 mM Tris/HCl (pH 7.6) at 30 0C.  The total reaction volume was 1 mL and 
the reaction was initiated by adding Mtr (6 nM). MSSnaph was usually dissolved in 50% 
acetonitrile since it is not sufficiently soluble in water. The concentration of Mtr used in 
all the inhibition studies was measured in terms of its FAD content (at an absorbance of 
450 nm using a molar extinction coefficient of 11300 M-1.cm-1).   
 
2.2.10 Generation of MSSM from MSSnaph 
 
MSSnaph (4 mg) was dissolved in 40 % acetonitrile (4 mL), TEA was then added to raise 
the pH to 8. Acetonitrile was then removed by passing a stream of nitrogen and 
dithiothreitol (DTT) (0.003 M) added. The solution was then acidified to pH 3 with TFA 
and purified on HPLC using a Phenomenex Phenyl-Hexyl preparative column (21.8 X 
250mm). The pH of the recovered fractions was then raised to 8 and the fractions left 
overnight to oxidise. For quantification purposes, ach fraction (20 µl) was treated with 
sodium borohydride (0.35 M) and incubated at 30 0C for 30 minutes after which the pH 
was lowered to 5 with 1 M acetic acid. Then dTdP (0.4 mM) was added to the 20 µl of 
the borohydride reduced fractions and the absorbance measured at 325 nm. To estimate 




Results and Discussion 
Cloning of the mtr gene and attempted expression 
 
3.1 Cloning of the mtr gene in pEC-XK99E 
 
The aim of this section was to clone the Mtb mtr gene into pEC-XK99E, an E.coli- C. 
glutamicum shuttle expression vector that is based on the mediu  copy number plasmid 
pGA1 and on a Ptrc promoter (Kirchner and Tauch, 2003). C glutamicum is a Gram-
positive soil bacterium that is extensively used in the fermentative production of amino 
acids such as L-valine, L-isoleucine, L-threonine, and L-glutamic acid. As such, the 
biotechnological importance displayed by this organism has led to significant 
improvements in its bioprocess as well as its molecular biology, which also make it an 
attractive vehicle with which to attempt protein expression (Hermann, 2003). 
 
The rationale behind the utilisation of C. glutamicum as an expression system was based 
on the fact that Mtb genes need relevant transcriptional and translation l machinery 
required to produce target proteins, and difficulties n over-expressing Mtb genes in well 
characterized host cells such as E.coli has led to the use of bacteria that are 
phylogenetically related to mycobacteria (Lakey et al., 2000). In addition, this expression 
system was utilised to see whether enhanced expression of Mtr could be obtained in C. 
glutamicum, since expression of Mtr using M. smegmatis and a heat shock promoter 
resulted in a recovery of only 3mg Mtr per liter of culture medium (Patel and Blanchard, 
1999). 
 
Since pEC-XK99E is not His6tagged, the first step towards the cloning of the mtr gene 






3.1.2 pEC-XK99E-his generation 
 
The hybridized oligomers (with Sac1 and EcoR1 restriction sites) coding for the His6-tag 
were cloned into pEC-XK99E (figure 3) digested with Sac1 and EcoR1. The ligation 
mixture was used to transform TOP10 competent cells and the positive clones were 
identified by restriction endonuclease digestion.  
 
 
Figure 3.0: pEC-XK99E developed for genetic engineeri g in C. glutamicum is based on the medium copy 
number pGA1, lacIq gene and on a Ptrc promoter. The vector map shows a multiple cloning site for cloning 
of PCR products and it also carries the kanamycin resistance gene aph(3’)-lla as a selectable marker. This 
figure was taken from Kirchner and Tauch, 2003. 
 
It was therefore, decided that since the restriction sites were close together it would be 
better to carry out sequential digestion. In view of the fact that Sac1 cannot be heat 
inactivated, as opposed to EcoR1, Sac1 was used first and the digestion carried out for 16 
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hours. The digestion mixture was then incubated at 75 0C for 30 min to inactivate EcoR1 
and left to cool for 30 min. An aliquot (2µl) was put aside for agarose gel analysis, EcoR1 
was then added to the remainder of the mixture and incubated at 37 0C for a further 16 
hrs, after which an aliquot was taken for analysis by agarose gel electrophoresis. 
 
Because the EcoR1 and Sac1 restriction sites were in close proximity it was not possible 
to ascertain whether both cleavage events or only a single one had occurred on the basis 
of a shift in mobility as determined by agarose gel el ctrophoresis. The gel bands were 
therefore excised, the DNA extracted using the Wizard® SV gel and PCR clean up system 
and ligation of the His6-tag insert was continued.  
 
The ligation reaction typically used an excess of the insert in a 1:3 vector:insert ratio, so 
as to increase the success of the ligation. The ligation reaction was used to transform 
TOP10 competent cells and the transformed cells were grown for 1 hour in SOC medium 
and were then plated on LB plates supplemented with kanamycin. 
 
3.1.3 Plasmid DNA preparations 
 
Individual colonies were selected and grown overnight at 37 0C in LB liquid medium 
supplemented with kanamycin, and the plasmids isolated using a QiAprep® Spin 
Miniprep kit. The presence of the recombinant pEC-XK99E-his was confirmed by 
digesting the vector with EcoRV and BamH1; as a control pEC-XK99E was digested 
with the same enzymes. 
 
The rationale behind this was that digestion of pEC-XK99E without the insert with these 
two restriction enzymes would result in excision of a 627 bp fragment while the His6-
tagged plasmid would give rise to a fragment that is 36bp larger, i.e. 663 bp when 
analysed on an agarose gel. It was therefore, decided to run increasing volumes on a 2% 
agarose gel. The bands observed suggested that the cloning was successful and a large 
scale plasmid isolation was carried out using a NUCLEOBOND AX® kit and submitted 
for sequencing. Although the original pEC-XK99E was not sequenced, figure 3.1 shows 
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part of the sequencing data of the modified region and contrasted with the original 
portion of the vector map of the cloning region as published in Pubmed (shown below 
figure 3.1). The complete original pEC-Xk99E sequence is shown in appendix 1B, which 
shows the promoter region to be between the TATA box and the ATG, where the A of 
ATG is actually residue 7016 at the end of the vector. I  is this ATG that was planned to 
be used for the initiation codon rather than the on at the start of the mtr gene sequence. 
 
 
Figure 3.1: Sequencing data showing the cloning of the His6tag sequence (bases 20-38) and the thrombin 
region (bases 47-64) regions into pEC-XK99E.  The plasmid is henceforth called pEC-KX99E-his.  
 
ctcgtataat gtgtggaatt gtgagcggat aacaatttca cacaggaaac agaccatg gaattcgagc 
tcggtacccg gggatcctct agagtcgacc tgcaggcatg caagcttggc 
 
 
5’-ATG G AAT TCA GCC ACC ACC ACC ACC ACC ACA GCA GCG GCC TGG CGC  
 
GCG GCA GCG AGC TC GGT ACC CGG GGA TCC TCT AGA GTC GAC CTG  
 
CAG GCA TG C AAG CTT-3’ 
Figure 3.1.1: Modified cloning region of pEC-XK99E. The region beyond the Sac1 restriction site was not 
tampered with and maintained as in figure 3 (multiple cloning site). The His6tag is shown in red, whereas 
















3.1.4 Amplification of the mtr gene 
 
The PCR reaction (section 2.1.6) utilised pfu which generates a blunt ended PCR product, 
and upon running an agarose gel, it was discovered that the amplification process was not 
as specific as it was intended as the gel showed two more bands. The band corresponding 
to the mtr gene was therefore excised and the DNA extracted and purified using the 
MinElute™ Gel Extraction and QiAprep® Spin Miniprep kit. The amplified mtr gene is 




Figure 3.2: Amplified mtr gene analysed on a 0.8% agarose gel. Lane 1, 1Kb ladder; lane 2 PCR reaction. 
DNA was visualised by ethidium bromide.  
 
3.1.5 Ligation into PCR blunt 
 
The ligation of the blunt mtr gene fragment into pCR-Blunt was performed according to 
the manufacturer’s instructions and as described in section 2.1.8. A useful feature of 
pCR®-Blunt is the presence of the lethal gene ccdB that promotes the ease and direct 
selection of positive recombinants. Expression of the lacZα-ccdB gene fusion protein is 
mtr 1380 bp 
1650 bp 
1000 bp 
       1         2          
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toxic to the cells, as a result, upon transformation, cells that contain a pCR®-Blunt with a 
functional ccdB gene are not viable whereas, successful ligation of a blunt pcr product 
disrupts the ccdB gene and consequent expression of the lacZα-ccdB gene fusion protein 
(Invitrogen manual catalogue numbers K2700, K2700-4).  
 
3.1.6 Transformation of TOP10 competent cells with PCRBlunt-mtr 
 
The transformed cells were grown at 37 0C for 1 hour in SOC medium and plated on LB 
plates supplemented with kanamycin. Twenty colonies w re inoculated into 50 mL of LB 
medium containing kanamycin and cultured for 16 hrs subsequent to plasmid isolation, 
the pCR®-Blunt containing the mtr gene pcr product was cleaved with kpn1 and Xba1 for 
16 hrs. All the colonies processed contained the plasmid. The digestion mixture was run 
on an agarose gel (0.8%). The band corresponding to the mtr gene (figure 3.3) was 




Figure 3.3 Restriction digests of PCRBlunt-m r and pEC-XK99E-his. Lane 1, 1kb ladder, lane 2: pEC-XK99E-his cut 
with Kpn1 and Xba1, lane 3: uncut pEC-XK99E-his, lane 4: Incompletely cut pEC-XK99E, lane 5: PCRBlunt-mtr cut 










   1           2           3           4         5    
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3.1.7 Ligation of the mtr gene into pEC-XK99E-his 
 
The mtr gene with kpn1 and Xba1 restriction ends was ligated, using a 3:1 insert:vector 
ratio, into pEC-XK99E-his that had been digested with the same enzymes at 4 0C for 16 
hrs. 
 
3.1.8 Transformation of TOP10 competent cells 
 
TOP10 competent cells were transformed with the ligation mixture (section 3.3.6) and 
increasing volumes of the transformation reaction plated on LB plates supplemented with 
kanamycin. Two colonies from each plate were inoculated into LB media containing 
kanamycin and plasmids isolated. Restriction digeston was carried out using kpn1 and 
Xba1 for 3 hrs followed by analysis on an agarose gel. DNA isolation was carried out 
from a total of 8 colonies (figure 3.4.1). Lanes 5, 9, 10, 11, & 12 were sent for 
sequencing and only 9 gave the desired result. Sequencing results confirmed the presence 
of the mtr gene through a blast search from the NCBI database and are shown in figures 




Figure 3.4.1: Restriction digests of plasmid DNA extracts. Analysis was carried out on a 0.8% agarose visualised 






mtr, 1380 bp  
1650 bp 
1000 bp 
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 Features in this part of subject sequence: 
   NADPH-dependent mycothiol reductase mtr gene 
 
 Score = 1127 bits (610), Expect = 0.0 
 Identities = 610/610 (100%), Gaps = 0/610 (0%) 
 Strand=Plus/Minus 
 












































Figure 3.4.2: Blast search of the mtr gene sequence performed in the NCBI database indicate  that the 
experimental nucleotide sequence had 100% similarity w h M. tuberculosis H37Rv mycothiol disulfide 
reductase. The result with the forward primer start with the start codon in the 10th position.  Sequencing 











Features in this part of subject sequence: 
   NADPH-dependent mycothiol reductase mtr 
 
 Score = 1382 bits (748), Expect = 0.0 
 Identities = 748/748 (100%), Gaps = 0/748 (0%) 
 Strand=Plus/Plus 
 





















































Figure 3.4.2.1: Blast search of the mtr gene sequence performed in the NCBI database indicate  that the 
nucleotide sequence had 100% similarity with M. tuberculosis H37Rv mycothiol disulfide reductase. The 
result with the reverse primer is for the non-coding strand and starts with the stop codon at 5’. Sequencing 




3.1.9 C. glutamicum electroporation with pEC-XK99E-his-mtr 
 
The colony that gave rise to PEC-XK99E-mtr-his (lane 9, figure 3.4) was grown in LB 
medium, a large scale plasmid isolation carried out and electroporated into competent C. 
glutamicum cells. After electroporation and heat shock, the transformation mixture was 
plated on LBG agar plates containing kanamycin and incubated at 30 0C for 2 days. As a 
rapid verification, colony PCR was carried out to confirm positive recombinants (figure 
3.5). Although the control of WT C. glutamicum was not run, the evidence that the vector 
contained the mtr gene rested mainly on lane 4. 
 
 
Figure 3.5: Agarose gel (0.8%) visualised by Ethidium bromide showing the result of a colony PCR carried 
out as a rapid confirmation of the pEC-XK99E-mtr-his in C. glutamicum. Lane 1, 1kb ladder, lane 2, TOP 
10 cells transformed with pEC-XK99E, lane 3, TOP 10 cells transformed with pEC-XK99E-his, lane 4, 














3.1.10 Induction of pEC-XK99E-mtr-his 
 
C. glutamicum electroporated with pEC-XK99E-mtr-his was grown at 30 0C in LB 
medium (500 mL) containing kanamycin until OD600 was 1. IPTG (1mM) was then added 
and the flasks transferred to 25 0C. SDS PAGE (figure 3.6) analysis of the samples did 
not show a band corresponding to Mtr (50 kDa band), this is despite the fact that the 
sequencing results indicated the mtr gene to be in-frame and that the plasmid is meant to 
ensure tight control of protein expression, since the insert is placed under the regulation 
of a strong E.coli promoter (Ptrc). 
 
Activity assays using MSSM as a substrate and C. glutamicum crude extracts also 
suggested that there was no expression of Mtr in act ve form. This is surprising since C. 




Figure 3.6: Attempted time course induction of the mtr gene in C. glutamicum. Lane 1, molecular weight 
markers, lanes 2 and 3 (pellet and its supernatant) uninduced. Lanes 4-11 pellets and their respective 
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Attempting induction at 18 0C using IPTG concentrations ranging from 0.8 mM to 2 mM 
resulted in more or less the same result as in figure 3.8. It has been noted however, that 
certain C. glutamicum strains possess very strong restriction systems that efficiently 
degrade foreign DNA or DNA with a foreign methylation pattern (Liebl et al., 1989).  
 
It was also suspected that the His6-tag could be interfering with the folding of the protein, 
and it was consequently undertaken to clone and express the mtr gene without the His6-
tag. A fresh PCR product of the mtr gene was prepared and cloned into the pCR®-Blunt 
as described previously. 
 
3.1.11 Generation of pEC-XK99E-mtr 
 
The pCR®-Blunt containing the mtr gene PCR product was cleaved with kpn1 and Xba1 
for 16 hrs (figure 3.7), the band corresponding to the mtr gene excised and the DNA 




Figure 3.7: Restriction digests of plasmid DNA extrac s. Lane 1, 1 kb ladder, lanes 2, 3, 5, and 6 DNA 
extracts digested with Kpn1 and Xba1. DNA was analysed on a 0.8% agarose gel, and was visualised using
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The purified mtr gene was then ligated into pEC-XK99E previously cleaved with Kpn1 
and Xba1. Transformed TOP10 cells were grown at 37 0C for 1 hour in SOC medium and 
plated on LB plates supplemented with kanamycin (30 µg/mL). Plasmid isolation and 
restriction digests were carried out using the above mentioned enzymes to confirm the 
presence of the insert (figure 3.8). Figures 3.9, 3.10, 3.11 show the nucleotide and protein 
alignments of the clone and published mtr, sequencing experiments were carried out at 





Figure 3.8: Restriction digests of plasmid DNA extrac s to confirm if the mtr gene was successfully cloned 
into pEC-XK99E. Lane 1, 1 kb ladder, lanes 2-9 DNA extracts digested with Kpn1 and Xba1. DNA was 








mtr, 1380 bp  
pEC-XK99E, 7020 bp 




Figure 3.9: Nucleotide sequence alignment of the published mtr and mtr cloned into pEC-XK99E, dashes 
(residues 640-662) indicate a gap (region not covered by the primers during sequencing experiments). The 
















Figure 3.11: Protein alignment of the cloned Mtr and published Mtb Mtr. BioEdit was used to convert the
nucleotide sequence into a protein sequence. Dashes (residues 214-221) indicate a gap (region not covered 















3.1.12 C. glutamicum electroporation with pEC-XK99E-mtr 
 
Electroporation of competent C. glutamicum was carried out as previously described in 
2.1.14.2 
 
3.1.13 Induction of pEC-XK99E-mtr 
 
Induction at 18 and 25 0C was attempted as before using IPTG (1mM). The SDSPAGE 
result was the same as in section 3.1.10, figure 3.6. The promoter region was suspected to 
have been disrupted or undergone some form of mutation during electroporation, as a 
result, large scale plasmid isolation was carried out in preparation for sequencing 
experiments, which showed the promoter region to be still intact. 
 
Moreover, at the time, no background activity could be detected when testing the C.
glutamicum crude extract, as C. glutamicum electroporated with pEC-XK99E was used 
as a control. Since MSH is the major thiol found in actenomycetes, it was speculated that 
perhaps C. glutamicum uses a different thiol as opposed to the MSH it had been thought 
to utilise. We therefore, proceeded to isolate the C. glutamicum thiol for structural 
comparisons with the published MSH structure (discus ed in chapter 4). 
 
3.1.14 Expression of the mtr gene in M. smegmatis (pSD26-mtr) 
 
Since the expression of mtr gene in C. glutamicum was not successful, expression in M. 
smegmatis was attempted using pSD26-mtr recombinants prepared in our lab. pSD26 
(Daugelat et al., 2003), is an M. smegmatis vector with an inducible acetamidase 
promoter, and allows expression of foreign genes by translational fusion with a C-
terminal his-tag. This expression vector is basically a modification of a pSD24 vector that 
is derived from a promoterless episomal E.coli-mycobacteria shuttle expression vector, 
pMV206-Hygro (Patel and Blanchard 2001 cross reference), the difference between 







Figure 3.12: Map of pSD24 E.coli-mycobacteria shuttle plasmid containing the inducible acetamidase 
promoter. pSD24 is derived from a promoterless pMV206-Hygro plasmid, the pSD26 is a derivative of 
pSD24. Partial sequences are shown below. The plasmid map and the partial sequences were taken from 
Daugelat et al., 2003. 
                                                         BamH1 PvuII 
pSD24         …….atg ccc gag gta gtt ttt atc cat gga tcc agc tgc aga ……. 
   M   P    E    V   V  F    I    H    G   S   S    C    R 
                                 (acetamidase) 
                                                         BamH1 EcoRV 
pSD26         …….atg ccc gag gta gtt ttt atc cat gga tcc gat atc cac cac cac cac cac cac tga ……. 
    M   P    E    V   V  F  I     H    G   S   S    I  H    H   H   H    H   H    * 
                                 (acetamidase)                                                     6 x his tag 
 
Since the acetamidase promoter is tightly regulated (Daugelat et al., 2003) and M. 
smegmatis is phylogenetically closer to Mtb, we expected the expression of mtr gene to 
proceed without difficulties. However, as can be sen in figure 3.13, no significant 
change in the band intensities could be seen, with the exception of Issabelle medium 
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(lane 7), where there was a slight increase in the band intensity, but not conclusive 
enough for us to proceed.  
 
A starter culture containing pSD26-mtr was used to inoculate LB, Middlebrook and 
Issabelle  and superbroth media (100 mL) supplemented with hygromycin and grown for 
16 hrs. Small samples were then transferred to separate flasks and cultured separately as 
control (uninduced). When OD600 had reached 1, acetamide (0.2%) was added (induction 
flasks) and the cultures incubated at this temperature for 16 hrs. Figure 3.9 shows an SDS 
PAGE of the attempted induction. Media components are shown in appendix 1A. 
 
3.1.15 Induction of PSD26-mtr 
 
According to experiments performed by Parish et al., 1997, which demonstrated that 
certain growth media contribute to the regulation of the acetamidase gene, we were 
encouraged to also explore the use of different media in an attempt to resolve the 
expression of the mtr gene. As such, four different media (LB, superbroth, Middlebrook 
and Issabelle medium) were used to determine whether the expression of the acetamidase 
gene can be enhanced and consequently express the mtr g ne.   
 
Unfortunately, there was no difference in the band intensities with all the growth media 
used (except for an elevation of a band between 43 kDa and 66 kDa in the presence of 
acetamide, the inducer) (figure 3.13), activity assay  were thus carried out, and instead of 
utilising the natural substrate, MSSM as before, MSSnaph was used as an alternative 
substrate (discussed in chapter 4) as it was found to be versatile and showed better 
activity than MSSM. Activity assays showed expression n M. smegmatis grown in 
Issabelle to be promising as compared to M. smegmatis grown in LB media (compared in 
section 3.1.16). In addition longer SDS PAGE gels were performed to effect better 






Figure 3.13: Attempted time course induction of the mtr gene in C. glutamicum. Lane 1, molecular weight 
markers, lanes 2 and 3, M. smegmatis transformed with pSD26-mtr grown in LB (uninduced and induced 
respectively), Lanes 4 and 5, M. smegmatis transformed with pSD26-mtr grown in Middlebrook 
(uninduced and induced respectively), lanes 6 and 7, growth in Issabelle medium (uninduced and induced), 
lanes 8 and 9, growth in superbroth (uninduced and induced). No Mtr bands corresponding to the expected 
50 kDa could be conclusively identified. Although the band below 67 KDa (lane 3) was suspected of being 
Mtr, activity assays carried out in section 3.1.16 excluded LB as growth media supportive of expressing the 
mtr gene.  
 
3.1.16 Activity assays 
 
Cells were grown (in LB, Middlebrook, Superbroth and Issabelle media respectively) and 
induced with acetamide as described in 3.1.14; this wa  followed by sonication and 
separation of cell debris from the cytosolic contents. The latter was dialysed overnight in 
1 mM Tris-HCl (pH7.6) and activity assays conducted using dialysed extracts. 
 
Activity results (from crude extracts) suggested that only cells grown in Issabelle and to a 
lesser extent LB media, showed potential for the induction of the mtr gene. Cells grown 
in Issabelle medium gave activities of 115 µmol/min/ g as opposed to 62.7 
µmol/min/mg noted for those grown in LB media, while uninduced cells grown in 
Issabelle medium gave activities of 48.2 µmol/min/mg. As a result, it was decided to 
optimise the induction of the mtr gene in Issabelle medium, in conjunction with the us of 
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3.1.17 Expression of the mtr gene in M. smegmatis, using different media at 20 0C 
 
Since expression in Issabelle medium seemed promising, it was decided to attempt 
expression in Issabelle and in rich media, Middlebrook (containing tryptone and yeast 
extract) media only using three different concentrations of acetamide (0.1, 0.2, and 
0.3%), and sampling after 15 hours. Induction was carried out at 20 0C (figure 3.14). The 
figure below showed mycothiol disulfide reductase to be expressed as inclusion bodies, 
as a result, variables such as temperature and the inducer were further investigated in an 




Figure 3.14: Attempted concentration dependent induction of the mtr gene in M. smegmatis. Lanes 2-4, 
pellet fractions of cells transformed with pSD26-mtr grown and induced (0.1%, 0.2% and 0.3% acetamide 
respectively) in Issabelle medium. Lanes 6-8, pellet fractions of cells transformed with pSD26-mtr grown 
and induced (0.1%, 0.2% and 0.3% acetamide respectively) in enriched Middlebrook media. Lane 10, 
molecular weight markers. Lanes 12-14, cytosolic fractions of cells transformed with pSD26-mtr grown 
and induced in Issabelle medium. Lanes 16-18, cytosolic fractions of cells transformed with pSD26-mtr 
grown and induced in enriched Middlebrook medium. Lane 19: marker lane: 10. The composition of the 











Since the temperature used for induction was significantly lower and judging from the 
SDS PAGE in figure 3.10 it seemed as if in addition t  the acetamide, there was also 
autoinduction by some components in the complex growth media used, as the protein still 
expressed as inclusion bodies in just 15 hrs. The phenomenon of autoinduction has been 
described by Studier, 2005, and Grossman et al., 1998, who observed that cultures 
growing in certain complex media tend to induce significant amounts of target protein 
upon approach to elevated cell growth in the absence of the inducer.  
 
However, in this case, there seemed to be this sort of induction even before the saturation 
point is reached. This prompted us to grow cultures at 20 0C in the absence of acetamide 
to verify if autoinduction described by Studier was the issue here. 
 
3.1.18 Expression of Mtr in M. smegmatis, using different media at 20 0C in the 
absence of the inducer (acetamide). 
 
A starter culture containing pSD26-mtr was used to inoculate Middlebrook and Issabelle 
media supplemented with hygromycin. Sampling was done at 15 hrs. Figure 3.15 shows 
an SDS PAGE of the attempted induction. Once more, th  Mtr was found to be 
concentrated in the insoluble fraction from cells grown in Issabelle medium in particular, 
















Figure 3.15: Confirmation of autoinduction expression of mtr in M. smegmatis. Lanes 1-4, soluble fractions 
of cells transformed with pSD26-mtr grown in normal Middlebrook, Issabelle, LB and enriched 
Middlebrook media without acetamide. Lane 6: molecular weight markers. Lanes 8, 9, 10 and 11: pellet 
fractions of cells transformed with pSD26-mtr grown in normal Middlebrook (lane 8), Issabelle (lane 9), 
LB (lane 10) and enriched middlebrook media (lane 11) without acetamide. 
 
The SDS PAGE above shows samples grown at 20 0C without acetamide for 15 hrs. The 
fact that the enzyme goes into inclusion bodies leads to speculations that there may be 
certain components in the media responsible for the observed induction as noted by 
Studier and others. It was therefore, decided to omit the glycerol in the Middlebrook and 















3.1.19 Expression of the mtr gene in M. smegmatis, using Issabelle and Middlebrook 
media at 17 0C in the absence of the inducer. 
 
SDS PAGE analysis of Issabelle and Middlebrook cultures incubated at 17 0C in the 




Figure 3.16: Lanes 1 and 3, soluble fractions of cells transformed with pSD26-mtr grown in Issabelle and 
Middlebrook media without acetamide. Lane 5, molecular weight markers. Lanes 7 and 9 pellet fractions f 
cells transformed with pSD26-mtr grown in Issabelle (lane 7), Middlebrook (lane 9).  
 
Due to unsuccessful attempts at expressing Mtr using pEC-XK99E and pSD26, pMV261 
was obtained from the Dept of Medical Microbiology at UCT and was used for the 
cloning and expression of Mtr. Briefly, the gene encoding M. tuberculosis mtr was 
expressed in M. smegmatis as described by Patel and Blanchard, with minor 
modifications: The forward primer was 5’-CCC CTA CAA GTT TAA ACG TAC GAC-
3’. To lower the level of constitutive expression of Rv2855 the transformed cells were 
cultured at 30 °C and expression was induced by raising the temperature to 42 °C. Under 
these conditions a ~160-fold increase in the level of mtr specific activity was achieved as 
compared to M. smegmatis lacking the pMV261 plasmid with Rv2855 insert. 








The unsuccessful expression of Mtr in C. glutamicum could not be explained, and more 
studies in the feasibility of using pEC-XK99E to clone and express Mtb proteins are 
required. One of a few published works dealing with expression of Mtb related proteins 
in C. glutamicum, which laid precedent to the adaptation of expressing the mtr gene (in 
this study) was carried out by Engels t al., 2004. These authors successfully managed to 
express a clgR gene (a transcriptional activator involved in the regulation and expression 
of the clpP1P2 operon) in C. glutamicum, using a different expression vector (pXMJ19). 
It is therefore possible to express foreign genes i C. glutamicum and perhaps the only 
difference lies in the expression vectors.  
 
Experiments involving the use of pSD26 as an expression vector suggested that the 
induction and subsequent expression of Mtr in M. smegmatis was influenced by certain 
components in the Issabelle medium since there was still expression of the enzyme (as 
seen by the intense band at 50 kDa, figure 3.10) even with the inducer absent. 
Middlebrook medium on the other hand seemed to lack components capable of inducing 
the enzyme, as can be seen when comparing figures 3.14 and 3.15, the common factor 
between the two being the absence of acetamide in the la ter. Whilst Issabelle medium 
contains yeast extract, peptone, NaH2PO4.H2O, and Ferric ammonium citrate; 
Middlebrook is much more complex in its composition a d it’s not clear whether the 
expression of the mtr gene observed with Issabelle (despite being insoluble) has to do 
with its simplicity and why it was unsuccessful with LB media which contains both 
peptone and the yeast extract. 
 
The only successful Mtr expression system so far is the one carried out by Patel and 
Blanchard, 1999, that utilises the pMV261 vector incorporating a heat shock promoter. 
Stover et al., 1991, successfully utilised pMV261 as an expression vector for some Mtb 
proteins and managed to show that the regulatory sequences of the BCG hsp60 and hsp70 
genes were capable of driving the expression of foreign antigen genes in BCG. Eckstein 
et al., 1998, have also demonstrated the generation of rec mbinant gene products in M. 
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smegmatis when foreign genes are cloned under the control of an hsp60 promoter using 
the abovementioned pMV261 (Stover t al., 1991). It is therefore plausible that certain 























Results and Discussion 
Isolation and characterization of mycothiol from C. glutamicum and 
evaluation of MSSnaph as an alternative substrate for Mtr 
 
4.1 Substrate preparation for activity assays  
 
MSSM was prepared as described by Steenkamp and Vogt, 2004, briefly, S-2-
(mycothiolyl)-6-hydroxynaphthyldisulfide (MSSnaph) (figure 4.1) was generated 
from a reaction between M. smegmatis crude extract and 2-S-(2’-thiopyridyl)-6-
hydroxynaphthyldisulfide. MSSnaph was purified by HPLC followed by reduction 
with NaBH4, the resultant MSH was then oxidised with diamide to generate MSSM. 
While MSSM was essentially needed for Mtr assays, we had anticipated to evaluate 
MSSnaph as a possible and alternative substrate for Mtr (discussed in section 4.3). 
Most importantly, the major thrust of this chapter c ntred on the characterisation of a 
C. glutamicum thiol and its comparison with authentic MSH. 
 
 
Figure 4.1: Structure of MSSnaph  
 
 
The inability to detect MSSM reduction using crude C. glutamicum extracts (induced, 
uninduced and the wild type) prompted us to structurally verify the major low 





4.2       Isolation of C. glutamicum thiol 
 
4.2.1 Activity assays using C. glutamicum thiol 
 
Initially a crude C. glutamicum thiol extract was injected on HPLC and the fraction 
that eluted at 21 minutes was oxidised with diamide. Since this is the normal retention 
time for authentic MSH, based on conditions outlined in section 2.1.19, it was 
reasoned that the thiol from C. glutamicum should have more or less the same 
retention time. 
 
Activity assays were once again carried out using the oxidized sample (C. glutamicum 
isolated thiol) instead of MSSM as substrate and still no activity was detected. A 
small scale thiol extraction was then carried out, derivatised with 2-bromo-
acetonaphthone (BAN) and incubated at 37 0C with mycothiol s-conjugate amidase 
(Mca). MSH-BAN (MSH previously isolated from M. smegmatis treated with BAN) 
was used as a control to assess the extent of Mca cleaved MSH-BAN from C. 
glutamicum. The reaction samples were then spotted and the TLC performed with 
butanol: acetic acid: water/2:1:1, as a mobile phase. The plates were air-dried and the 
spots detected under UV light, to assess the extent of cleavage by Mca.   
 
The Mca activity observed gave preliminary indications that the thiol could be similar 
to mycothiol, however, this was not conclusive enough due to incomplete conversion 
of the starting material, MSH-BAN (Rf = 0.015). In fact, the spot corresponding to 
the product, α-DGI (Rf = 0.65) on the TLC was very faint, even after long incubation 
periods. As a result, a large scale thiol extraction was carried out in preparation for 
structural studies. 
 
4.2.2 C. glutamicum thiol isolation and structural elucidation 
 
C. glutamicum thiol extract was derivatised with BAN at pH 8 and purified on a 
Vydac C18 low pressure column using acetonitrile (50%). The extracts were 
spectrophotometrically monitored at 248nm, the absorbance maximum of BAN 
(molar extinction coefficient, 34000 M-1.cm-1) (figure 4.2). These fractions were 
pooled and purified by HPLC on a preparative phenyl-hexyl column, lyophilised and 
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submitted for 600MHz NMR analysis at the Central Analytical Facility at the 
University of Stellenbosch. A small scale comparative elution was carried out using 
M. smegmatis extract derivatised with BAN (figure 4.3, panels A and B). The thiol 
extracts from C. glutamicum showed the same retention time (21 min) as the M. 
smegmatis extract, both of which corresponded to MSH-BAN. At this stage, it was 
becoming even more evident that C. glutamicum contained MSH. Nevertheless, it was 
decided to continue and carry out a full NMR analysis of the compound isolated as 












     
 
 
Figure 4.3: Analytical HPLC traces showing C. glutamicum thiol extract (Panel A) and that of M. 
smegmatis (Panel B). Both extracts had the same retention time as MSH-BAN. HPLC was carried out 
in accordance with the gradient conditions in table 4 below, using a phenyl-hexyl column at a flow rate 
of 0.8 ml/min and at a wavelength of 248 nm. 
 
 
Table 4: HPLC conditions for monitoring the formation of C. glutamicum-BAN thiol (Panel A) and M. 
smegmatis-BAN thiol (Panel B) 
Time (min) 0 5 30 33 35 37 
TFA (0.1%) A 90% 75% 65% 10% 10% 90% 







M. smegmatis-BAN derivatised thiol 
A BAN 
C. glutamicum-BAN derivatised thiol 
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Analysis of the 1H-NMR spectrum (figure 4.4) showed consistency with published 
data for MSH (Spies and Steenkamp, 1994), with the exception of the downfield 
region where the BAN moiety substituted the bimane us d to derivatise the original 
isolate. Expansions on figure 4.4 confirmed the diagnostic features (figure 4.5) of the 
glucosamine, inositol and the acetyl-cysteine moieties of MSH-BAN from C. 
glutamicum to be comparable to published MSH data. 
 
Figure 4.4: 1H-NMR spectrum of BAN derivatised mycothi l isolated from C. glutamicum. 
 
Figure 4.5: Structure of MSH derivatised with BAN isolated from C. glutamicum 
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The stereochemistry at C-1, C-2’ and C-2 was confirmed by a doublet, a triplet and a 
doublet of doublets in the 600MHz 1H-NMR spectrum shown above and expanded in 
figure 4.6 below at δ 4.979, δ 4.04, and δ 3.816 respectively, with coupling constants 
of 3.66 Hz, 2.81 Hz for H-1 and H-2’ respectively and integrating for one proton each 
whilst H-2 had a J value of 10.5 Hz, 3.66 Hz also integrating for one proton. The 
expanded spectrum below also showed the α-proton with a chemical shift of 4.495 
ppm and appearing as a doublet of doublets with a coupling constant of 8.91 Hz, 5.13 
Hz, also integrating for one proton. H-3 and H-4 appeared at 3.694 ppm (dd, J= 10.74 
Hz, 8.79 Hz) and 3.31 ppm (t, J= 9.32) respectively. H-3 could be easily identified 
from expanding the region between 3.8 to 3.6 ppm (figure 4.7). 
 
Figure 4.6: 1H NMR expanded region showing the anomeric (δ 4.979), H-2’ (δ 4.04), H-2 (δ 3.816), H-
3 (δ 3.694) protons and the α proton (δ 4.495), all integrating for one proton each. The peak at 4.2 ppm 
is a solvent peak. (The appearance of a minor doublet at δ 5 ppm indicates the presence of a minor 
glycoside which has not been identified.) 
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Figure 4.7: 1H NMR expanded region showing H-2 (δ 3.816), H-3 (δ 3.694), H-5 and H-6a&b protons in 
detail. 
 
H-5, H-6a and H-6b were also identified from figure 4.7 above where H-5 and H-6a 
appeared as multiplets between 3.76 and 3.715 ppm, whilst H-6b also appeared as a 
multiplet between 3.67 and 3.64 ppm. This is further substantiated by the integration 
of four protons in figure 4.6 (3.76-3.64 ppm), which ncludes H-3. 
 
The remaining signals corresponding to the inositol portion were detected at 3.417 
ppm for H-1’ (dd, J= 10.01 Hz, 2.93 Hz), 3.35 ppm for H-3’ (dd, J= 9.89 Hz, 2.81 
Hz), 3.476 ppm for H-4’ (dd, J= 9.5 Hz, 9.11 Hz), 3.135 ppm for H-5’ (t, 3.52 Hz) 
whilst H-6’ appeared as a multiplet (figures 4.6 and 4.7) between 3.63-3.58 ppm and 
integrating for one proton. Figure 4.8 shows the 1H NMR spectrum for the remainder 
of the inositol protons mentioned above as well as H-βA&B  protons of acetyl cysteine 
moiety, where H-βA appeared at 2.99 ppm (dd, J= 14.04 Hz, 5.13 Hz) and H- βB at 






Figure 4.8: 1H NMR spectrum showing chemical shifts and integrations for H-1’ (3.417 ppm), H-3’ 
(3.35 ppm), H-4’ (3.476 ppm), H-5’ (3.135 ppm), H-βA (2.99 ppm), and H-βB (2.795 ppm). 
 
The N-acetyl-methyl group of the thiol appeared as a singlet at 1.901 ppm integrating 













Figure 4.9: 1H NMR spectrum showing chemical shift for the –CH3 group (1.901 ppm). 
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The assignment of the BAN portion of the molecule revealed a total of seven protons 
as expected (figure 4.10), where H-6 and H-7 (BAN portion) appeared as triplets 
integrating for one proton each. Since H-5 and H-8 are equivalent, they appeared at 
around 8.74 ppm integrating for two protons, whilst H-2 and 4 appeared as doublets at 
around 8.02 and 7.92 ppm respectively. 
Figure 4.10: Figure 4.10: Downfield region of the 1H-NMR spectrum showing the BAN protons. 
However, the CH2 signal could not be detected due to the protons being in enol-keto tautomerism and, 
therefore, exchangeable with the solvent deuterium. The interconversion of the two forms involves the 
movement of a proton and the shifting of bonding electrons where the carbonyl group is in rapid 











Table 4.1 below summarizes published mycothiol proton assignments in comparison 
with mycothiol isolated from C. glutamicum. 
 
Table 4.1: Spectral data of published MSH and MSH isolated from C. glutamicum 
Published MSH data (Spies & Steenkamp, 1994) MSH data from the C. glutamicum isolate 
Compound Proton Chemical 
shift (ppm) 
and J (Hz) 
Compound Proton Chemical 
shift (ppm) 
and J (Hz) 
Glucosamine 1 5.097 (d, 3.7) Glucosamine 1 4.979 (d, 
3.66) 
 2 3.940 (dd, 
10.8, 3.7) 
 2 3.816 (dd, 
10.5, 3.66) 
 3 3.790 (dd, 
10.8, 8.9) 
 3 3.694 (dd, 
10.74, 8.79) 
 4 3.456 (dd, 
9.9, 8.9) 
 4 3.31 (t, 
9.32) 
 5 3.83  5 & 6A m, 3.76-
3.715 
 6A 3.84    
 6B 3.76  6B m, 3.67-
3.64 
      
Inositol 1’ 3.552 (dd, 
10.1, 2.8) 
Inositol 1’ 3.417 (dd, 
10.01, 2.93) 
 2’ 4.165 (t, 2.8)  2’ 4.04 (t, 
2.81) 
 3’ 3.498 (dd, 
10.0, 2.8) 
 3’ 3.35 (dd, 
9.89, 2.81) 
 4’ 3.605 (dd, 
10.0, 9.1) 
 4’ 3.476 (dd, 
9.5, 9.11) 
 5’ 3.262 (t, 9.3)  5’ 3.135 (t, 
9.52) 
 6’ 3.740 (dd, 
10.1, 9.5) 








Continuation of table 4.1 
N-Acetylcysteine α 4.548 (dd, 
8.4, 5.2) 
N-Acetylcysteine α 4.495 (dd, 
8.91, 5.13) 
 βA 3.123 (dd, 
13.9, 5.2) 
 βA 2.99 (14.04, 
5.13) 
 βB 2.939 (dd, 
13.9, 8.4) 
 βB 2.795 
(14.04, 
8.79) 





























In addition to the H1 NMR data shown above, mass spectral data also confirmed the 
isolate as MSH-BAN as shown in figure 4.11 below. Mass spectroscopy was carried 
out at the Central Analytical Facility, University of Stellenbosch, South Africa, on a 





Figure 4.11: Mass spectrometric analysis of MSH-BAN. The analysis worked best in the ESI negative 
mode. Panel A shows the ESI negative spectrum, the 653 signal is the M-1 ion. The m/z 451 (panel B) 







It is interesting to note that soon after we had confirmed mycothiol to be the major 
low molecular mass thiol in C. glutamicum, Feng et al., 2006, published similar data 
where they had isolated mycothiol from the same organism and showed that 
maleylpyruvate isomerase from this bacterium uses it a a cofactor. In addition, they 
demonstrated that mycothiol functions as an essential growth factor for C. glutamicum 
when gentisate and 3-hydroxybenzoate were supplied as carbon sources. However, 
this is the first time that mycothiol from C. glutamicum has been characterised using 
NMR and mass spectroscopy and compared with the original published data. In 
addition, this study was able to show BAN as an alternative derivatising agent as 
compared to monobromo-bimane. Over and above being photosensitive, bimanes 
have a tendency to be carcinogenic. 
 
4.3 MSSnaph as an alternative substrate for Mtr 
 
During the isolation of MSH from M. smegmatis using the procedure described in 
materials and methods and briefly examined in the op ning section of this chapter 
(section 4.1 and figure 4.1), MSSnaph is formed as a precursor to MSH, and whilst 
MSH can be easily oxidised to MSSM it was of interest to investigate MSSnaph as a 
possible substrate for Mtr. In addition, MSSnaph can be easily converted to MSSM 
should the need arise (as described in section 2.2.10)  
 
The double reciprocal plot (figure 4.12) generated in the exploration of MSSnaph as a 
substrate for Mtr resulted in kinetic parameters which suggested that MSSnaph was a 
better substrate for the reductase as compared to the natural substrate, where the km,app  
was found to be 23 µM, whilst kcat and kcat/km were calculated to be 15.56 s
-1 and 8.17 
x 105 respectively. This was an improvement to the kinetic parameters observed for 
MSSM with a higher km,app (73 µM) and a lower kcat/km (1.64 x 10
5). Studies in our 
lab have also shown MSSnaph to be versatile as it can also be used to assay Mca 





MSSnaph Lineweaver Burk plot





















Figure 4.12: Double reciprocal plot of MSSnaph. Mtrwas incubated with the substrate (10 -55 µM) and 
used NADPH as an electron donor.  
 
Since Mtr inhibition studies are severely restricted by the scarcity of MSH and 
MSSM, which are difficult to prepare in sufficient quantities via chemical (Jardine et 
al., 2002 and Nicholas et al., 2002) or whole cell synthesis (Steenkamp and Vogt, 
2004). Hamilton et al., 2009, recently synthesized the mixed disulfide, (figure 4.13a) 
to establish its suitability as an Mtr substrate.  
 
Figure 4.13a: 5-(benzyl 2(-N-acetyl-L-cysteinyl) amino-2-deoxy-a-D-glucopyranoside)-dithio-2-
nitrobenzoate. 
 
Interestingly, the authors found the Km value of 43 to be approximately 1.5-fold 
lower than that of the symmetrical disulfide, 44, (figure 4.13b discussed in section 
1.6), and only twice as large as that of the native substrate MSSM. In terms of overall 
substrate efficiency, the kcat/Km value for 43 was found to be nearly 5-fold greater 
than that of 44 and 70% of that observed for MSSM. Whilst, our study finds the Km 



















Isolation of MSH from C. glutamicum was largely based on the fact that no reductase 
activity could be observed when investigating Mtr expr ssion (chapter 3), and as 
explained before, this consequently led to speculations that perhaps this bacterium 
makes use of a different substrate.  
 
The successful isolation of mycothiol and its characterisation reinforced the notion 
that indeed all actinomycetes depend on this low molecular mass thiol for regulating 
their redox chemistry, and offers C. glutamicum as an alternative for the study of 
mycothiol dependant enzymes pathways and their isolat on. Moreover, given the 
resurgence of diphtheriae infections in recent years, particularly within the eastern 
European regions (Dover et al., 2004) targeting MSH dependant pathways may lead 
to the development of new drugs against C.diphtheriae. 
 
The demonstration that MSSnaph is a better substrate for Mtr than MSSM which has 
a significantly higher km than MSSnaph leads to speculations that the active site of 
Mtr is perhaps capable of accommodating aromatic α-DGI derivatives, which may be 
a valuable feature in the design of drugs targeting Mtr. However, this remains to be 
established until the crystal structure of the reductase is solved.  
 
The fact that both Mtr and Mca can concurrently utilise MSSnaph as an alternative 
substrate means that it is possible to design drugs based on the α-DGI scaffold that 
can target both enzymes. Yet again, this would be greatly facilitated once both crystal 






Synthesis of compounds 35-38 
 
The goal of this work was to prepare compounds of the general type I shown below, 
where the core 2-deoxy-2-amino-glucose unit has a suit ble aglycone R2 and is tethered 











Synthesis of suitable glycoside of 2-deoxy-2-amino-β-D-glucose   
 
The first goal of the synthetic work was to prepare  suitably protected glycoside of 
glucosamine, having a free amine for later coupling to the substituted naphthoquinone.  
The initial focus was on the synthesis of the protected pseudodisaccharide 5 (scheme 1), 
via glycosylation of D-2,3,4,5,6-penta-O-acetyl-myo-inositol 2 with the protected (2’,4’-
dinitrophenylamino)-2-deoxy-α D-glucosyl bromide 4. The resulting glycoside could 
then be selectively deprotected to form the corresponding 2-deoxy-2-amino glucoside, for 
subsequent amide coupling.  
 
The selectively deprotected D-2,3,4,5,6-penta-O-acetyl-myo-inositol 2 and glucosyl 
bromide 4 were prepared from precursors 1 and 3 respectively (Scheme 1) according to a 
literature procedure (Jardine et al., 2002). The attempted Koenings-Knorr coupling of 2 
and 4 to afford the desired α-linked glycoside 5 was, however, not successful, and use of 
a different glycosyl donor, the trichloroacetimidate (9, Scheme 2), also did not give rise 
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to the desired glycoside, but instead gave a major pr duct tentatively identified as the 











































3 4  
Scheme 1: Reagents and conditions: (i) H2/Pd, EtOAc, RT, 3 hrs; (ii) HBr (30% in acetic acid), CH3Cl, RT, 
8hrs; (iii) AgOTf, CH2Cl2, 2,4,6-lutidine, RT, 30 hrs. 
 
Scheme 2: Reagents and conditions: (i) NaOMe, MeOH, TfN3, RT, 18hrs, then Ac2O, pyridine, RT, 10hrs. 
(ii) THF, piperidine, RT, 16hrs. (iii) CH2Cl2, Cl3CCN, K2CO3, RT. 
 
However, the glycosylation of inositol 2 using the imidate 9 also proved unsuccessful 
despite attempts to optimize reaction conditions including increasing the number of 
equivalents of 2, raising the temperature, ensuring anhydrous solvents, addition of 
powdered molecular sieves (4Å) and use of TMSOTf as a promoter. In all cases, TLC 
revealed the conversion of the starting materials into a new product, but after separation 
by column chromatography the major (least polar) product was tentatively identified as 





































Scheme 3:  Reagents and conditions: CH2 l2, TMSOTf, 4Å molecular sieves, 0 
0C to RT, 30 hrs. 
 
These failed attempts prompted a further change in focus towards producing 
thioglycosides as analogues for the inositol glycosides. This was justified, as mentioned 
earlier, from the observation that the phenylthioglycoside analogue of the mshB substrate 
had been shown to be a competitive substrate, and that thioglycosides have been found to 
be more resistant towards glycosidases than the corr sponding O-glycosides. 
 
The 2-azido-α-phenylthioglycoside 12 was identified as a key precursor for generating 
the amine required for subsequent coupling to naphthoquinone-bearing carboxylic acids 
and was prepared as shown in Scheme 4. Glucosamine hydrochloride (6) was treated with 
triflic azide followed by acetylation with acetic anhydride to give the acetylated 2-
azidoglucose 7 in 50% yield. Treatment of this with thiophenol in the presence of 
BF3.Et2O gave an inseparable mixture (3:1 α/β) of phenyl glycosides 11. However, 
crystallization of the product mixture from absolute ethanol gave the pure α-isomer 12 in 
65% yield (scheme 4). Confirmation of the α-stereochemistry was obtained from 
appearance in the 1H NMR spectrum of a doublet for H-1 at δ 5.61 ppm, with coupling 
constant (J1,2) of 5.6Hz consistent with an axial-equatorial coupling , whilst the diagnostic 
signals for the phenyl group were also observed in the region 7.51-7.29 ppm integrating 
for five protons.  
 
The 2-azido-thioglucoside 12 was then reduced with H2 over Pd/C in ethanol to generate 
phenyl-3,4,6-tri-O-acetyl-2-amino-2-deoxy-1-thio-α D-glucopyranoside 13. 1H NMR 
spectroscopy confirmed the reduction, with the presence of the -NH2 protons evident 
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from the signal at 1.50 ppm with all the other signals conserved as for phenyl 3,4,6-tri-O-












































Scheme 4: Reagents and conditions: (i) NaOMe, MeOH, TfN3, RT, 18hrs, then Ac2O, pyridine, RT, 10hrs; 




First attempt at developing coupling strategy to incorporate tethered 
naphthoquinone 
 
With 2-amino-phenylthioglucoside 13 in hand attention was turned to methods for 
coupling this to the naphthoquinone unit via suitable spacers. Our initial attempts to 
derivatize plumbagin (see below) involved inserting a side chain terminated by an amine, 
in the hope that a simple strategy for coupling two amines could be developed via 
suitable derivatization of one amine.  Initially, oxalyl chloride was tried as a coupling 
agent (scheme 5), in the hope that intermediate acid chloride 14 could be isolated, but 
although starting material was consumed in this reaction, TLC analysis of the reaction 
mixture did not show formation of a single product, suggesting that 14 may not be stable.  
 
To ascertain if 14 had indeed formed, a one pot reaction was attempted wh re, upon the 
disappearance of the starting material, aniline wasadded to try to trap the acid chloride. 
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Although several products were isolated from this experiment, they did not show the 
spectroscopic features of the expected product, with the anomeric proton signal absent 
and the integration of signals for the acetoxy groups indicating less than the expected 
nine protons. The 13C NMR spectra of the three isolated products also did not reveal the 


















Scheme 5: Reaction and conditions: CH2 l2, pyridine, oxalyl chloride, 0 
0C, 30 mins. 
 
In an alternative approach, treatment of 13 with chloroacetyl chloride in CHCl3 gave 
phenyl-3,4,6-tri-O-acetyl-2-chloroacetamido-2-deoxy-1-thio-α-D-glucopyranoside (15) in 
excellent yield (scheme 6). TLC showed complete conversion of the starting material and 
no side products, such that 15 could be recovered after washing with 1M HCl and water, 
and used without further purification. 
The 1H NMR spectrum of 15 confirmed the presence of a chloromethylene group from 
the two-proton singlet at 3.98 ppm whilst the 13C NMR spectrum exhibited the 
corresponding chloroacetyl carbon signal at 42 ppm, with a DEPT experiment confirming 


























Preparation of first set of naphthoquinone derivatives 
 
Taking into account the objective of the study to synthesize naphthoquinone derivates 
that would be more potent and specific to the Mtb reductase, and the fact that the catalytic 
residues of the enzyme’s active site have not yet be n characterised, it was decided to 
incorporate alkyl chains of variable length as spacers between plumbagin and 
thioglucoside 13 for the purposes of probing the active site. The synthesis of plumbagin 
derivatives was carried out following the approach of Salmon-Chemin et al, 2001, where 
Boc-protected amino acids where attached to plumbagin using an oxidative 
decarboxylation. 
 
The Boc-protected amino acids 17a-d were prepared from the corresponding amino-acids 
by reported methods. The spectroscopic data for these was consistent with that reported 
by Salmon-Chemin et al, 2001, with the diagnostic signals for the tert-butyloxycarbonyl 
group in 1H NMR spectra appearing at 1.36 ppm and integrating for nine protons as 
expected, and the secondary amine appearing as a triplet hat integrates for one proton. 
The 13C NMR spectrum revealed the presence of methyl groups from the single peak at 
28.94 ppm. 
The butyloxycarbonyl-amino acids 17a-d were then reacted with 5-hydroxy-2-methyl-
1,4-naphthoquinone 16 (plumbagin) to give alkylated naphthoquinones 18a-d (scheme 7) 
in low to moderate yields. In these reactions, it was observed that 16 was never 
completely consumed, while reaction times longer than 10 hrs generated side products 
that complicated the purification process. Reactions were therefore not carried out for 
longer than 8 hrs. In trying to improve the yield, the number of equivalents of ammonium 
persulfate added was varied whilst maintaining silver(I) in catalytic amounts, and in all 
attempts the average yield obtained was 58% with a small amount of unreacted 


































Scheme 7: Reagents and conditions: 30% CH3CN, (NH4)2S2O4, AgNO3, 7.5hrs, 70 
0C. 18a-d were 
recovered in yields of 34%, 31%, 32%, and 31% respectively. 
 
Spectroscopic values of 18a-d were consistent with those reported in literature. The 1H 
NMR signals for the aromatic protons in the quinone moiety appeared as expected 
between 7.6 ppm and 7.2 ppm, with the hydroxyl group signal appearing at around 12 
ppm and integrating for one proton. The diagnostic ignal for the Boc-protected amino 
acids appeared at around 1.4 ppm, integrating for nine protons. The conjugated 1,4-
dicarbonyl unit was evident from two characteristic ignals in the 13C NMR spectrum at 
190 and 184 ppm respectively. 
 
Oxidative decarboxylation of butyloxycarbonyl-amino acids was also attempted with 5-
hydroxy-1,4-naphthoquinone (juglone), an analogue of plumbagin which is not 
substituted at C-2 or C-3 of the quinonoid ring. In this case both mono- and di-
substitution is possible, and this was evident from TLC of the reaction products which 
showed two overlapping spots. Attempts to separate the two products were unsuccessful 
and NMR analysis of the crude sample was complicated by the presence of a further side 
product in proximity to the two products of interest. It was therefore decided to only 
proceed with the plumbagin derivatives. 
 
Acid hydrolysis of the butyloxycarbonyl-amino acids gave the amines 19 – 22 in yields 
around 60% (scheme 8). The absence of the tert-butyloxycarbonyl group was evident 
from both 1H and 13C NMR spectra, which also confirmed the presence of the primary 




















Scheme 8: Reagents and conditions: CH2 l2, TFA, 0 
0C, 1hr. 19-22 were recovered in yields of 30%, 27%, 
29%, and 28% respectively. 
 
Attempted coupling of naphthoquinonylalkylamines 19 - 22 to alkyl chloride 15 
 
Having successfully generated 3-substituted quinones 19, 20, 21, and 22, the next step 
involved coupling them to the chloroacetylated aminoglucoside 15, described earlier. 
Refluxing 21 or 22 with 15 in CH3CN afforded 23 or 24 (schemes 9) in poor yields and 
low levels of purity. The reactions did not go to cmpletion even after 2 days, whilst 
column purification was complicated by the co-elution of the side products associated 
with the target compound. Relatively pure samples were eventually obtained by 
preparative TLC so that the structures of the products could be confirmed by NMR 
spectroscopy. The presence of the proton signals of the quinone and phenyl moieties was 
evident from the signals between 7.6 and 7.2 ppm integrating for 8 protons. The hydroxyl 
signal appeared at 12.05 ppm, which was consistent with previous naphthoquinone 
spectra. In addition, the diagnostic signal for the anomeric proton of the glucopyranosyl 
moiety was detected at 5.82 ppm, with an axial-equatorial coupling constant (J1,2) of 5.64 
Hz confirming the α-configuration, whilst the signals for the acetoxy groups appeared at 
around 2 ppm, integrating for 12 protons as expected. However, despite the detection of 
these diagnostic signals, the NMR revealed signals for contaminants which were difficult 
to remove. 
  
The naphthoquinone derivatives 19 and 20 (scheme 10) were however not successfully 
converted to the desired products, with a substantial amount of unreacted 15 recovered 
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together with unidentified minor products. In an attempt to drive the reactions to 














































































































Scheme 10: Reagents and conditions: (i) CH3 N, NaHCO3, 80 




Alternative strategy: use of naphthoquinonyl carboxylic acids 
 
The mixed success of the coupling approach described a ove prompted consideration of a 
different strategy, illustrated in scheme 11. This involved formation of naphthoquinone-
terminated carboxylic acids II via oxidative decarboxylation of diacids with plumbagin, 
and coupling of these to amine 13 using well-established coupling reagents HOBt and 
EDC. In this method the carbodiimide EDC reacts with a carboxyl group to form a highly 
reactive O-acylisourea intermediate that readily reacts with amines. However, since the 
O-acylisourea is inclined to contribute to racemisation, hydroxybenzotriazole, HOBt, is 
normally used as a reactive nucleophile to intercept the O-acylisourea and form a further 

























Scheme 11: Envisaged formation of naphthoquinonyl carboxylic acids II and coupling via amide bonds to 
amine 13. 
 
A series of naphthoquinonyl carboxylic acids 27 – 30 was therefore prepared, from 
plumbagin (16) and dicarboxylic acids succinic, glutaric, adipic, and pimelic acid, using 





















29 30  
The spectroscopic data for 27, 28, 29, and 30 was consistent with that for 19, 20, 21, and 
22 prepared earlier, where the signal for the 5-hydroxyl group appeared at 12.09 ppm in 
the 1H NMR spectrum, and the 13C NMR signal for the carboxyl group was detected at 
173.64 ppm. The signals for the three protons of the p enyl appeared in the 1H NMR 
spectrum between 7.7 and 7.26 ppm. All of these diagnostic signals, together with those 
for the alkyl methylene groups in the 1H NMR and 13C NMR spectra confirmed the 
assigned structures. 
With compounds 27-30 in hand, we then proceeded to form peptide bonds with 13 using 
HOBt and EDC. The amides 31, 32, 33, and 34 were obtained in reasonable yields (39%, 
56.6%, 42.6%, and 50% respectively) from the reaction of 13 and each of 27-30 in a 
mixture of CH2Cl2/THF in the presence of EDC and HOBt. The reactions did not go to 
completion and there was difficulty in obtaining better yields even when reaction times 
were prolonged. Interestingly, improved yields were obtained when the number of molar 
equivalents of HOBt was reduced from 1.1 to 0.5 eq. This observation is consistent with 
data published by Nozaki, 1999, where it was noted that 0.02-0.1 HOBt molar 
equivalents were sufficient in enhancing chemical yie ds of tripeptides. Unfortunately, 
due to insufficient starting material the reactions could not be repeated, in order to 















































The 1H NMR spectra for 31-34 showed signals for the anomeric proton as a doublet at 
5.72 ppm with an axial-equatorial coupling constant of 5.2Hz confirming the alpha 
configuration of the thioglycoside. The presence of the naphthoquinone portion was 
confirmed by the appearance of the signal for the 5-hydroxyl group at 12.0 ppm, whilst 
the three aromatic protons together with those from the aromatic portion of the 
phenylthioglycoside appeared between 7.59 and 7.26 ppm, integrating for 8 protons. The 
acetoxy groups were accounted for by the signals appe ring at 2.05, 2.04, and 2.03 ppm, 
and integrating for nine protons, whilst the 13C NMR revealed the carbonyls of the 
acetoxy groups and the naphthoquinone between 205.4 and 180 ppm, with the carbonyl 
of the peptide bond appearing at 173.6 ppm.  
 
Treatment of acetylated derivatives 31-34 in methanol with catalytic NaOMe and 
subsequent neutralisation with Dowex-50WX-200 resin (H+ form) gave the target 
compounds 35-38 in 34%, 46%, 60%, and 52% yields respectively (scheme 12). The 1H 
NMR and 13C NMR spectroscopic data was consistent with that observed for 31-34, 
except that the signals corresponding to the acetoxy groups were absent, indicating the 
formation of the respective triols. The presence of unprotected triols was further 
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confirmed by 1H NMR spectra of D2O-washed samples, which made it possible to 
identify exchangeable protons and assign the final structures.  
 
 
Scheme 12: Reagents and conditions: (i) PhSH, BF3.Et2O, 55 °C, 12 h, followed by crystallization from 
EtOH. (ii) H2, Pd/C, EtOH, rt, 5 h. (iii) HO2C(CH2)nCO2H, 30% aq CH3CN, AgNO3, NH4(S2O8)2, 70 °C, 8 
h. (iv) EDC, HOBt, CH2Cl2/THF, rt, 18 h. (v) cat. NaOMe, MeOH, Dowex-50WX-200 resin, rt, 1 h. 






All solvents used were freshly distilled. Dichloromethane was distilled over phosphorus 
pentoxide, while lutidine and tetrahydrofuran were distilled over sodium wire under 
nitrogen. Other solvents were purified using established procedures (Perrin, Armarego, 















R = Ac, R1 = N3

































R = Ac, n = 2-5
R = H, n = 2 -5
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stated. All reactions were performed under an inert atmosphere of nitrogen in flame dried 
glassware.  
 
Reactions were monitored by thin-layer chromatography (TLC) carried out on Merck 
F254 silica plates and products visualised under UV light and by wetting the plate with a 
solution of anisaldehyde and sulphuric acid in ethanol, followedby heating. Column 
chromatography was performed on glass columns loaded with Merck silica gel 60 (70-
230 mesh) eluting with mixtures of light petroleum and ethyl acetate. 
 
Nuclear magnetic resonance spectra (1H and 13C) were recorded on either a Varian 
Mercury (300 MHz) or Varian Unity (400 MHz) with CDCl3 as the solvent and TMS (δ = 
0 ppm) as the internal standard. All chemical shift are reported in ppm. Melting points 




5-hydroxy-2-methyl-1,4-naphthoquinone, 5-hydroxy-1,4 naphthoquinone, 2-hydroxy-
1,4-naphthoquinone, adipic acid, 6-amino-hexanoic ac d, β-alanine, 4-aminobutyric acid, 
5-amino-hexanoic acid, 5-amino-pentanoic acid, glutaric acid, acetic anhydride, 
trifluoromethanesulfonic acid, acetic anhydride, Di-tert-butyl dicarbonate, acetonitrile-d3, 
DMSO-d6, acetone- d6, CD3OD, D2O, glucosamine hydrochloride, pyridine, silver nitrate, 
trifluoroacetic acid, thiophenol, hydroxybenzotrizole hydrate, N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, chloroacetyl chloride, oxalyl 
chloride, Lawesson’s reagent, cyclohexene and pimelic acid were purchased either from 
SigmaAldrich or Fluka. Lutidine, sodium azide, and ZnCl2 were obtained from BDH. 
They were all used as received. The rest of the chemicals were analytical reagent grade. 
 
  2-azido-2-deoxy-3,4,6-tri-O-acetyl-α,β-D-glucopyranosyl acetate (Martin-Lomas et 












To a round bottomed flask equipped with a nitrogen inlet containing NaN3 (0.17 mol, 
3.6g) water (32 mL) was added followed by CH2 l2 (30 mL). The emulsion was stirred 
and cooled at 0 0C, dry Tf2O (0.0354 mol, 6mL) added via syringe and the reaction 
mixture was stirred at 0 0C for 2 hrs, then at 25 0C for 15 min. The organic layer was then 
extracted with CH2Cl2 (2x10 mL) And the combined organic layers were neutralised with 
a saturated solution of NaHCO3, washed with water, and dried over MgSO4 and filtered 
to recover the triflic azide (TfN3). 
 
In a separate 3 necked flask equipped with a nitrogen inlet, D-glucosamine hydrochloride 
(0.0167 mol, 3.6g) was dissolved in anhydrous methanol (100 mL), and NaOMe (32 mL 
of 0.5 M solution in MeOH) was added and the reaction stirred for 30 min. DMAP (2g) 
was then added and the reaction mixture was diluted further with additional MeOH (40 
mL). The freshly prepared solution of TfN3 was added to this reaction mixture via 
syringe and the reaction left to stir at room temperature for 18 hrs. The solvent was then 
removed in vacuo to give a dark yellow oil which was then acetylated by dissolving in 
anhydrous pyridine (100 mL) at 0-4 0C and adding anhydrous acetic anhydride (100 mL), 
then stirring for 10 hrs at room temperature. On completion, the reaction mixture was co-
evaporated with toluene (4x100 mL) to give a brown sticky residue. Chromatography of 
the crude product on silica (EtOAc/petroleum ether 40:60) gave the desired product (7) as 
a mixture of α and β anomers as colourless oil (3g , 50%). 1H NMR (CDCl3): δ 6.27 (d, 
1H, J = 3.66 Hz, H-1α), 5.52 (d, J = 8.57 Hz, H-1β), 5.01 (m, 3H), 5.42 (t, 1H, J = 8.0, 
5.14 Hz), 5.1-4.8 (m 3H), 4.29-4.23 (m 2H), 4.12-4.0 (m, 4H), 3.79-3.75 (m, 1H), 3.65-
3.61 (m, 2H), 2.16 (s, 6H), 2.065 (s, 3H), 2.06 (s, 3H), 2.04 (6H), 2.01 (s, 3H), 1.98 (3H). 
13C NMR (CDCl3): δ 170.5, 170, 169.7, 169.6, 169.5, 168.5, 168.4, 92.6, 90, 72.8, 72.8, 














BF3.OEt2 (2.6 mL, 18.1 mmol,) was added to a solution of 7 (1.5 g, 4.0 mmol) and 
thiophenol (0.862 mL, 8.0 mmol) in CH2Cl2 (30 mL) at 0 0C. The reaction mixture was 
stirred at 55 0C for 12 hrs. On completion, the reaction mixture was diluted with CH2Cl2, 
washed with brine and the organic layer separated. The aqueous layer was extracted with 
CH2Cl2. The combined organic layers were dried over MgSO4 and concentrated under 
reduced pressure. Silica gel chromatography (EtOAc/ petroleum ether 10: 90) of the 
crude mixture afforded 3 as an α/β mixture (1.03g, 61%). The α-anomer was obtained as 
white crystals by crystallization from absolute ethanol: mp 93 - 97 oC.  1H-NMR (400 
MHz) 7.51-7.47 (m, 2H, Ar-H), 7.34-7.29 (m, 3H, Ar-H), 5.61 (d, 1H, H-1, J=5.6Hz), 
5.31 (dd, 1H, H-3, J=9.2Hz, J=10.5Hz), 5.01 (dd, 1H, H-4, J=9.2Hz, J=10.3Hz), 4.56 
(ddd, 1H, H-5, J=2.3Hz, J=5.1Hz, J=10.3Hz),  4.26 (dd, 1H, H-6a,  J=5.1Hz, J=12.4Hz), 
4.04 (dd, 1H, H-6b, J=6.1Hz, J=11.1Hz),  2.07 (s, 3H CH3),  2.02 (s, 3H, CH3), 1.99 (s, 
3H, CH3). 
13C-NMR (CDCl3) δ 170.4, 169.7, 132.4, 132.2, 129.2, 128.0, 86.5 (C-1), 76.6, 
72.0, 68.7, 68.5, 61. 9, 61.5, 20.6, 20.5. Anal. calcd. for C18H21N3O7S: C 51.06, H 5.19, N 














A suspension of 12 (0.844 g, 2.0 mmol,) and palladium on carbon (0.424 g) in ethanol 
(48 mL) under hydrogen (1 atm.) was stirred for 5 hrs at room temperature. The reaction 
mixture was then filtered through celite and furthe purified by silica column 
chromatography (EtOAc/petroleum ether 60:40) to yield 14 (0.739g, 93%)as a white 
solid, m.p. 72-74oC. 1H NMR (CDCl3): δ 7.425-7.23 (m, 5H, Phenyl), 5.56 (d, 1H, J 
= 5.2 Hz, H-1), 5.05 (dd, 2H, J = 2.2, 10.25 Hz, H-4, H-6a), 4.6 (m, 1H, H-5), 4.32 (dd, 
1H, J = 5.12, 12.29 Hz, H-2), 4.07 (dd, 1H, J = 2.3, 12.25 Hz, H-3), 3.32 (dd, 1H, J = 
5.19, 10.22 Hz, H-6b), 2.1 (s, 3H), 2.04 (s, 6H).13C NMR (CDCl3): δ 170.70, 170.57, 
169.78, 133.50, 131.88, 129.13, 127.74, 91.23, 74.72, 69.00, 62.30, 55.15, 20.68 
 












To a solution of 14 (1.723 mmol, 0.684 g) and 2.6 lutidine (2.585 mmol, 0.301 mL) in 
chloroform (7 mL), chloroacetyl chloride (1.723 mmol, 0.137 mL) was added at -10 0C. 
The reaction mixture was allowed to stir between -10 0C and 0 0C for 1 hr. On 
completion, the mixture was diluted with chloroform and washed twice with HCl (1 M). 
The organic layer was separated and the aqueous layer extracted with chloroform. The 
combined organic layers were then washed with ice cold NaHCO3, then with water, dried 
over MgSO4 and evaporated under reduced pressure to yield 16 (0.9g, 75%) as off-white 
crystals.  m.p. 112-114 oC. 1H-NMR (400 MHz) 7.44-7.42 (m, 2H, Ar-H), 7.31-7.26 (m, 
3H, Ar-H), 6.91(d, 1H, NH, J=8.5 Hz), 5.65 (d, 1H, H-1, J=5.4Hz), 5.17 (td, 2H,  H-3&4, 
J=9.3Hz, J=20.7Hz), 4.55- 4.48 (m, 2H,  H-2&5), 4.28 (dd, 1H, H-6a, J=4.9Hz &12.3 
Hz), 4.08 (dd, 1H, H-6b, J=2.3Hz, J=12.4Hz), 3.98 (d, 2H, COCH2-,  J=1.3Hz), 2.04, 
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2.03, 2.02 (s, 9H, 3x-COCH3). 
13C-NMR (CDCl3) δ 171.2, 170.5, 169.3, 166.2, 132.7, 
131.8, 129.2, 128.0, 87(C-1), 70.9, 69.1, 68.08, 62.2, 61.9, 53.08, 42.2, 20.61 
 
General procedure for the preparation for (N-tert-Butyloxycarbonyl) aminoalkyl 
acids 
 
To a solution of aminoalkyl acid (11.2 mmol, 1 g) in dioxane/H2O (30 mL) was added 1 
M NaOH (10 mL). Upon cooling to 0 0C, Boc2O (10.5 mmol, 2.3 g) was added and after 
stirring at room temperature for 16 hrs, the solvent was removed and the residue was 
taken up in EtOAc.  The organic layer was washed with 5% citric acid (100 mL), dried 
over MgSO4, filtered and the solvent evaporated to give the N-tert-Butyloxycarbonyl)-
amino acid. as a white solid. 
 






Solid (1.36g, 69%). White solid; 1H NMR (DMSO-d6) δ 11.93 (bs, 1H, COOH, 
exchanged with D20), 6.72 (t, 1H, 5.06Hz, NH), 3.11 (t, 2H, J=7.01Hz, CH2-NH), 2.34 (t, 
2H, J=7Hz, CH2-COOH), 1.34 (s, 9H, Boc). 
13C NMR (DMSO-d6) δ 172.2, 154.3, 76.7, 












Solid (0.73g, 93%). 1HNMR (DMSO-d6) δ 12.01 (bs, 1H, COOH, exchanged with D20), 
6.75 (t, 1H, J=5.07Hz, NH), 2.90 (q, 2H, J=6.21Hz, CH2-NH), 2.17 (t, 2H, J=7.44Hz, 
CH2-COOH), 1.58 (qt, 2H, J=7.3Hz, CH2), 1.37 (s, 9H, Boc).
 13C NMR (DMSO-d6) δ 
174.8, 156.3, 78.1, 60.4, 31.7, 28.9, 25.6.  
 






Solid (1.32g, 71%). 1HNMR (DMSO-d6) δ 11.91 (bs, 1H, COOH) 6.72 (t, 1H, 5.06Hz, 
NH), 2.90 (q, 2H, J=6.68Hz, CH2-NH), 2.19 (t, 2H, J=7.21Hz, CH2-COOH), 1.52-1.33 
(m, 13H, (CH2)2, Boc).
 13C NMR (DMSO-d6) δ 174.2, 155.5, 77.24, 39.7, 28.9, 24.5. 
 







Solid (1.4g, 79.5%). 1HNMR (DMSO-d6) δ 11.94 (bs, 1H, COOH), 6.69 (t, 1H, 
J=5.15Hz, NH), 2.87 (q, 2H, J=6.88Hz, CH2-NH), 2.16 (t, J=7.37Hz, CH2-COOH), 1.47 
(qt, 2H, J=7.25Hz, CH2), 1.35-1.14 (m, 13H, (CH2)2, Boc); 
13C NMR (DMSO-d6) δ 175, 
156.3, 78, 60.4, 34.3, 28.9, 26.5, 24.9. 
 
 
General procedure for the preparation of N-Bocaminoalkyl derivatives 
 
A solution of 5-hydroxy-2-methyl-1.4-naphthoquinone (3.2 mmol, 0.6 g) and Boc amino 
acid (9.66 mmol, 1.8 g) in 30% CH3CN (26 mL) was stirred at 65 0C for 1 hr, after which 
AgNO3 (0.96 mmol, 0.163 g) was added. A solution of ammonium persulphate (4.152 
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mmol, 0.947 g) in 30% CH3CN (6.6 mL) was then added drop wise over a period of 3.5 
hrs. The mixture was maintained between 65 and 70 0C for a further 4 hrs. On cooling, 
the mixture was diluted with EtOAc, then the organic layer was separated, washed with 
water, dried over MgSO4, and the solvent removed under reduced pressure. Silica gel 
chromatography (EtOAc/petroleum ether 10:90), of the crude extract afforded 18a (34%) 
(light orange solid), 18b (47%) (light orange solid), 18c (40%) (deep yellow solid), and 
18d (31%) (yellow solid). 
 
N-tert-Butyloxycarbonyl-2-(8-hydroxy-3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-







1H-NMR (CDCl3) δ (400 MHz) 12.09 (OH, 1H), 7.69 (dd, 1H, H-6, J=7.5Hz, J=8.4Hz), 
7.57 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz),7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz), 4.73 (bs, 
1H, NH-CO), 3.33 (q, 2H, J= 6.6 Hz, CH2-NH), 2.87 (t, 2H, J=6.82 Hz, CH2), 2.23 (s, 
3H, CH3), 1.39 (s, 9H, Boc).
 13C-NMR (CDCl3) δ 190.1, 184.3, 161.3, 155.1, 146.4, 















1H-NMR (CDCl3) δ (400 MHz) 12.13 (s, 1H, OH), 7.69 (dd, 1H, H-6, J=7.5Hz, 
J=8.4Hz), 7.57 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz),7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz),  
4.74 (bs, 1H, NH-CO), 3.18 (q, 2H, J=6.53 Hz, CH2-NH), 2.66 (m, 2H, CH2), 2.18 (s, 
3H,CH3), 1.68 (qt, 2H, J=7.53 Hz, CH2-CH2-NH), 1.44 (s, 9H, Boc). 
13C-NMR (CDCl3) 
δ 190.2, 184.3, 161.3, 155.9, 146.3, 145.1, 136, 132.2, 123.8, 118.9, 114.9, 79.3, 40.3, 










1H-NMR (CDCl3) δ (400 MHz) 12.12 (s, 1H, OH), 7.69 (dd, 1H, H-6, J=7.5Hz, 
J=8.4Hz), 7.57 (dd, 1H, H-7, J=1.1Hz, J=7.48Hz), 7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz), 
4.56 (bs, 1H, NH-CO), 3.17 (q, 2H, J=6 Hz, CH2-NH), 2.79 (t, 2H, 7.0 Hz, CH2), 2.17 (s, 
3H, CH3), 1.64-1.42 (m, 13H, CH2-CH2-NH, CH2-(CH2)2-NH, Boc). 
13C-NMR (CDCl3) δ 













1H-NMR (CDCl3) δ (400 MHz) 12.1 (s, 1H, OH), 7.69 (dd, 1H, H-6, J=7.5Hz, J=8.4Hz), 
7.57 (dd, 1H, H-7, J=1.1Hz, J=7.48Hz), 7.25 (dd, 1HH-5, J=1.1Hz, J=8.4Hz), 4.53 (bs, 
1H, NH-CO), 3.12 (q, 2H, J=6.5Hz, CH2-NH), 2.6 (t, 2H, J=7.1 Hz, CH2), 2.16 (s, CH3), 
1.56-1.43 (m, 15H, CH2-CH2-NH, CH2-(CH2)2-NH, CH2-(CH2)3-NH, Boc). 
13C-NMR 
(CDCl3) δ 190, 184.5, 161.2, 156, 146.9, 144.6, 135.9, 132.2, 123.7, 118.8, 114.9, 77.4, 
40.4, 29.9, 28.4, 27, 26.3, 12.7. 
 
General procedure for the preparation of napthoquinonyl carboxylic acids  
 
A similar procedure to the one outlined for 18a-d was followed except that 5-hydroxy-2-
methyl-1,4-naphthoquinone (2.66 mmol, 0.5 g) and an appropriate diacid (7.98 mmol, 
0.942 g) were used. Preparative thin layer chromatogr phy (MeOH/DCM 2.5:97.5) gave 
27 as a dark orange solid (32%), 28 as an orange solid (40%), 29 as an orange solid 
(40%), and 30 as a red solid (50%) 
 







1H-NMR (Acetone-d6) δ (300 MHz) 12.09 (OH, 1H),  7.70 (dd, 1H, H-6, J=7.5Hz, 
J=8.4Hz),  7.57 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz), 7.26 (dd, 1H, H-5, J=1.2Hz, J=8.4Hz),  
2.96 (t, J=8.2, 2H, CH2-COOH ), 2.58 (t, 2H, CH2-CH2- COOH, J=7.9Hz), 2.22 (s, 3H, 
CH3);. 
13C-NMR (Acetone-d6) δ 190.4, 184, 173, 162, 145.7, 145, 136.4, 133, 123.5, 












1H-NMR (Acetone-d6) δ (400 MHz) ppm 12.09 (OH, 1H), 7.69 (dd, 1H, H-6, J=7.5Hz, 
J=8.4Hz), 7.57 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz),7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz),  
2.74 (t, J=7.9, 2H, CH2-COOH),  2.44 (t, J=7.2, 2H, CH2-(CH2)2- COOH), 2.21 (s, 3H, 
CH3), 1.84 (m, 2H, CH2-CH2- COOH). 
13C-NMR 190.4, 184, 173.4, 161, 146, 145, 136, 
132, 123, 118, 115, 32.9, 25.5, 23.3, 12.  
 







1H-NMR (Acetone-d6) δ (400 MHz) ppm 12.1 (OH, 1H), 7.69 (dd, 1H, H-6,  J=7.5Hz, 
J=8.4Hz), 7.56 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz),  7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz), 
2.69 (t, J=7.8, 2H, CH2-(CH2)3- COOH), 2.36 (t, J=7.3, 2H, CH2-COOH), 2.2 (s, 3H, 
CH3),  1.73 (td, 2H, CH2-CH2- COOH,  J=7.1Hz, J=14.5Hz), 1.60 (m, 2H, CH2-(CH2)2- 
COOH); 13C-NMR 190.4, 184, 174, 162, 146.5, 144.7, 136, 133, 24, 119, 115, 33, 25.9, 
25, 11.9. 
 











1H-NMR (Acetone-d6) δ (400 MHz) ppm 12.1 (OH, 1H), 7.69 (dd, 1H, H-6,  J=7.5Hz, 
J=8.4Hz), 7.56 (dd, 1H, H-7, J=1.1Hz, J=7.5Hz), 7.25 (dd, 1H, H-5, J=1.1Hz, J=8.4Hz), 
2.67 (t, J=7.9, 2H, CH2-COOH),  2.31 (t, J=7.3, 2H, CH2-(CH2)4- COOH), 2.2 (s, 3H, 
CH3), 1.67 (td, 2H, CH2-CH2-COOH, J=7.2Hz, J=14.6Hz), 1.54 (m, 4H, (CH2)2-(CH2)2- 
COOH); 13C-NMR 190.2, 184.4, 173.8, 161, 146.6, 145, 136.3, 132.3, 12.43, 118.4, 
114.9, 33.3, 25.9, 24.3, 11.9. 
 
General procedure for coupling reactions: 
 
A mixture of phenyl-2-amino-1-thioglycoside 14 (0.378 mmol, 0.15 g), and each of 
carboxylic acids 27, 28, 29, and 30 (0.090 g, 0.34 mmol), EDC (0.0797 g, 0.416 mmol), 
and HOBt (0.0562 g, 0.416 mmol) were dissolved in a mixture of CH2Cl2 (5 mL) and 
THF (10 mL) under nitrogen. After stirring for 18 hrs at room temperature, the solvents 
were evaporated. The residue was washed with 5% NaOH (5 mL), 0.5 M HCl (2.5 mL), 
and then dried under vacuum. Preparative TLC (MeOH/DCM 2.5:97.5) was performed to 
yield 31 as an orange solid (57%), mp 163-165oC; 32 as a yellow solid (84%), mp 157-


















1H-NMR (CDCl3) δ (300 MHz) 12.0 (s, 1H, OH), 7.59-7.52 (m, 2H, Ar-H), 7.42-7.39 (m, 
2H, Ar-H), 7.31-7.26 (m, 5H, Ar-H), 6.00(d, 1H, NH, J=8.5 Hz), 5.72 (d, 1H, H-1, 
J=5.2Hz), 5.18-5.14 (m, 2H, H-3&4), 4.61- 4.47 (m, 2H,  H-2&5), 4.27 (dd, 1H, H-6a 
,J=5.0Hz, J=12.4Hz),4.07(dd, 1H, H-6b, J=2.3Hz, J=12.3Hz), 2.93 (dd, J=6.6Hz, 
J=8.5Hz, , 2H, CH2-CONH ), 2.41 (dd, 2H, CH2-CH2- CONH, J=6.6Hz, J=8.5Hz), 2.2 
(3H, CH3),  2.05, 2.04, 2.03 (s, 9H, 3x-COCH3). 
13C-NMR: δ 190, 184, 171.8, 171.4, 
170.7, 169.4, 161.5, 145.9, 145.1, 136.2, 132.9, 132.3, 131.7, 129.4, 128.09, 124.1, 119.2, 
115.0, 87.6(C-1), 71.5, 69.2, 68.3, 62.2, 53.0, 34.9, 22.7, 20.8, 20.8, 13.0. Anal. calcd. for 
C32H33NO11S: C, 60.08; H 5.2; N 2.19; S 5.01; found: C 59.21, H 5.21; N 1.65; S 4.27. 
[M-H] + calcd for C32H33NO11S: 638.1695; found 638.0262. 
 
Phenyl-3,4,6-tri-O-acetyl-2-deoxy-2-[3'-(8''-hydroxy-3''-methyl-1'',4' '-dioxo-1'',4''-










O OH  
 
 
1H-NMR (CDCl3) δ (300 MHz) 12.0 (s, 1H, OH), 7.6-7.56 (m, 2H, Ar-H), 7.44-7.41 (m, 
2H, Ar-H), 7.30-7.20 (m, 5H, Ar-H), 6.08(d, 1H, NH, J=8.5 Hz), 5.76 (d, 1H, H-1, 
J=5.4Hz), 5.21-5.16 (m, 2H, H-3&4), 4.65- 4.48 (m, 2H,  H-2&5), 4.28 (dd, 1H, H-6a 
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,J=4.9Hz, J=12.4Hz), 4.09(dd, 1H, H-6b, J=2.3Hz, J=12.3Hz), 2.73-2.56 (m, 2H, CH2-
CONH), 2.29 (t, 1H, J=7.1Hz, CH2-(CH2)2- CONH), 2.15 (3H, CH3), 2.06, 2.049, 2.048 
(s, 9H, 3x-COCH3), 1.80 (m, 2H, CH2-CH2- CONH). 
13C-NMR: δ 189, 184, 172, 171.5, 
170.5, 169.2, 161.2, 145.9, 145.4, 136, 132.8, 132.1, 131.4, 129.2, 127.8, 123.9, 118.9, 
114.9, 87.5(C-1), 71.2, 68.9, 68.2, 62, 52.7, 35.9, 25.6, 24.1, 20.7, 20.6, 20.5, 12.7. Anal. 
calcd. for C33H35NO11S: C 60.63; H 5.4; N 2.14; S 4.91; found: C  59.78; H 5.75; N 

















1H-NMR (CDCl3) δ (300 MHz) 12.0 (s, 1H, OH), 7.6-7.56 (m, 2H, Ar-H), 7.44-7.41 (m, 
2H, Ar-H), 7.30-7.20 (m, 5H, Ar-H), 5.9(d, 1H, NH, J=8.5 Hz), 5.76 (d, 1H, H-1, 
J=5.4Hz), 5.17-5.13 (m, 2H, H-3&4), 4.65- 4.48 (m, 2H,  H-2&5), 4.28 (dd, 1H, H-6a 
,J=4.9Hz, J=12.4Hz), 4.09(dd, 1H, H-6b, J=2.3Hz, J=12.3Hz), 2.63 (dt, 1H, J=1.5Hz, 
J=7.1Hz, CH2-CONH), 2.25 (dt, 1H, J=2.3Hz, J=7.2Hz, -CH2-(CH2)3- CONH), 2.15 (3H, 
CH3), 2.05, 2.04, 2.03 (s, 9H, 3x-COCH3), 1.7-1.6 (m, 2H, CH2-CH2- CONH),1.5-1.4(m, 
2H, CH2-(CH2)2- CONH). 
13C-NMR 190, 184, 172, 171.6, 170.5, 169.2, 161.2, 146.4, 
144.8, 136.8, 135.9, 132.8, 132.1, 131.4, 129.2, 127.8, 123.8, 118.8, 114.9, , 87.6(C-1), 
71.3, 68.9, 68.1, 62, 52.7, 36.1, 27.9, 25.9, 25.5, 20.7, 20.66, 20.6, 12.7. Anal. calcd. for 
C34H37NO11S: C 61.16; H 5.59; N 2.1; S 4.8; found C 60.27; H 5.67; N 1.63; S 3.91. [M-















O OH  
 
1H-NMR (CDCl3) δ (300 MHz) 12.0 (s, 1H, OH), 7.6-7.56 (m, 2H, Ar-H), 7.44-7.41 (m, 
2H, Ar-H), 7.30-7.20 (m, 5H, Ar-H), 5.9(d, 1H, NH, J=8.5 Hz), 5.76 (d, 1H, H-1, 
J=5.4Hz), 5.17-5.13 (m, 2H, H-3&4), 4.65- 4.48 (m, 2H,  H-2&5), 4.28 (dd, 1H, H-6a 
,J=4.9Hz, J=12.4Hz), 4.09(dd, 1H, H-6b, J=2.3Hz, J=12.3Hz), 2.6-2.5(m, 2H, CH2-
CONH), 2.2-2.18 (m, 2H, CH2-(CH2)4- CONH), 2.2 (3H, CH3), 2.058, 2.056, 2.04 (s, 9H, 
3x-COCH3), 1.6-1.5 (m, 2H, CH2-CH2- CONH),1.5-1.4(m, 4H, (CH2)2-CH2- CONH).  
13C-NMR 190, 184, 172, 171.6, 170.5, 169.2, 161.2, 146.4, 144.8, 136.8, 135.9, 132.8, 
132.1, 131.4, 129.2, 127.8, 123.8, 118.8, 114.9, 87.6(C-1), 71.3, 68.9, 68.1, 62, 52.7, 
36.1, 27.9, 25.9, 25.5, 20.7, 20.66, 20.6, 12.7. Anal. calcd for C35H39NO11S: C 61.66; H 
5.77; N 2.05; S 4.7; found: C 63.9; H 6.14; N 1.6; S 3.47. [M-H]+ calcd for C35H39NO11S: 
680.2165; found 679.5982. 
 
General procedure for deacetylation: 
 
A portion of 0.2 M NaOMe in MeOH was added to a stirred suspension of acetylated 
glycoside (31-34 respectively) in MeOH, at room temperature. When TLC showed 
complete conversion to a single product with lower polarity (typically after 1h) Dowex-
50WX-200(H+) ion exchange resin was added to the reaction mixture until a neutral pH 
was reached. The dowex resin was then removed by filtration and the clear filtrate 
concentrated in vaccuo to give deacetylated product: 35 as a red/brown solid (18mg, 
34%), mp 238-241 oC; 36 as a yellow/brown solid (25mg, 46%), mp 196-199 oC; 37 as a 
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brown solid (32mg, 60%), mp 170-173oC; and 38 as a brown/orange solid (30mg, 52%), 

















1H-NMR (DMSO-d6) δ (400 MHz) 12.0 (s, 1H, OH),8.09 (d, 1H, NH, J=6.5Hz), 7.69 (t, 
1H, H-7, J=8.0Hz), 7.5- 7.4 (m, 1H, H-5,1H), 7.38- 7.35(2H, m, Ar-H), 7.31-7.24(4H, m, 
Ar-H), 5.60 (d, 1H, H-1, J=5.1Hz), 5.12 (d, 1H, OH, J=5.6Hz),  4.85 (d, 1H, OH, 
J=5.6Hz), 4.51 (t, 1H, OH, J=6.0Hz), 3.87-3.80(2H, m, H-2&3), 3.58-3.54 (2H, m,H-
5&6a), 3.46-3.40(1H, m,H-6b ), 3.3-3.2 (1H, m, H-4), 2.8-2.7 (m, 2H, CH2-CONH ), 
2.38-2.34 (m, 2H, CH2-CH2- CONH), 2.1 (3H, CH3). 
13C-NMR 183.8, 172, 171.9, 159.7, 
145.1, 136.2, 134.2, 131.6, 130.9, 129.08, 129.03, 128.9, 127, 123.3, 118.4, 114.5, 87(C-
1), 73.8, 70.37, 70.30, 70, 60, 54.5, 54.4, 33.52, 33.48, 22.2, 12.4. [M+H] calcd for 






















O OH  
 
1H-NMR (DMSO-d6) δ (300 MHz) 12.0 (s, 1H, OH), 7.86 (d, 1H, NH,J=6.6Hz), 7.69 
(dd, 1H, J=7.6Hz, J=8.3Hz), 7.51 (dd, 1H, J=1.1Hz, J=7.5Hz), 7.40-7.37(m, 2H, Ar-H), 
7.29-7.18(m, 4H, Ar-H), 5.64 (d, 1H, H-1, J=5.1Hz), 5.01 (d, 1H, OH,  J=5.6Hz), 
4.76(d, 1H, OH,  J=5.6Hz),  4.39 (t, 1H, OH,  J=5.6Hz), 3.9-3.8(m, 2H,H-2&3 ), 3.6-
3.5(m, 2H, H-5&6a ), 3.49-3.41(m, 1H, H-6b), 3.29-3.23(m,1H, H-4), 2.6-2.5(2H, m, 
CH2-CONH), 2.3-2.2(2H, m, CH2-(CH2)2- CONH ), 2.0(3H, s, CH3),  1.7-1.6(2H, m, 
CH2-CH2- CONH). 
13C-NMR 189, 184, 172, 160, 146, 145, 136, 135, 132, 1, 129, 127, 
123, 118, 88(C-1), 74, 71, 70, 61, 55, 34, 28, 25, 24, 12.  [M-H]+ calcd for C27H29NO8S 
526.1536; found 526.1526. 
 
Phenyl-2-deoxy-2-[3'-(8''-hydroxy-3''-methyl-1'',4' '-dioxo-1'',4''-

















1H-NMR (DMSO-d6) δ (300 MHz) 12.0 (s, 1H, OH), 7.86 (d, 1H, NH, J=6.5Hz), 7.69 
(dd, 1H, J=7.6Hz, J=8.3Hz), 7.51 (d, 1H, J=7.4Hz), 7.40-7.3(m, 2H, Ar-H), 7.26-
7.16(m, 4H, Ar-H), 5.6 (d, 1H, H-1, J=5.1Hz), 5. (d, 1H, OH,  J=5.5Hz), 4.76(d, 1H, 
OH,  J=5.5Hz),  4.39 (t, 1H, OH,  J=5.8Hz), 3.9-3.8(m, 2H, H-2&3), 3.6-3.5(m, 2H, H-
5&6a), 3.5-3.4(m, 1H, H-6b), 3.3-3.2(m,1H,H-4), 2.6-2.5(2H, m, CH2-CONH), 2.2-
2.1(2H, m, -CH2-(CH2)3- CONH), 2.0(3H,s, CH3), 1.63-1.57(2H, m, CH2-CH2- CONH), 
1.5-1.4(2H, m, CH2-(CH2)2- CONH). 
13C-NMR 189, 184, 173, 160, 146, 144, 136, 135, 
132, 131, 129, 128, 127, 123, 118, 114, 87(C-1), 74, 70.4, 70.1, 61, 55, 35, 27, 26, 25,12. 













O OH  
 
1H-NMR (DMSO-d6) δ (300 MHz) 12.0 (s, 1H, OH), 7.86 (d, 1H, NH, J=6.5Hz), 7.7 (t, 
1H, J=8.3Hz), 7.51 (d, 1H, J=7.5Hz), 7.4(td, 2H, J= 1.2 & 8.2, Ar-H), 7.3-7.2(m, 4H, 
Ar-H), 5.6 (d, 1H, H-1, J=4.8Hz), 5.1 (d, 1H, OH,  J=5.7Hz), 4.8(d, 1H, OH,  J=5.8Hz),  
4.5 (t, 1H, OH,  J=6.1Hz), 3.9-3.8(m, 2H, H-2&3), 3.6-3.5(m, 2H, H-5&6a), 3.5-3.4(m, 
1H, H-6b), 3.3-3.2(m,1H, H-4), 2.6-2.5(2H, m, CH2-CONH), 2.2-2.1(2H, m, CH2-(CH2)4- 
CONH), 2.1(3H, s, CH3), 1.63-1.57(2H, m, CH2-CH2- CONH), 1.5-1.4(4H, m, (CH2)2-
CH2- CONH ). 
13C-NMR 189.7, 184, 173.5, 160, 146.8, 144.5, 136.6, 135, 132, 131.5, 
129, 127, 123.6, 118, 114, 87.9(C-1), 74, 70.8, 70.6, 60.7, 55, 35, 29, 27.9, 26, 25,12.6. 






Results and Discussion 
Evaluation of subversive substrates (35-38), thioglycosides, O-glycosides 
and INH-NAD(P) adducts against Mtr 
 
 
6.1 Effects of INH-NAD(P) adducts on crucial Mtb proteins: Overview 
 
Isoniazid (INH) and ethionamide (ETH) are essential drugs in the treatment of 
tuberculosis, even though ETH is generally considere  a second line drug for TB. The 
use of ethaniomide has significantly increased over th  years due to the appearance of 
cases of MDR and XDR (Argyrou, et al., 2006b and Wang et al., 2007).  
 
INH and ETH are pro-drugs that require activation by KatG, a catalase peroxidase 
(Johnsson et al., 1995 and Zhang et al., 1992), and ethA, a flavin monooxygenase (Wang 
et al., 2007) respectively to form adducts with NAD+ resulting in concomitant inhibition 
of InhA, an NADH-dependant enoyl-acyl carrier protein reductase of the fatty acid 
biosynthesis type II system (Rozwarski et al., 1998; Vilcheze et al., 2006; Lei et al., 
2000 and Marrakchi, et al., 2000). The formation of these adducts proceeds through the 
oxidative activation of INH by KatG to generate an isonicotinoyl radical that reacts non-
enzymatically with NAD(P) to generate a mixture of INH-NAD(P) isomers (figure 6.1) 
(Nguyen et al., 2001). Over the last few years, it has also become evident that INH 
resistance is predominantly due to mutations in the KatG and inhA genes.  
 
In addition to the NADH-dependant enoyl-ACP reductase, INH-NAD(P) adducts have 
also been shown to inhibit the M. tuberculosis NADPH-dependant dihydrofolate 
reductase (DHFR) with nanomolar affinity (Argyrou et al., 2006a). A proteome wide 
profiling of Mtb using both the INH-NAD and INH-NADP adducts identified 16 other 
proteins, most of which were predicted to be pyridine nucleotide-dependant 
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Figure 6.1: Chemical structures of the INH-NAD and INH-NADP adducts. The adenosine diphosphoribose 
(for INH-NAD) and 2’-phosphoadenosine diphosphoribose (for INH-NADP) moieties of the molecules are 
designated by ADPRP(P). The acyclic forms are in equilibrium with the corresponding pair of 
diastereomeric, cyclic, and hemiaminal forms. The figure was adapted from Argyrou et al., 2007. 
 
6.2 Percentage inhibition of Mtr by INH-NAD(P) adduct mixture 
 
INH-NAD and INH-NADP adduct mixtures were prepared and purified using Sep-pak C-
18 cartridges as described by Ducasse-Cabanot et al., 2004. Briefly, 2mM INH, 2mM 
NAD+ and 4mM MnIII -PyrPh in 100 mM sodium phosphate buffer, pH7, were incubated 
for 20 min at room temperature to generate INH-NAD. The INH-NADP adduct was 
prepared in exactly the same way except that NAD+ was replaced with NADP+. 
Unfortunately, the preparation of ethionamide adducts (ETH-NAD(P)) using the same 
procedure was not successful, as no product peak formed at 326 nm even after 1 hr of 
incubation, whilst INH-NAD(P) adducts formed after 20 mins as reported. 
 
Although ETH is structurally similar to INH and although the primary target for both 
drugs is the mycolic acid biosynthetic pathway (Takayama et al., 1972; Winder et al., 
1971), it has been demonstrated that while INH requi s activation by KatG to form INH-
NAD(P), activation of ETH involves ethA, which encodes a flavin monooxygenase that 
catalyzes the Baeyer-Villiger reaction (Fraaijie et al., 2004). To date, in-vitro activation 
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of ETH has not been possible by either chemical or enzymatic methods, the only viable 
method being a cell based approach devised by (Wang et al., 2007).  
 
Even though Mtr has been shown to have a 13-fold preference for NADPH over NADH 
based on V/K values (Patel and Blanchard, 1999), preliminary percentage inhibitions of 
Mtr by INH-NAD(P) adducts were carried out using NADH due to the fact that the km 
value for the binding of NADPH by Mtr is only 7 µM, at which concentration the 
absorbance at 340nm will be only 0.0435. This would have made it difficult to obtain 
accurate results. 
 
Inhibition experiments were thus performed as described in section 2.2.9, where 
increasing concentrations of INH-NAD and INH-NADP adduct mixtures were incubated 
with MSSnaph, NADH for 1 minute at 30 0C and the reaction initiated by the addition of 
Mtr. The percentage inhibitions shown in table 6.1 increase with increasing adduct 
concentration and show more than 50% inhibition because MSSNaph and MSSM are not 
saturating (MSSnaph and MSSM concentrations were kept constant at 25 µM), moreover, 
the amount of data presented is rather limited. 
 
Control experiments showed that INH, NAD+ or MnIII -PyrPh alone (concentrations of up 
to 1mM) had no effect on Mtr activity. When MSSnaph was substituted with MSSM, a 
similar trend was observed where the highest INH-NAD(P) adduct concentration used 
(10 uM) resulted in 66% inhibition, comparable to that obtained with 10 µM INH-











Table 6.1: Percentage inhibitions of Mtr by INH-NAD(P) adducts, MSSnaph and MSSM were kept 
constant at 25 µM. 
MSSnaph used 
as a substrate 
 [INH-NAD] Percentage 
inhibition 
 2 uM 29.5 % 
4 uM 35.4 % 
6 uM 54.5 % 
10 uM 60.9 % 
  
MSSnaph used 
as a substrate 
 [INH-NADP]  
 2 uM 16.4 % 
4 uM 37.7 % 
6 uM 55.5 % 
10 uM 65.5 % 
  
MSSM used as a 
substrate 
 [INH-NADP]  
 2 uM 16.8 % 
4 uM 26 % 
6 uM 53 % 









6.3 Inhibition of Mtr by INH-NAD(P) adduct mixture 
 
The classic double reciprocal plots of Mtr inhibition by INH-NAD(P) adducts showed 
variable inhibition (figures 6.2, 6.3, 6.4), where inhibition was initially mostly slope 
effects, approximating competitive inhibition at low inhibitor concentrations and then 
slowly changing over into uncompetitive inhibition, where the uncompetitive part seemed 
to suggest that INH-NAD(P) could also bind to the reduced enzyme in such a way that it 
cannot be reversed by NADH. 
  
Moreover, the adducts only showed incomplete inhibition when either substrate (NADH 
or MSSnaph) was varied at five fixed levels of INH-AD(P). Figure 6.5, shows the 
degree of incomplete inhibition of Mtr by INH-NADP at substrate saturation. 
Incidentally, Blanchard and Patel, 1999, also found that the reduction of Mtr by NADPH 
was only partial (reducing only one FAD in the dimer). 
 
Whilst the inhibition observed on double reciprocal plots with INH-NADP starts with 
slope effects, because INH-NADP competes with NADH for the same binding site, 
another type appears which could be binding of inhibitor to the reduced enzyme resulting 
in no further slope effects. Moreover, the fact that inhibition appears to be incomplete 
suggests probable half sites reactivity. The study is still ongoing to fully clarify the 







































Figure 6.2: Representative plot of 1/V vs 1/ [NADH].  Assays contained 24 nM Mtr, 25 µM MSSnaph, 
variable NADH (19, 28, 38, 47, and 67 µM) at five fixed levels (0, 3.5, 7, 10.5, and 14 µM) of INH-NAD. 
Data points represent the average of duplicate determinations. 
 
















































Figure 6.3: Representative plot of 1/V vs 1/ [MSSnaph].  Assays contained 24 nM Mtr, 105 µM NADH, 
variable MSSnaph (8, 10, 20, 30, and 40 µM) at five fix d levels (0, 3.5, 7, 10.5, and 14 µM) of INH-NAD. 
Data points represent the average of duplicate determinations. 
 



















































Figure 6.4: Representative plot of 1/V vs 1/ [NADH].  Assays contained 24 nM Mtr, 25 µM MSSnaph, 
variable NADH (19, 28, 38, 47, and 67 µM) at five fixed levels (0, 3.5, 7, 10.5, and 14 µM) of INH-NADP. 

















Figure 6.4.1: Slope vs [INH-NADP]. Re-plot of figure 6.4. The data of the inhibitor experiments showed 
that slopes change dramatically for INH-NADP up to about 2micromolar INH-NADP and then less so, 
while intercepts change. This also seems to differ quantitatively for INH-NAD. Inhibition of Mtr by INH-




Although data points (figure 6.4) were all collected from 3.5 micromolar upwards, the 
experiment has been repeated several times, but at s bmicromolar concentrations of INH-
NADP, where the inhibition was found to be truly competitive (unpublished 
observations, this laboratory). 
Vmax vs INH-NADP
INH-NADP (µM)










Col 1 vs Predicted 
Col 6 vs Col 7 
 
Figure 6.5: Represents the rate of the enzymatic rea tion as a function of INH-NADP at different fixed 
levels of the variable substrate (NADH). The dots are experimental data (intercepts) and the curve 
represents the theoretical values of the parameter (y) from Equation 1 (shown below) fitted to these 
experimental points. The fact that hyperbolic decay fits the data quite well suggests that a maximal degree 
of inhibition exists. 
 
The equation used to generate figure 6.5 is the one f r a three parameter hyperbolic 
decay, equation 1: 
 y = y0 +  ab 
                         b + x……………………………………………………… ……… (1) 
 
Then the Vmax values fit the predicted curve of y’s, where yo = 0.08914 + .01605, a = 
0.1307 + .01557 and b = 7.485 + 2.196. So when INH-NADP is very large y = yo and 
when there is no INH-NADP y =  yo  + a  which equals  (0.08914 + 0.01605)  +  (0.1307 
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+ 0.01557). Given the relatively large standard errors on the parameters, at infinite INH-
NADP the inhibition at Vmax is about 60%, which means that the Ki for the uncompetitive 
part of the inhibition could be as high as 7.485µM. Equation 1 can also be rearranged to 
show that: 
y – yo = a Ki.  =       a             where a, is the extent of the inhibition and b is Ki. 
             I + Ki      1   +   I/ Ki 
 
6.3.1 Conclusion (INH-NAD(P) adducts) 
 
An interesting observation made in this study is that while Mtr is inhibited by both INH-
NAD and INH-NADP, most of the other enzymes (e.g. dihy rofolate reductase and the 
enoyl-ACP-reductase) are specifically inhibited by one of the two adducts (as discussed 
in section 6.1). The effects of these INH-NAD(P) complexes on Mtr are thus likely to be 
additive. Moreover, INH will likely generate both INH-NADH and INH-NADP, both of 
which will inhibit Mtr and that the inhibition constants that can be estimate fall probably 
below 1µM for the competitive part of inhibition by the entire INH-NADP mixture and at 
about 7.5µM for the uncompetitive part of the inhibition, again for the mixture. However, 
is not yet known what the effect of mixtures of INH-NADP and INH-NAD will be on 
Mtr. While insights with regard to the mechanism of inhibition of the mycobacterial fatty 
acid biosynthesis pathway (FAS II), the enoyl-ACP and the dihydrofolate reductases by 
INH have been provided by a number of studies as discussed in section 6.1, it was only 
recently that Argyrou, et al., 2006b managed to identify a number of additional 
reductases in mycobacteria that can bind adducts formed between INH and NAD(P). 
However, Mtr was not amongst the newly identified targets.  
 
In this study, the use of INH-NAD(P) adducts against Mtr indicated that the enzyme was 
not completely inhibited (noted in section 6.3) as a result, the inhibition observed was 
mainly of interest from a mechanistic point of view and also in practical terms, because it 
means complete inhibition by the adducts in the low micromolar range is not attainable. 
Despite this, the study was able to demonstrate Mtr as a possible target for INH, however, 
more in depth studies (e.g. crystallography) are requi d to explain the exact interaction 
of Mtr with activated INH. 
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One of the problems frequently encountered with the preparation of the INH-NAD(P) 
adducts was that although they were quick and easy to prepare, they seemed to be 
unstable immediately after the Sep-pak C18 step (given by the decline of absorbance at 
326 nm). Moreover, after storage overnight a broad absorbance peak at 4-500 nm 
develops and it was also found that even when stored at -80 oC the mixture was no longer 
inhibitory. As a result, it became extremely important to collect the kinetic data as 
quickly as possible and certainly within a day.  
 
A possible explanation for the observed decline in absorbance was attributed to the fact 
that perhaps an equilibrium between the different isomeric forms had not yet been 
established, or that the adduct itself undergoes changes that go beyond that of isomeric 
equilibrium. Because of this, it is not certain whether the different phases of Mtr 
inhibition can be ascribed to interactions with different isomers in the mixture, whereas, 
with DHFR and InhA, the inhibition was observed to be very tight and selective for one 
isomer. Also, because the inhibition was classically competitive, although bisubstrate 
competitive, it was possible to obtain reliable Ki’s, while in our case, a mixture of 
different inhibition types was observed which made it difficult to assign Ki’s to the 
different stages. 
 
6.4 Evaluation of 35-38 
 
6.4.1 Effect of 35-38 against MshB 
 
Given the fact that naphthoquinones can readily accept electrons from flavoproteins, we 
envisaged that naphthoquinones linked to α-DGI or, as in our case, a thiophenol moiety, 
would offer specificity towards Mtr whilst discriminating against the host’s glutathione 
reductase, and with the successful synthesis of 35-38 (discussed in chapter 5), we 





Compounds 35-38 were tested (Marakalala, M.J., 2008) for inhibition of MshB utilising a 
fluorescence-detected HPLC assay in which acetyl-α-DGI was used as substrate. 
Inhibition of MshB was obtained by measuring the extent of acetyl-α-DGI cleavage in 
the presence of each of 35-38. Compound 38 was found to be the most active against 
MshB, inhibiting the enzyme by 94.8% at 500 µM, whilst 37 and 36 exhibited about 81% 
inhibition, with moderate levels displayed by 35 (57.4%).  
 
Inhibition of MshB seemed to be directly correlated to the length of the alkyl chain 
linking the quinone and the glucosamine moiety, as the deacetylase activity decreased 
when 35 was present and was virtually absent with 38. Since the compounds were limited 
to a five-carbon spacer, the use of longer spacers would be of much interest in future 
studies. The Ki (µM) values for 35, 37 and 38 were found to be 162.7 ± 15, 93.9 ± 11, 
and 16.8 ± 1.9 respectively. Comparing the activity of these compounds to the reported 
Km of about 340 ± 80 µM (Newton et al., 2006b) for the cleavage of GlcNAc-Ins by 
MshB it becomes apparent that 35, 37, and 38 are the most potent inhibitors of MshB yet 
described.  
 
6.4.2 Effect of 35-38 against Mca 
 
MshB is not essential for growth or synthesis of MSH in Mtb, since Mca exhibits low 
levels of the deacetylase activity that allows for the formation of MSH in the absence of 
MshB. The compounds were therefore, also tested4 as Mca inhibitors, but were found to 
be less potent inhibitors of this enzyme than of MshB. 
 
The crystal structures of the two enzymes with 35-38 co-crystallised may reveal 
interesting information with regard to interactions between the enzyme’s active site and 
the inhibitors. However, in light of the difficulties frequently experienced in obtaining 
suitable crystals of proteins, perhaps 38, which exhibited the highest inhibition with both 
enzymes will have to be utilised for crystal and subsequent docking studies. Indeed, the 
inhibition of Mca by 35-38 is an interesting and useful foundation on which alternative 
143 
 
and more potent inhibitors can be designed to add onto those that have already shown 
significant inhibitory properties, as described in chapter 1.  
 
Rawat et al., 2004, suggested that MSH can form stable S-conjugates (figure 6.6) when 
exposed to naphthoquinones, and as such, these conjugates may be suitable substrates for 
Mca. An interesting observation made with 35-38 is that they inhibited both MshB and 
Mca4, confirming that substituted (on carbon 3) naphthoquinones may be a suitable basis 












































































Figure 6.6: Hypothetical formation of mycothiol S-conjugate when mycothiol is exposed to plumbagin. 
Cleavage by Mca results in the generation of α-DGI with AcCys-5-hydroxy-2-methyl-1,4-naphthoquinone 
being disposed out of the cell. However, with the us  of compounds 35-38 the C-3 position is already 





6.4.3 Effect of 35-38 against Mtr 
 
The use of naphthoquinones as subversive substrates for reductases is well documented 
and previous studies have successfully demonstrated th  utility of quinones against 
trypanothione reductases of pathogens such as those of Trypanosoma congolense (Cenas 
et al., 1994) and Trypanosoma cruzi (Salmon-Chemin et al., 2001). And recently, 
towards the completion of the synthesis of subversi substrates used in this study 
Mahapatra et al., 2007, reported on the use of 7-methyljuglone derivatives as subversive 
substrates for Mtr and their activity against Mtb.  
 
In this study plumbagin derivatives linked to a glucosamine through variable chain 
lengths were assessed as alternative substrates (with a v ew of using them as subversive 
substrates) and inhibitors of Mtr. Investigation of 35-38 as alternative substrates was 
limited to 40 µM since they were predominantly hydrophobic and poorly soluble above 
this concentration, and their specific activities were compared to that of plumbagin. They 
were thus evaluated and compared at the same concentration. The hydrophobicity of the 
compounds became evident when evaluating them in spectrophotometric assays, and this 
made the generation of catalytic constants difficult and unreliable. 
 
6.4.4 Specific activities of 35-38 
 
Since naphthoquinones are readily reduced by reductases (discussed in chapter 1) and 
since compounds 35-38 are conjugates of plumbagin and phenyl-2-amino-1-
thioglycoside it was of interest to observe how they would compare with unconjugated 
plumbagin when reduced by Mtr. The ability of Mtr to reduce 35-38 was assayed as 
described in materials and methods. High specific activity was found with 37 (0.42 
µmol/min/mg) followed by 36 (0.37 µmol/min/mg), 38 (0.32 µmol/min/mg) and 35 (0.29 
µmol/min/mg) with the least activity, whilst plumbagin demonstrated a specific activity 




Since the compounds showed comparable activities with plumbagin, further quinone 
reductase activity utilising cytochrome c was not attempted. Coupling semiquinone 
formation to the reduction of cytochrome c, is usually used to measure the amount of one 
electron reduction of the naphthoquinones by reductases. 
 
The results do not show any direct correlation betwe n the specific activity observed and 
the spacer used. Compound 35 employs a 2-carbon spacer as opposed to the 5-carbon 
spacer found in 38, and both of these compounds have more or less similar specific 
activities as plumbagin. Compounds 36 and 37 with 3 and 4-carbon spacers respectively 
proved to be slightly better substrates as compared to plumbagin.  
 
 
Figure 6.7: Comparative specific activities of plumbagin, 35, 36, 37, and 38. The capability of Mtr to 
reduce plumbagin, 35-38 was determined by monitoring the oxidation of NADPH at 340 nm. The reaction 
mixture contained, in a final volume of 1 mL: 50 mM Tris/HCl (pH 7.6), NADPH (0.11 µmoles), and 35-
38 (each compound measured at 40 µM) at 30 0C. The reaction was started by adding Mtr (48 nM). Stock 
solutions of 35-38 were prepared in DMSO. Data points represent the average of duplicate determinations. 
 
6.4.5 35-38 as competing substrates or inhibitors of Mtr 
 
The biological activities of 35-38 (tested at a concentration of 40 µM) as competing 
substrates or inhibitors of Mtr were evaluated according to the procedure described in 
section 2.2.3. As far as the percentage inhibition was concerned, the compounds were 
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not found to be promising inhibitors (table 6.2) with the highest inhibition displayed by 
38 at 14%, as a result no further exploration was attempted. The poor activities displayed 
by these compounds (which lack the N-acetyl group of the N-acetyl moiety as found in 
MSH) seem to support the observation made by Newton e  al., 2005, in which the 
activity of Mtr was found to be more substantial with the natural substrate than with 
desacetylmycothiol or N-succinylated mycothiol (succ-Cys-GlcN-Ins). This indicates 
that the presence of the N-acetyl group of the N-acetyl moiety of mycothiol seems to be 
crucial for the activity of mycothiol analogues as substrates for Mtr, features that are 
absent on compounds 35-38. 
 
Table 6.2 Compounds 35-38 and their percentage inhibitions against Mtr. The compounds were evaluated 




















































Despite the minimal inhibition shown in figure 6.7, the relationship between the kind of 
spacer used and inhibition displayed appears to be related. Compound 35 with a 2-carbon 
spacer showed 0% inhibition as opposed to 38 (utilising a 5-carbon spacer) showing 14% 
inhibition. It would be interesting to explore the effects of these compounds when 
concentrations above 40 µM are used. Studies looking at substituting the phenyl group 
with inositol are in progress (using a fused bicyclic thioglycoside) in a bid to encourage 
solubility, and consequent evaluation at high concentrations. 
 
6.4.6 Anti-mycobacterial activities of 35-38 
 
Anti-mycobacterial activities of the compounds toward Mtb are shown in figure 6.8. 
Bactericidal activity was shown only by 35, whilst 36 and 37 resulted in growth indexes 
of 87, 38 did not show significant inhibitory properties after 4 days, a trend almost 
similar to that observed for the control. 
 






















Figure 6.8:  Anti-mycobacterial activities of 35-38 on Mtb were assessed using the radiometric respiratory 
technique based on the Bactec system. The assay was carried out by Dr Wiid, Department of Medical 
Biochemistry at the University of Stellenbosch, South Africa. 
 
The trend observed in figure 6.8 is in direct contrast to that observed in figure 6.7 and 
table 6.2, where 35 was shown to exhibit low specific activity and no enzyme inhibition 
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but elevated antimycobacterial properties as compared to 36 and 37. It is possible that 35 
interacts with other metabolic pathways not considere  in this study or that perhaps 
metabolic products of 35 are more active than 35. This remains an intriguing observation 
worth investigating further. The lack of correlation between antibacterial activity and 
kinetic parameters has also been observed in a previous study involving the activity of 7-
methyljuglone derivatives against Mtr (Mahapatra et l., 2007). 
 
Mahapatra et al., also postulated that the reason their methyljuglone derivatives lacked 
specificity between antitubercular activity and subversive substrate efficiency with Mtr 
could be ascribed to a possible interaction with oter flavoproteins such as lipoamide 
dehydrogenase and thioredoxin. It is also probable that 35, which showed more or less 
the same specific activity as plumbagin, had ambiguous interactions with other 
flavoproteins, hence the observed diminished growth index of Mtb after 4 days (figure 
6.8).  
 
6.5 Thioglycosides as Mtr inhibitors 
 
The necessity to assess whether thioglycosides can a t as possible Mtr inhibitors is 
derived from established observations where aminoglyc sides have been shown to act as 
broad spectrum antimicrobial agents that are widely used in the treatment of a range of 
Gram-positive and negative bacterial infections (Miller et al., 1995; Wright, 1995). And 
since an aminoglycoside based pseudodisaccharide (α-DGI) is the foundation of MSH 
and subsequent MSSM, it was thought necessary to test a variety of these compounds so 
as to find a lead compound that might be useful in the establishment of a potent Mtr 









Table 6.3: Structures of the thioglycosides used and their percentage inhibition of Mtr. The thioglycosides 
used in this study were obtained from Prof. Spencer Knapp, Rutgers University chemistry department. The














6.6 O-glycosides as Mtr inhibitors 
 
As a comparative measure a series of O-glycosides was also tested as inhibitors of Mtr 
and is shown in table 6.4. 
 
Table 6.4: Structures and percentage inhibitions of Mtr by O-glycosides. The O-glycosides were obtained from 
Prof. D.G Gammon, Chemistry department, University of Cape Town, South Africa. The compounds were 

































As observed for the thioglycosides tested in section 6.5, the maximum inhibition 
achieved with this range of O-glycosides was 20% (Th7), followed by Th6 with 12% 
whereas, Th1-Th3 showed 0% inhibition. In general, inhibition observed with both O-
glycosides and thioglycosides including 35-38 was extremely poor and raises questions 
over the use of a thiophenol or cyclohexane as a substit te for inositol in designing Mtr 
inhibitors. Efforts aimed at solving the crystal structure of Mtr are currently underway, 
and until such time studies pertaining to structure-activity relationships will be valuable 




The consistent Mtb infections and increasing prevalence of drug resistant strains is of 
great concern; hence the search for new anti-mycobacteri ls as outlined in this chapter 
and by numerous other studies. Whilst our efforts were focused on the development of a 
class of compounds (35-38) targeted against Mtr, it was their observed activity against 
MshB and Mca that proved valuable. As this showed them as lead compounds to which 
further modifications such as improving their solubility, incorporating an N-acetyl group 
(mentioned in section 6.4.5) may lead to the development of a dual inhibitor for the two 
enzymes (MshB and Mtr).  
 
Evaluation of O-glycosides (Th1-7) and thioglycosides (SPh2-7) was motivated by 
studies carried out by Patel and Blanchard, 1998, and Stewart et al., 2008 where the O-
benzyl, O-methyl and des-myoinositol-glycoside derivatives of MSSM have previously 
been shown to be recognised as alternative substrate  by Mtr. The Km values for these 
substrates were found to be 3-6 fold greater than for MSSM, which demonstrated a 
relatively modest compromise in substrate recognitio  for quite significant changes to the 
aglycone moiety. For all the compounds tested as Mtr inhibitors, the weak inhibition is 
more likely attributed to the collective effects of modification of the aglycone as well as 






Although Mtr from Mycobacterium tuberculosis had been cloned, expressed in 
Mycobacterium smegmatis and purified (Patel and Blanchard, 1999), this study attempted 
to explore alternative expression systems in a quest to recover increased enzyme yields 
since the original expression resulted in modest recov ries as discussed in chapter 3. 
Unfortunately, the two expression systems tried were not successful. However, whilst 
exploring the use of C. glutamicum, MSH was isolated using an alternative and 
inexpensive derivatizing agent (2-bromoacetonaphthone, BAN), purified, characterised 
and confirmed to be a low molecular mass thiol exclusively used by C. glutamicum as 
had been expected. Furthermore, MSSnaph was shown to be an alternative substrate for 
M. tuberculosis Mtr with a Km,app value of 23 µM which is 3-5 times lower than values 
previously reported for the reduction of MSSM. 
 
As discussed in section 1.6, the suitability of a few different aglycons instead of inositol 
in mycothiol were explored in an attempt to shed light on the substrate specificity of Mtr, 
and the benzyl group was found to be the most suitable (Stewart et al., 2008). In addition, 
an earlier study by Knapp et al., 2002 showed that Mca was active against a mycothiol-S-
bimane analogue. These findings provided the impetus for a successful design of a set of 
compounds (35-38) targeted at Mtr in which plumbagin was tethered via 2 to 5 methylene 
carbons and an amide linkage to phenyl-2-deoxy-2-amino-1-thio-a-D-glucopyranoside. 
Although the compounds did not show promise as potential subversive substrates as had 
been initially envisaged, they were however, found to be the most potent inhibitors of 
MshB, and also displayed some activity against Mca (G mmon et al., 2010).  In spite of 
the compound’s poor activity against Mtr, only compound 35 showed bactericidal 
activity. An interesting and unexpected finding made in this study is that Mtr is also 
inhibited (although incomplete) by both INH-NADP and INH-NAD adducts. Although 
the adducts were easy to prepare, they were nonetheless unstable, most probably due to 
the re-oxidation of the nicotinamide ring over time to produce a more conjugated 
molecule as being the decomposition product. The study is still in progress and more in 
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depth studies (e.g. crystallography) will be required to explain the exact interaction of 









4.7g Middlebrook in 800 mL dH2O  
50 mL glycerol  
0.5g Tween 80  




10g Tryptone  
5g Yeast extract  
5g NaCl  




35g Tryptone  
20 Yeast extract  
5g NaCl  
Dissolved in 800 mL, pH adjusted to 7.5, made up to 1L with dH20 and autoclaved.  
 
Issabelle media  
 
40g Glucose  
15g Yeast extract  
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15g Peptone  
1.75g NaH2PO4.H2O  
0.04g Ferric ammonium citrate  
Dissolved in 900 mL, pH adjusted to 7.5 and autoclaved  
N.B. Glucose was filter sterilised  
 
Appendix 1B: pEC-XK99E sequence. The multiple cloning site is 
underlined.  
 
LOCUS AY219683 7018 bp DNA circular SYN 05- 
SEP-2003  
DEFINITION Shuttle expression vector pEC-XK99E, complete sequence.  
ACCESSION AY219683  
VERSION AY219683.1 GI:29164935  
KEYWORDS .  
SOURCE Shuttle expression vector pEC-XK99E  
 ORGANISM Shuttle expression vector pEC-XK99E  
 other sequences; artificial sequences; vectors.  
REFERENCE 1 (bases 1 to 7018)  
 AUTHORS Kirchner,O. and Tauch,A.  
 TITLE Tools for genetic engineering in the amino acid-producing  
bacterium  
 Corynebacterium glutamicum  
 JOURNAL J. Biotechnol. 104 (1-3), 287-299 (2003)  
 PUBMED 12948646  
REFERENCE 2 (bases 1 to 7018)  
 AUTHORS Kirchner,O. and Tauch,A.  
174 
 
 TITLE Direct Submission  
 JOURNAL Submitted (15-JAN-2003) Department of Genetics, University  
of  Bielefeld, Universitaetsstrasse 25, Bielefeld D-33615,  
Germany  
FEATURES Location/Qualifiers  
 source 1..7018  
 /organism="Shuttle expression vector pEC-XK99E"  
 /mol_type="genomic DNA"  
 /db_xref="taxon:224638"  
 /note="Escherichia coli-Corynebacterium glutamicum shuttle  
 vector"  
 terminator 263..306  
 /note="terminator T1"  
 terminator 438..465  
 /note="terminator T2"  
 gene complement(705..920)  
 /gene="per"  
 CDS complement(705..920)  
 /gene="per"  
 /note="positive effector of replication"  
 /codon_start=1  
 /transl_table=11  
 /product="Per"  
 /protein_id="AAO65195.1"  
 /db_xref="GI:29164936"  
 /translation="MDLSDVALESDALDAAVDLKTVIGFFRALDTTDAPASRDWASAA  
 SDLETLVADLEELADELRARQRQEDAQ"  
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 gene complement(1563..3026)  
 /gene="repA"  
 CDS complement(1563..3026)  
 /gene="repA"  
 /note="replication protein"  
 /codon_start=1  
 /transl_table=11  
 /product="RepA"  
 /protein_id="AAO65196.1"  
 /db_xref="GI:29164937"  
 









VKTAILDARSQSVAD  PSTRELAGELGVSERRIQQVRKALGMEAKRGRPRAEN"  
 gene 3556..4350  
 /gene="aph(3')-IIa"  
 CDS 3556..4350  
 /gene="aph(3')-IIa"  
 /note="aminoglycoside phosphotransferase"  
 /codon_start=1  
 /transl_table=11  
 /product="Aph(3')-IIa"  
 /protein_id="AAO65197.1"  
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 /db_xref="GI:29164938"  





RY QDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF"  
 rep_origin 5038  
 /note="oriV"  
 gene 5628..6710  
 /gene="lacIq"  
 CDS 5628..6710  
 /gene="lacIq"  
 /note="Lac-repressor"  
 /codon_start=1  
 /transl_table=11  
 /product="LacIq"  
 /protein_id="AAO65198.1"  








LAPNT QTASPRALADSLMQLARQVSRLESGQ"  
 promoter 6767..7012  




 1 gaattcgagc tcggtacccg gggatcctct agagtcgacc tgcaggcatg caagcttggc  
 61 tgttttggcg gatgagagaa gattttcagc ctgatacaga ttaa tc ga acgcagaagc  
 121 ggtctgataa aacagaattt gcctggcggc agtagcgcgg tggtcccacc tgaccccatg  
 181 ccgaactcag aagtgaaacg ccgtagcgcc gatggtagtg tgg tctcc ccatgcgaga  
 241 gtagggaact gccaggcatc aaataaaacg aaaggctcag tcga agact gggcctttcg  
 301 ttttatctgt tgtttgtcgg tgaacgctct cctgagtagg acaa tccgc cgggagcgga  
 361 tttgaacgtt gcgaagcaac ggcccggagg gtggcgggca ggacgcccgc cataaactgc  
 421 caggcatcaa attaagcaga aggccatcct gacggatggc cttttgcg  ttctacaaac  
 481 tctttttgtt tatttttcta aatacattca aatatgtatc cgctcatgaa ttaattccgc  
 541 tagatgacgt gcggcttcga cctcctgggc gtggcgcttg ttggcgcgct cgcggctggc  
 601 tgcggcacga cacgcgtctg agcagtattt tgcgcgccgt cctcgtgggt caggccgggg  
 661 tgggatcagg ccaccgcagt aggcgcagct gatgcgatcc tcca ta tg cgcgtcctcc  
 721 tggcgctgcc gagcacgcag ctcgtcggcc agctcttcaa ggtcggccac aagcgtttct  
 781 aggtcgctcg cggcacttgc ccagtcgcgt gatgctggcg cgtctgtcgt atcgagggcg  
 841 cggaaaaatc cgatcaccgt ttttaaatcg acggcggcat cgagtg tc ggactccagc  
 901 gcgacatcgg agagatccac cgctgatgct tcaggccagt tttggtactt cgtcgtgaag  
 961 gtcatgacac cattataacg aacgttcgtt aaaaattcta gccccaattc tgataatttc  
 1021 ttccggcact cctgcgaaaa cctgcgagac ttcttgccca gaa aaacgc caagcgcagc  
 1081 ggttaccgca ctttttttcc aggtgatttc accctgacca gg agcggc actttagtgc  
 1141 atgaggtgtg cccctggttt cccctctttg gagggttcaa cc aaaaag cacacaagca  
 1201 aaaatgaaaa tcatcatgag caagttggtg cgaagcagca acgcgct gc tccaaaaagg  
 1261 tctccaggat ctcgaggaga tttttgaggg ggagggagtc ggaagagc cagagcagaa  
 1321 ggcggggaac cgttctctgc cgacagcgtg agcccccctt aaaaatcagg ccggggagga  
 1381 accggggagg gatcagagct aggagcgaga caccctaaag ggggggaacc gttttctgct  
 1441 gacggtgttt cgtttattag ttttcagccc gtggatagcg gagg tgagg gcaagtgaga  
 1501 gccagagcaa ggacgggacc cctaaagggg ggaaccgttt ttgc gacg gtgtttcgtt  
 1561 tattagtttt cagcccgtgg acggccgcgt ttagcttcca tt agtgc ctttctgact  
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 1621 tgttggatgc gcctttcact gacacctagt tcgcctgcaa gtcacgagt cgagggatca  
 1681 gcaaccgatt gagaacgggc atccaggatc gcagttttga cgc agttc gagcaactcg  
 1741 cctgtcattt ctcggcgttt gtttgcttcc gctaatcgct gt gcgtctc ctgcgcatac  
 1801 ttactttctg ggtcagccca tctgcgtgca ttcgatgtag cgcg cccg tcgccccatc  
 1861 gtcgctagag ctttccgccc tcggctgctc tgcgtttcca cgacgagc agggacgact  
 1921 ggctggcctt tagccacgta gccgcgcaca cgacgcgcca tcgtcaggcg atcacgcatg  
 1981 gcgggaagat ccggctcccg gccgtctgca ccgaccgcct gg aacgtt gtacgccact  
 2041 tcatacgcgt cgatgatctt ggcatctttt aggcgctcac cag agcttt gagctggtat  
 2101 cccacggtca acgcgtggcg aaacgcggtc tcgtcgcgcg ctcgct tgg atttgtccag  
 2161 agcactcgca cgccgtcgat caggtcgccg gacgcgtcca gggcgctcgg caggctcgcg  
 2221 tccaaaatcg ctagcgcctt ggcttctgcg gtggcgcgtt gt cc cttc aatgcgggcg  
 2281 cgtccgctgg aaaagtcctg ctcaatgtac tttttcggct tctgtgatcc ggtcatcgtt  
 2341 cgagcaatct ccattaggtc ggccagccga tccacacgat cat c ggca gtgccattta  
 2401 taggctgtcg gatcgtctga gacgtgcagc ggccaccggc ta ctatg cgaaaaagcc  
 2461 tggtcagcgc cgaaaacacg agtcatttct tccgtcgttg cagccagcag gcgcatattt  
 2521 gggctggttt tacctgctgc ggcatacacc gggtcaatga gcc gatgag ctggcatttc  
 2581 ccgctcagcg gattcacgcc gatccaagcc ggcgcttttt ctagg gtgc ccatttctct  
 2641 aaaatcgcgt agacctgcgg gtttacgtgc tcaatcttcc cgccggcctg gtggctgggc  
 2701 acatcgatgt caagcacgat caccgcggca tgttgcgcgt gcgtcagcgc aacgtactgg  
 2761 caccgcgtca gcgcttttga gccagcccgg tagagctttg gt g gtttc gccggtatcc  
 2821 gggtttttaa tccaggcgct cgcgaaatct cttgtcttgc tgc ctggaa gctttcgcgt  
 2881 cccaggtgag cgagcagttc gcggcgatct tctgccgtcc accgcgtga gccgcagcgc  
 2941 atagcttcgg ggtgggtgtc gaacagatcg gcggacaatt tc cgcgct agctgtgact  
 3001 gtgtcctgcg gatcggctag agtcatgtct tgagtgcttt ctcccagctg atgactgggg  
 3061 gttagccgac gccctgtgag ttcccgctca cggggcgttc aactttttca ggtatttgtg  
 3121 cagcttatcg tgttttcttc gtaaatgaac gcttaactac ct gttaaac gtggcaaata  
 3181 ggcaggattg atggggatct agcttcacgc tgccgcaagc actcagggcg caagggctgc  
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 3241 taaaggaagc ggaacacgta gaaagccagt ccgcagaaac gtgctgacc ccggatgaat  
 3301 gtcagctact gggctatctg gacaagggaa aacgcaagcg caa agaaa gcaggtagct  
 3361 tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc aagcgaaccg  
 3421 gaattgccag ctggggcgcc ctctggtaag gttgggaagc cct aaagt aaactggatg  
 3481 gctttcttgc cgccaaggat ctgatggcgc aggggatcaa gatctgatca agagacagga  
 3541 tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggtt tcc ggccgcttgg  
 3601 gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc tgatgccgcc  
 3661 gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga cctgtccggt  
 3721 gccctgaatg aactccaaga cgaggcagcg cggctatcgt ggct gccac gacgggcgtt  
 3781 ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gg ctggct gctattgggc  
 3841 gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgc gagaa agtatccatc  
 3901 atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc attcgaccac  
 3961 caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct tgtcgatcag  
 4021 gatgatctgg acgaagagca tcaggggctc gcgccagccg aa tgttcgc caggctcaag  
 4081 gcgcggatgc ccgacggcga ggatctcgtc gtgacccatg ggatgcctg cttgccgaat  
 4141 atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct gggtgtggcg  
 4201 gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa  
 4261 tgggctgacc gcttcctcgt gctttacggt atcgccgctc cgattcgca gcgcatcgcc  
 4321 ttctatcgcc ttcttgacga gttcttctga gcgggactct ggggttcgcg gaatcatgac  
 4381 caaaatccct taacgtgagt tttcgttcca ctgagcgtca ga cccgtag aaaagatcaa  
 4441 aggatcttct tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc  
 4501 accgctacca gcggtggttt gtttgccgga tcaagagcta cca ctcttt ttccgaaggt  





 4621 ccaccacttc aagaactctg tagcaccgcc tacatacctc gct gctaa tcctgttacc 
 4681 agtggctgct gccagtggcg ataagtcgtg tcttaccggg tt actcaa gacgatagtt  
 4741 accggataag gcgcagcggt cgggctgaac ggggggttcg tcacacagc ccagcttgga  
 4801 gcgaacgacc tacaccgaac tgagatacct acagcgtgag ctatgagaaa gcgccacgct  
 4861 tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc ag t ggaa caggagagcg  
 4921 cacgagggag cttccagggg gaaacgcctg gtatctttat ag cctgtcg ggtttcgcca  
 4981 cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg gggc gagcc tatggaaaaa  
 5041 cgccagcaac gcggcctttt tacggttcct ggccttttgc tg cttttg ctcacatgtt  
 5101 ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga  
 5161 taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gt agc agg aagcggaaga  
 5221 gcgcctgatg cggtattttc tccttacgca tctgtgcggt atttcacacc gcatatggtg  
 5281 cactctcagt acaatctgct ctgatgccgc atagttaagc cagtatacac tccgctatcg  
 5341 ctacgtgact gggtcatggc tgcgccccga cacccgccaa cacccgctga cgcgccctga  
 5401 cgggcttgtc tgctcccggc atccgcttac agacaagctg taccgtctc cgggagctgc  
 5461 atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga ggcagcagat caattcgcgc  
 5521 gcgaaggcga agcggcatgc atttacgttg acaccatcga atg tgcaaa acctttcgcg  
 5581 gtatggcatg atagcgcccg gaagagagtc aattcagggt gtgaatgtg aaaccagtaa  
 5641 cgttatacga tgtcgcagag tatgccggtg tctcttatca ga cgtttcc cgcgtggtga  
 5701 accaggccag ccacgtttct gcgaaaacgc gggaaaaagt ggaagc gcg atggcggagc  
 5761 tgaattacat tcccaaccgc gtggcacaac aactggcggg caaacagtcg ttgctgattg  
 5821 gcgttgccac ctccagtctg gccctgcacg cgccgtcgca aattgtcgcg gcgattaaat  
 5881 ctcgcgccga tcaactgggt gccagcgtgg tggtgtcgat ggt gaacga agcggcgtcg  
 5941 aagcctgtaa agcggcggtg cacaatcttc tcgcgcaacg cgtcagtggg ctgatcatta  
 6001 actatccgct ggatgaccag gatgccattg ctgtggaagc tgcctgcact aatgttccgg  
 6061 cgttatttct tgatgtctct gaccagacac ccatcaacag tattatt tc tcccatgaag  
 6121 acggtacgcg actgggcgtg gagcatctgg tcgcattggg tcaccagcaa atcgcgctgt  
 6181 tagcgggccc attaagttct gtctcggcgc gtctgcgtct gg ggctgg cataaatatc  
 6241 tcactcgcaa tcaaattcag ccgatagcgg aacgggaagg cg ct gagt gccatgtccg  
 6301 gttttcaaca aaccatgcaa atgctgaatg agggcatcgt tcc ac gcg atgctggttg  
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 6361 ccaacgatca gatggcgctg ggcgcaatgc gcgccattac cgagtc ggg ctgcgcgttg  
 6421 gtgcggatat ctcggtagtg ggatacgacg ataccgaaga cgctcatgt tatatcccgc  
 6481 cgtcaaccac catcaaacag gattttcgcc tgctggggca aac gcgtg gaccgcttgc  
 6541 tgcaactctc tcagggccag gcggtgaagg gcaatcagct gtt ccgtc tcactggtga  
 6601 aaagaaaaac caccctggcg cccaatacgc aaaccgcctc tc gcgcg ttggccgatt  
 6661 cattaatgca gctggcacga caggtttccc gactggaaag cgggcagtga gcgcaacgca  
 6721 attaatgtga gttagcgcga attgatctgg tttgacagct ttcatcgac tgcacggtgc  
 6781 accaatgctt ctggcgtcag gcagccatcg gaagctgtgg tat c gtg caggtcgtaa  
 6841 atcactgcat aattcgtgtc gctcaaggcg cactcccgtt ctggataatg ttttttgcgc  
 6901 cgacatcata acggttctgg caaatattct gaaatgagct gtt acaatt aatcatccgg  
 6961 ctcgtataat gtgtggaatt gtgagcggat aacaatttca cacaggaaac agaccatg  
 
 Appendix 1C: Mycothiol disulfide reductase protein sequence 
[Mycobacterium tuberculosis H37Rv]  
 
LOCUS YP_177910 459 aa linear BCT 29- 
MAR-2010  
DEFINITION mycothione reductase [Mycobacterium tuberculosis H37Rv].  
ACCESSION YP_177910  
VERSION YP_177910.1 GI:57117030  
DBLINK Project:224  
DBSOURCE REFSEQ: accession NC_000962.2  
KEYWORDS complete genome.  
SOURCE Mycobacterium tuberculosis H37Rv  
 ORGANISM Mycobacterium tuberculosis H37Rv  





 Corynebacterineae; Mycobacteriaceae; Mycobacterium;  
Mycobacterium  tuberculosis complex.  
REFERENCE 1  
 AUTHORS Camus,J.C., Pryor,M.J., Medigue,C. and Cole,S.T.  
 TITLE Re-annotation of the genome sequence of Mycoba terium  
tuberculosis  H37Rv  
 JOURNAL Microbiology (Reading, Engl.) 148 (PT 10), 2967-2973 (2002)  
 PUBMED 12368430  
REFERENCE 2 (residues 1 to 459)  
 AUTHORS Cole,S.T., Brosch,R., Parkhill,J., Garnier,T., Churcher,C.,  
 Harris,D., Gordon,S.V., Eiglmeier,K., Gas,S., Barry,C.E. III,  
 Tekaia,F., Badcock,K., Basham,D., Brown,D., Chillingworth,T.,  Connor,R., Davies,R., 
Devlin,K., Feltwell,T., Gentles,S., Hamlin,N., Holryd,S., Hornsby,T., Jagels,K., Krogh,A., 
McLean,J.,  Moule,S., Murphy,L., Oliver,K., Osborne,J., Quail,M.A.,  Rajandream,M.A., 
Rogers,J., Rutter,S., Seeger,K., Skelton,J.,  Squares,R., Squares,S., Sulston,J.E., Taylor,K., 
Whitehead,S. and  Barrell,B.G.  
TITLE Deciphering the biology of Mycobacterium tuberculosis from the complete genome 
sequence  
 JOURNAL Nature 393 (6685), 537-544 (1998)  
PUBMED 9634230  
 REMARK Erratum:[Nature 1998 Nov 12;396(6707):190]  
REFERENCE 3 (residues 1 to 459)  
 CONSRTM NCBI Genome Project  
TITLE Direct Submission  
 JOURNAL Submitted (13-SEP-2001) National Center for Biotechnology  
 Information, NIH, Bethesda, MD 20894, USA  
COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The 
reference sequence was derived from CAE55526.  
 Method: conceptual translation.  
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FEATURES Location/Qualifiers  
 source 1..459  
 /organism="Mycobacterium tuberculosis H37Rv"  
 /strain="H37Rv"  
 /db_xref="taxon:83332"  
 Protein 1..459  
 /product="mycothione reductase"  
 /EC_number="1.8.1.7"  
 /function="INVOLVED IN REDUCTION OF MYCOTHIOL."  
 /calculated_mol_wt=49815  
 Region 3..459  
 /region_name="PRK07846"  
 /note="mycothione/glutathione reductase; Reviewed;  
 PRK07846"  
 /db_xref="CDD:136532"  
 Region 174..252  
 /region_name="NADB_Rossmann"  
 /note="Rossmann-fold NAD(P)(+)-binding proteins;  
cl09931"  
 /db_xref="CDD:164178"  
 Region 345..454  
 /region_name="Pyr_redox_dim"  
 /note="Pyridine nucleotide-disulphide oxidoreductase,  dimerization domain; pfam02852"  
 /db_xref="CDD:145812"  
 CDS 1..459  




 /locus_tag="Rv2855"  
 /coded_by="NC_000962.2:3165205..3166584"  
 /experiment="experimental evidence, no additional  
details  recorded"  
 /note="catalyzes the reduction of mycothione or  
 glutathione to mycothione or glutathione  
disulfide"  
 /transl_table=11  
 /db_xref="GeneID:887773"  
ORIGIN  
 1 metydiaiig tgsgnsilde ryaskraaic eqgtfggtcl nvgciptkmf  
vyaaevakti  
 61 rgasrygida hidrvrwddv vsrvfgridp ialsgedyrr capnidvyrt  
htrfgpvqad  
 121 gryllrtdag eeftaeqvvi aagsrpvipp ailasgvdyh tsdtvmriae  
lpehivivgs  
 181 gfiaaefahv fsalgvrvtl virgscllrh cddticerft riastkwelr  
thrnvvdgqq  
 241 rgsgvalrld dgctinadll lvatgrvsna dlldaeqagv dve grvivd  
eyqrtsargv  
 301 falgdvsspy llkhvanhea rvvqhnllcd wedtqsmivt dhryvpaavf  
tdpqiaavgl  
 361 tenqavakgl disvkiqdyg dvaygwamed tsgivklite rgsgrllgah  
imgyqassli  
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